WO2022122037A1 - 一种二氢异喹啉酮衍生物及其应用 - Google Patents
一种二氢异喹啉酮衍生物及其应用 Download PDFInfo
- Publication number
- WO2022122037A1 WO2022122037A1 PCT/CN2021/137254 CN2021137254W WO2022122037A1 WO 2022122037 A1 WO2022122037 A1 WO 2022122037A1 CN 2021137254 W CN2021137254 W CN 2021137254W WO 2022122037 A1 WO2022122037 A1 WO 2022122037A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- alkoxy
- substituted
- optionally substituted
- compound
- Prior art date
Links
- WGLUNLJVYNJMBU-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-n-[(3-methyl-1-oxo-2,4-dihydroisoquinolin-3-yl)methyl]decanamide Chemical class C1=CC=C2C(=O)NC(CN(CCN(C)C)C(=O)CCCCCCCCC)(C)CC2=C1 WGLUNLJVYNJMBU-UHFFFAOYSA-N 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 248
- 150000003839 salts Chemical class 0.000 claims abstract description 197
- 239000002207 metabolite Substances 0.000 claims abstract description 195
- 239000000651 prodrug Substances 0.000 claims abstract description 195
- 229940002612 prodrug Drugs 0.000 claims abstract description 195
- 239000012453 solvate Substances 0.000 claims abstract description 142
- 101000771599 Homo sapiens WD repeat-containing protein 5 Proteins 0.000 claims abstract description 32
- 102100029445 WD repeat-containing protein 5 Human genes 0.000 claims abstract description 32
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 425
- -1 polymorph Substances 0.000 claims description 298
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 266
- 150000002367 halogens Chemical class 0.000 claims description 260
- 238000006467 substitution reaction Methods 0.000 claims description 255
- 229910052736 halogen Inorganic materials 0.000 claims description 250
- 125000000623 heterocyclic group Chemical group 0.000 claims description 214
- 230000000155 isotopic effect Effects 0.000 claims description 194
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 188
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 187
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 182
- 125000001424 substituent group Chemical group 0.000 claims description 177
- 125000004076 pyridyl group Chemical group 0.000 claims description 151
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 148
- 125000002883 imidazolyl group Chemical group 0.000 claims description 139
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 138
- 125000004193 piperazinyl group Chemical group 0.000 claims description 128
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 124
- 125000001041 indolyl group Chemical group 0.000 claims description 123
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 123
- 125000003386 piperidinyl group Chemical group 0.000 claims description 118
- 125000002757 morpholinyl group Chemical group 0.000 claims description 115
- 125000001072 heteroaryl group Chemical group 0.000 claims description 111
- 125000002393 azetidinyl group Chemical group 0.000 claims description 106
- 125000001425 triazolyl group Chemical group 0.000 claims description 105
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 103
- 229910052757 nitrogen Inorganic materials 0.000 claims description 99
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 95
- 125000004306 triazinyl group Chemical group 0.000 claims description 90
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 83
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 83
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 82
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 81
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 81
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 80
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 79
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 74
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 69
- 125000002947 alkylene group Chemical group 0.000 claims description 63
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 claims description 60
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 58
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 58
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 55
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 55
- 125000003545 alkoxy group Chemical group 0.000 claims description 54
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 52
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 51
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 49
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 48
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 46
- 125000000217 alkyl group Chemical group 0.000 claims description 45
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 45
- 125000005493 quinolyl group Chemical group 0.000 claims description 42
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims description 41
- 125000003566 oxetanyl group Chemical group 0.000 claims description 40
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 37
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 35
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 32
- 125000004450 alkenylene group Chemical group 0.000 claims description 30
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 29
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 28
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 229910052760 oxygen Inorganic materials 0.000 claims description 27
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 claims description 26
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 26
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims description 26
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 claims description 26
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 26
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 26
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 26
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 25
- 125000003965 isoxazolidinyl group Chemical group 0.000 claims description 25
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 claims description 25
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims description 24
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 24
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 23
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 23
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 23
- 125000001624 naphthyl group Chemical group 0.000 claims description 23
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 22
- 229910052801 chlorine Inorganic materials 0.000 claims description 21
- 229910052731 fluorine Inorganic materials 0.000 claims description 21
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 20
- 125000005138 alkoxysulfonyl group Chemical group 0.000 claims description 20
- 125000003107 substituted aryl group Chemical group 0.000 claims description 20
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 19
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 19
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 18
- 125000001153 fluoro group Chemical group F* 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 18
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- 229920006395 saturated elastomer Polymers 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000004122 cyclic group Chemical group 0.000 claims description 13
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 12
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 12
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 10
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 10
- 125000002837 carbocyclic group Chemical group 0.000 claims description 9
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims description 9
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 9
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 9
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- YIIOTOBXQVQGSV-UHFFFAOYSA-N [1,3]dioxolo[4,5-b]pyridine Chemical compound C1=CN=C2OCOC2=C1 YIIOTOBXQVQGSV-UHFFFAOYSA-N 0.000 claims description 7
- 125000004069 aziridinyl group Chemical group 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 6
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000005544 phthalimido group Chemical group 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 208000007367 Kabuki syndrome Diseases 0.000 claims description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 2
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical compound O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 claims description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 2
- 208000003609 Bile Duct Adenoma Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 201000005262 Chondroma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000005101 LEOPARD Syndrome Diseases 0.000 claims description 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 2
- 206010062901 Multiple lentigines syndrome Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010029748 Noonan syndrome Diseases 0.000 claims description 2
- 208000010708 Noonan syndrome with multiple lentigines Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims 53
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 9
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 3
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 claims 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 230000004850 protein–protein interaction Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000002585 base Substances 0.000 description 39
- 125000004432 carbon atom Chemical group C* 0.000 description 28
- 239000000460 chlorine Substances 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 9
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000011593 sulfur Chemical group 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 5
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical class 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 101100477411 Dictyostelium discoideum set1 gene Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101001008892 Homo sapiens Histone-lysine N-methyltransferase 2C Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 108700025694 p53 Genes Proteins 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical group O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- JPPREFOETTUXDK-UHFFFAOYSA-N 1h-1,3-diazepine Chemical compound N1C=CC=CN=C1 JPPREFOETTUXDK-UHFFFAOYSA-N 0.000 description 1
- ODSNARDHJFFSRH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindole Chemical compound C1CCCC2CNCC21 ODSNARDHJFFSRH-UHFFFAOYSA-N 0.000 description 1
- 125000005938 2,3-dihydro-1H-isoindolyl group Chemical group 0.000 description 1
- JPPZWICGMJJBIH-JEDNCBNOSA-N 2-aminoacetic acid;(2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CC1=CNC=N1 JPPZWICGMJJBIH-JEDNCBNOSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- GXWNSJYVSIJRLS-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyrazine Chemical compound CC1=NC(Br)=CN2C=CN=C12 GXWNSJYVSIJRLS-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101100033032 Caenorhabditis elegans rbbp-5 gene Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 102100027755 Histone-lysine N-methyltransferase 2C Human genes 0.000 description 1
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 description 1
- 101000703089 Homo sapiens Set1/Ash2 histone methyltransferase complex subunit ASH2 Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108700039010 SET domains Proteins 0.000 description 1
- 102000051614 SET domains Human genes 0.000 description 1
- 102100030733 Set1/Ash2 histone methyltransferase complex subunit ASH2 Human genes 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- NVSPJDGXKBDYIZ-UHFFFAOYSA-N [1,2,4]triazolo[4,3-a]pyrazine Chemical compound C1=NC=CN2C=NN=C21 NVSPJDGXKBDYIZ-UHFFFAOYSA-N 0.000 description 1
- AYSYSOQSKKDJJY-UHFFFAOYSA-N [1,2,4]triazolo[4,3-a]pyridine Chemical compound C1=CC=CN2C=NN=C21 AYSYSOQSKKDJJY-UHFFFAOYSA-N 0.000 description 1
- YRACHDVMKITFAZ-UHFFFAOYSA-N [1,2,4]triazolo[4,3-b]pyridazine Chemical compound C1=CC=NN2C=NN=C21 YRACHDVMKITFAZ-UHFFFAOYSA-N 0.000 description 1
- XUFCBCHWTOAVAA-UHFFFAOYSA-N [1,2,4]triazolo[4,3-c]pyrimidine Chemical compound C1=CN=CN2C=NN=C21 XUFCBCHWTOAVAA-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004475 heteroaralkyl group Chemical class 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical class [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 102000049285 human KMT2A Human genes 0.000 description 1
- 102000046603 human KMT2C Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- VTVRXITWWZGKHV-UHFFFAOYSA-N imidazo[1,2-b]pyridazine Chemical compound N1=CC=CC2=NC=CN21 VTVRXITWWZGKHV-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical group 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004354 sulfur functional group Chemical group 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Definitions
- the present invention relates to the field of medicinal chemistry, in particular, to a novel heterocyclic compound that can be used as a WDR5 protein-protein interaction inhibitor, a pharmaceutically acceptable salt thereof, or an enantiomer or diastereomer thereof Conformers, tautomers, solvates, isotopic substitutions, prodrugs or metabolites.
- the present invention also relates to a preparation method of such compounds, pharmaceutical compositions containing such compounds, and use of such compounds for preparing medicines for treating diseases or conditions related to abnormal WDR5 activity.
- WDR5 belongs to the WD40 domain repeat protein family (WD40-repeat protein).
- WD40 is an important structural domain consisting of about 40 amino acid residues.
- the WDR domain contains a ring-shaped seven-leaf ⁇ -propeller domain. Each contains the conserved serine-histidine (SH) and tryptophan-aspartic acid (WD) sequences.
- the WDR5 protein contains a central cavity formed by a 7-lobed ⁇ -helix that runs up and down.
- the WDR5 protein mainly plays a regulatory role through a deep arginine binding pocket, that is, the WIN site forms a core catalytic complex with MLL1, and forms the core catalytic complex of MWRAD (MLL1, WDR5, RbBP5, ASH2L and DYP-30) with other proteins. , catalyzes histone H3 methylation, activates gene transcription and participates in epigenetic regulation.
- MLL family protein complex which is widespread in eukaryotes, is an important class of histone methyltransferases that catalyze the methylation of histone H3K4, either by catalyzing the methylation of H3K4 and/or by recruiting other transcription-related proteins to interact with Mediators, which activate transcription, play a crucial role during development. Mutations in these proteins, including genomic translocations where they fuse with other transcription factors, can cause a variety of diseases, such as mixed lineage leukemia (MLL), lymphoma, and Kabuki syndrome.
- MLL mixed lineage leukemia
- MLL1 is the 3775-3786 amino acid (MLL1 AS , activation segment) inserted into the barrel structure of WDR5. center, while MLL3 is an amino-terminal insertion of the SET domain into WDR5.
- WDR5 as a drug target, compounds designed for the WIN pocket where WDR5 binds to histones and MLL1 can reduce the expression of genes downstream of WDR5 and treat MLL rearrangement-dependent leukemia.
- the TP53 gene is the most frequently mutated gene in tumors, and TP53 mutations occur in 50% of human cancers.
- the high frequency of missense mutations and the high expression level of mutant p53 (mp53) protein in cancer cells promote mp53 protein to have new functions (“gain of function” (GOF)), and also actively promote cancer development and progression.
- GAF gain of function
- the growth of tumor cells driven by mutations in the p53 gene depends on the binding of WDR5 to MLL. MLL, MOZ and histone modifications are all regulated by the expression of GOF p53. Therefore, WDR5 protein interaction inhibitors can also be used to treat TP53-mutated tumors.
- MYC is a class of oncoproteins with transcription factor functions, which are overexpressed in most malignant tumors. MYC can bind to the regulatory sequences of thousands of target genes, regulate target gene expression, and affect processes such as cell growth, proliferation, metabolism, genome stability, and apoptosis. Earlier studies have found that the extensive binding of MYC to chromatin also depends on the interaction of WDR5, and that MYC binds to the hydrophobic cleft on the surface of WDR5 through its evolutionarily conserved "MYC box IIIb" sequence, which plays an important role in tumorigenesis in vivo. Therefore, by blocking the WDR5 protein-protein interaction, MYC function can be blocked and the ability of MYC to drive carcinogenesis can be inhibited.
- the object of the present invention is to provide a compound of formula I or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt thereof, and the compound or pharmaceutical composition thereof in the prevention and treatment of and WDR5 Abnormal-related diseases or conditions.
- a compound of formula I or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvate thereof , polymorphs, prodrugs or metabolites:
- Ring A is a substituted or unsubstituted 3-8 membered saturated or unsaturated carbocyclic ring or a substituted or unsubstituted 3-8 membered saturated or unsaturated heterocyclic ring, the heterocyclic ring contains 1-2 independently selected from N, O and heteroatoms of S;
- X 3 is selected from CR 5 and N;
- X 5 is selected from N and CR 5 ;
- L 1 is selected from bond, optionally substituted C1-C6 alkylene, optionally substituted C1-C6 alkylene-O-, optionally substituted C1-C6 alkylene-NH-, optionally substituted C1 -C6 alkylene-S- and optionally substituted C2-C4 alkenylene;
- L 2 is selected from bond, optionally substituted C1-C6 alkylene, optionally substituted C1-C6 alkylene-O-, optionally substituted C1-C6 alkylene-NH-, optionally substituted C1 -C6 alkylene-S- and optionally substituted C2-C4 alkenylene;
- R 0 is selected from H, C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, -C(O)NR 3 R 4 , -CH 2 OR 3 and - NR 3 R 4 substituted C1-C6 alkyl;
- R 1 is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted amino and guanidino;
- R is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl;
- R 3 and R 4 are each independently selected from H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, optionally substituted 4-10 membered Heterocyclyl and optionally substituted 5-10 membered heteroaryl; alternatively, R and R together with the nitrogen atom to which they are attached form an optionally substituted 4-10 membered heterocyclyl or 5-10 membered heteroaryl ;
- R 5 is selected from H, halogen, C1-C6 alkyl, halogenated C1-C6 alkyl and C1-C6 alkoxy;
- R 6 is selected from H, C1-C6 alkyl, halogenated C1-C6 alkyl and C1-C6 alkoxy.
- ring A is C3-C8 cycloalkyl or 3-7 membered heterocyclyl.
- Ring A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl , piperazinyl, oxetanyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl and morpholinyl.
- ring A is substituted with 1, 2 or 3 C1-C6 groups selected from halogen, hydroxy, cyano, C1-C6 alkyl, halogenated C1-C6 alkyl, hydroxy Alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a R b , -NR a R b substituted carbonyl, -NR a R b substituted C1-C6 alkyl, C1-C6 Alkylcarbonyl, C1-C6alkoxycarbonyl, optionally substituted 6-14-membered aryl, optionally substituted 5-10-membered heteroaryl, optionally substituted 4-10-membered heterocyclyl, optionally substituted 6-14-membered aryl, optionally substituted 5-10-membered heteroaryl, optionally substituted 4-10-membered heterocyclyl, optionally substituted 6-14-membered aryl, optionally substituted 5-10-
- Ring A is cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, oxetanyl, azetidine or tetrahydrofuranyl,
- Ring A is optionally surrounded by 1, 2 or 3 selected from F, Cl, Br, CF3 , CH3 , -OH, -OCH3 , -NH2 , - Substituents of NHCH 3 ,-NH 2 (CH 3 ) 2 are substituted.
- R 0 is a C1-C6 alkyl group substituted by -NR 3 R 4 ; wherein R 3 and R 4 are each independently selected from H, optionally by 1, 2, 3, 4, 5 or 6 C1-C6 alkyl substituted with substituents selected from halogen, cyano, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a R b and hydroxy, or R 3 and R 4 together with the nitrogen atom to which it is attached forms azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, 2-piperazinone, morpholinyl, pyridyl, pyrrolyl, pyrazolyl , imidazo
- R 0 is a C1-C6 alkyl substituted with -NR 3 R 4 , and wherein R 3 and R 4 together with the nitrogen atom to which they are attached form an azetidinyl group , pyrrolidinyl, piperidinyl, piperazinyl, 2-piperazinone, morpholinyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazine base, indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl,
- R 0 is a C1-C6 alkyl substituted by -NR 3 R 4 , wherein R 3 and R 4 together with the nitrogen atom to which they are attached form an azetidinyl group, Pyrrolidinyl, piperidinyl, piperazinyl, 2-piperazinone, morpholinyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl , indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzis
- the compounds of formula I described in the present invention or their pharmaceutically acceptable salts, or their enantiomers, diastereomers, tautomers, isotopic substitutions, solvates,
- X 3 and/or X 5 are CR 5 .
- R 5 is selected from H and C1-C4 alkyl.
- X 4 is -(CH 2 ) n -, and n is 1 or 2; and wherein the -(CH 2 ) n - is optionally selected from 1 or 2 by 1 or 2 Substituents of halogen, hydroxy, amino, C1-C6 alkyl and halogenated C1-C6 alkyl are substituted.
- L 1 is selected from C1-C6 alkylene, C1-C6 alkylene-O-, C1-C6 alkylene-NH-, C1-C6 alkylene- S- and C2-C4 alkenylene, the C1-C6 alkylene, C1-C6 alkylene-O-, C1-C6 alkylene-NH-, C1-C6 alkylene-S- and The C2-C4 alkenylene group is optionally substituted with 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl and hydroxy.
- L1 is selected from C1 -C6 alkylene or C1-alkylene optionally substituted with 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl and hydroxy C6 alkylene-NH-.
- R 1 is selected from optionally substituted C3-C8 cycloalkyl, optionally substituted 6-14-membered aryl, optionally substituted 5-10-membered heteroaryl and Optionally substituted 4-10 membered heterocyclyl, and each of said cycloalkyl, aryl, heteroaryl and heterocyclyl may be optionally Substituent substitution of -C6 alkyl, halogen, hydroxy, C1-C6 alkoxy, C1-C6 haloalkyl and cyano; wherein, the optionally substituted amino is -NR a R b , wherein R a and R b is each independently H or C1-C6 alkyl.
- R 1 is selected from optionally substituted phenyl, naphthyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, Triazinyl, indolyl, isoindolyl, indazolyl, benzimidazolyl, pyridoimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl, Pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, pyranyl, pyridodihydrofuranyl, pyri
- the L 1 is C1-C4 alkylene or C1-C4 alkylene-NH-
- R 1 is pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl or The pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl or Optionally substituted with 1 or 2 substituents selected from halogen, C1-C4 alkyl and -NR a R b , wherein R a and R b are each independently H or C1-C4 alkyl.
- L 2 is selected from a bond and a C1-C6 alkylene group, wherein the C1-C6 alkylene group is optionally surrounded by 1, 2 or 3 selected from halogen, C1 Substituent substitution of -C3 alkyl, C3-C5 cycloalkyl and hydroxy.
- R 2 is optionally replaced by 1, 2 or 3 selected from -NR a R b , cyano, C1-C6 alkyl, halogen, hydroxy, C1-C6 alkoxy base, halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkyl-O-, 6-14-membered aryl, 5-10-membered heteroaryl and cyano substituents; wherein, R a and R b are each independently H or C1-C6 alkyl; and wherein, the heteroaryl group is preferably a heteroaryl group containing 1 or 2 ring nitrogen atoms, preferably
- R 2 is selected from 6-14-membered aryl, 5-10-membered heteroaryl and 4-10-membered heterocyclic group, the 6-14-membered aryl, 5- 10-membered heteroaryl and 4-10-membered heterocyclyl are optionally surrounded by 1, 2 or 3 members selected from -NR a R b , cyano, C1-C6 alkyl, halogen, hydroxy, C1-C6 alkoxy , halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkyl-O-, 6-14-membered aryl, 5-10-membered heteroary
- R 2 is selected from phenyl, naphthyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl, Indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl, azetidine Alkyl, pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, pyranyl, pyridodihydrofuranyl, pyr
- L 2 is C1-C4 alkylene
- R 2 is 1 or 2 selected from C1-C6 alkoxy, halogen, C1-C6 alkyl, cyano, 6-14-membered aryl, 5-10-membered nitrogen-containing heteroaryl or 4-10-membered heterocyclic substituted by substituents of C3-C8 cycloalkyl-O- and halogenated C1-C6 alkoxy, preferably Phenyl, pyridyl, pyrazolyl, pyrrolopyridyl, pyridodihydrofuranyl, pyrido1,3-dioxocyclopentenyl or indolyl.
- ring A is a C3-C6 cycloalkyl or a 4-8 membered heterocyclyl, and the cycloalkyl or heterocyclyl is optionally selected from 1, 2 or 3 Substituents from halogen, C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy;
- X 3 and X 5 are both CH;
- X 4 is CH 2 ;
- L 1 is C1-C4 alkylene
- R 1 is a 5- or 6-membered nitrogen-containing heteroaryl optionally substituted with 1 or 2 substituents selected from halogen, C1-C4 alkyl and -NR a R b , the 5 or 6-membered nitrogen-containing heteroaryl
- the group is preferably pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl or wherein, R a and R b are each independently H or C1-C4 alkyl;
- L 2 is C1-C4 alkylene
- R 2 is phenyl, 5-10-membered nitrogen-containing heteroaryl or 4-10-membered heterocyclic group, preferably pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyrazinyl, pyrrolopyridyl , pyridodihydrofuranyl, pyrido1,3-dioxocyclopentenyl or indolyl, each of said phenyl, 5-10-membered nitrogen-containing heteroaryl and 4-10-membered heterocyclyl is optional ground is substituted with 1 or 2 substituents selected from C1-C6 alkoxy, halogen, C1-C6 alkyl, cyano, C3-C8 cycloalkyl-O- and halogenated C1-C6 alkoxy;
- R 0 is C1-C4 alkyl substituted by -NR 3 R 4 ; wherein, R 3 and R 4 are each independently selected from H, C1 optionally substituted with 1-6 substituents selected from hydroxy, cyano and halogen -C6 alkyl and optionally 1, 2 or 3 selected from halogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a 4-8-membered heterocyclic group substituted by substituents of R b and hydroxy, wherein R a and R b are each independently H or C1-C4 alkyl; or R 3 and R 4 together with the nitrogen atom to which they are attached form optionally by 1, 2 or 3 selected from halogen, C1-C6 alkyl, C3-C6 cycloalkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, hal
- Ring A is a C3-C6 cycloalkyl optionally surrounded by 1, 2 or 3 selected from halogen, C1-C4 alkyl and halogenated C1 Substituent substitution of -C4 alkyl;
- X 3 and X 5 are both CH;
- X 4 is CH 2 ;
- L 1 is C1-C4 alkylene
- R 1 is a 5- or 6-membered nitrogen-containing heteroaryl substituted by 1 or 2 substituents selected from C1-C4 alkyl and -NR a R b , preferably pyridyl, pyrrolyl, pyrazolyl, imidazolyl , triazolyl, pyrimidinyl, pyrazinyl, triazinyl, or wherein, R a and R b are each independently H or C1-C4 alkyl;
- L 2 is C1-C4 alkylene
- R 2 is a 5-10-membered nitrogen-containing heteroaryl group or a 4-10-membered heterocyclic group, preferably pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyrazinyl, pyrrolopyridyl, pyrido Dihydrofuranyl, pyrido1,3-dioxolyl or indolyl, each of the 5-10-membered nitrogen-containing heteroaryl or 4-10-membered heterocyclic group is optionally selected from 1 or 2 Substituents from C1-C6alkoxy, C1-C6alkyl, C3-C8cycloalkyl-O-, halogenated C1-C6alkoxy, halogen and cyano;
- R 0 is -NR 3 R 4 substituted C1-C4 alkyl, wherein R 3 and R 4 are each independently selected from H and optionally by 1, 2, 3, 4, 5 or 6 selected from hydroxyl, cyano A C1-C6 alkyl group substituted with a halogen substituent, or R3 and R4 together with the nitrogen atom to which they are attached form optionally substituted by 1 , 2 or 3 groups selected from halogen, hydroxy, C1-C4 alkoxy, C3 -C6 alkoxy and C1-C4 alkyl substituted 4-8-membered heterocyclic group, preferably, the 4-8-membered heterocyclic group is selected from azetidinyl, pyrrolidinyl, piperidinyl, Piperazinyl, Morpholinyl,
- a compound of formula II or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvate, Polymorphs, prodrugs or metabolites:
- Ring A is a substituted or unsubstituted 3-8 membered saturated or unsaturated carbocyclic ring or a substituted or unsubstituted 3-8 membered saturated or unsaturated heterocyclic ring, the heterocyclic ring contains 1-2 independently selected from N, O and heteroatoms of S;
- L 2 is selected from bond, optionally substituted C1-C6 alkylene, optionally substituted C1-C6 alkylene-O-, optionally substituted C1-C6 alkylene-NH-, optionally substituted C1 -C6 alkylene-S- and optionally substituted C2-C4 alkenylene;
- R 0 is selected from H, C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, -C(O)NR 3 R 4 , -CH 2 OR 3 , - NR 3 R 4 substituted C1-C6 alkyl;
- R is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl;
- R 3 and R 4 are each independently selected from H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, optionally substituted 4-10 membered Heterocyclyl and optionally substituted 5-10 membered heteroaryl; alternatively, R and R together with the nitrogen atom to which they are attached form an optionally substituted 4-10 membered heterocyclyl or 5-10 membered heteroaryl ;and
- Rc and Rd are each independently H or C1-C4 alkyl.
- ring A is C3-C8 cycloalkyl or 3-7 membered heterocyclyl.
- Ring A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl , piperazinyl, oxetanyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl and morpholinyl.
- ring A is substituted with 1, 2 or 3 C1-C6 groups selected from halogen, hydroxy, cyano, C1-C6 alkyl, halogenated C1-C6 alkyl, hydroxy Substituent substitution of alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a R b , C1-C6 alkylcarbonyl and C1-C6 alkoxycarbonyl, the R a and R b is each independently selected from H and C1-C6 alkyl.
- ring A is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexane, azetidine, oxetanyl, azetidine, tetrahydrofuran base or oxane.
- Ring A is optionally surrounded by 1, 2 or 3 selected from F, Cl, Br, CF3 , CH3 , -OH, -OCH3 , -NH2 , - Substituents of NHCH 3 ,-NH 2 (CH 3 ) 2 are substituted.
- R 0 is a C1-C6 alkyl group substituted by -NR 3 R 4 ; wherein R 3 and R 4 are each independently selected from H, optionally by 1, 2, 3, 4, 5 or 6 C1-C6 alkyl substituted with substituents selected from halogen, cyano, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a R b and hydroxy, or R 3 and R 4 together with the nitrogen atom to which it is attached forms azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, 2-piperazinone, morpholinyl, pyridyl, pyrrolyl, pyrazolyl , imidazo
- R 0 is a C1-C6 alkyl substituted with -NR 3 R 4 , and wherein R 3 and R 4 together with the nitrogen atom to which they are attached form an azetidinyl group , pyrrolidinyl, piperidinyl, piperazinyl, 2-piperazinone, morpholinyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazine base, indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl,
- R 0 is a C1-C6 alkyl substituted by -NR 3 R 4 , wherein R 3 and R 4 together with the nitrogen atom to which they are attached form an azetidinyl group, Pyrrolidinyl, piperidinyl, piperazinyl, 2-piperazinone, morpholinyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl , indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzis
- Rc and Rd are each independently H or methyl.
- L 2 is selected from a bond and a C1-C6 alkylene group, wherein the C1-C6 alkylene group is optionally surrounded by 1, 2 or 3 selected from halogen, C1 Substituent substitution of -C3 alkyl, C3-C5 cycloalkyl and hydroxy.
- R 2 is optionally replaced by 1, 2 or 3 selected from -NR a R b , cyano, C1-C6 alkyl, halogen, hydroxy, C1-C6 alkoxy base, halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkyl-O-, 6-14-membered aryl, 5-10-membered heteroaryl and cyano substituents; wherein, R a and R b are each independently H or C1-C6 alkyl; and wherein, the heteroaryl group is preferably a heteroaryl group containing 1 or 2 ring nitrogen atoms, preferably
- R 2 is selected from 6-14-membered aryl, 5-10-membered heteroaryl and 4-10-membered heterocyclic group
- the 6-14-membered aryl, 5- 10-membered heteroaryl and 4-10-membered heterocyclyl can be optionally surrounded by 1, 2 or 3 members selected from -NR a R b , cyano, C1-C6 alkyl, halogen, hydroxy, C1-C6 alkoxy base, halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkyl-O-, 6-14-membered aryl, 5-10-membered hetero
- R 2 is selected from phenyl, naphthyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl, Indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl, azetidine Alkyl, pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, pyranyl, pyridodihydrofuranyl, pyr
- L 2 is C1-C4 alkylene
- R 2 is phenyl, pyridyl, pyrazolyl, pyrrolopyridyl, pyridodihydrofuranyl, pyrido1 ,3-dioxolyl or indolyl
- the phenyl, pyridyl, pyrazolyl, pyrrolopyridyl, pyridodihydrofuranyl, pyrido1,3-dioxolyl or indolyl optionally by 1 or 2 selected from C1-C6 alkoxy, halogen, C1-C6 alkyl, cyano, C3-C8 cycloalkyl-O-
- Ring A is a C3-C6 cycloalkyl optionally substituted with a substituent selected from F, Cl, hydroxy or C1-C4 alkyl, or contains 1 nitrogen or 1 C4-C6 heterocyclyl of O, preferably cyclopropyl, cyclobutyl, oxetanyl or azetidine optionally substituted by F or C1-C4 alkyl;
- R 0 is a C1-C4 alkyl substituted by H or -NR 3 R 4 , wherein R 3 and R 4 are each independently selected from H, 4-6 membered heterocyclyl and optionally 1, 2, 3, 4, C1-C6 alkyl substituted with 5 or 6 substituents selected from hydroxy, cyano and halogen, or R3 and R4 taken together with the nitrogen atom to which they are attached form optionally substituted by 1, 2 or 3 substituents selected from halogen, 4-6-membered heterocyclic group substituted by hydroxyl, C1-C4 alkoxy, C3-C6 cycloalkyl and C1-C4 alkyl; wherein, the 4-6-membered heterocyclic group preferably contains oxygen and/or nitrogen
- the heterocyclic group is preferably selected from oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, 2-pipe
- L 2 is C1-C4 alkylene
- R 2 is a 6-14-membered aryl group, a 5-10-membered nitrogen-containing heteroaryl group or a 4-10-membered heterocyclic group, preferably phenyl, pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyridine oxazinyl, indolyl, pyrrolopyridyl, pyridodihydrofuranyl, pyrido1,3-dioxolyl,
- the 6-14-membered aryl group, 5-10-membered nitrogen-containing heteroaryl group or 4-10-membered heterocyclic group are each optionally selected from 1 or 2 C1-C6 alkoxy, C1-C4 alkyl, halogen , C3-C6 cycloalkyl-oxy, halogenated C1-C4 alkoxy and cyano substituents;
- Rc and Rd are each independently H or C1-C4 alkyl.
- ring A is a C3-C6 cycloalkyl or a 4-8 membered heterocyclyl, and the cycloalkyl or heterocyclyl is optionally selected from 1, 2 or 3 Substituents from halogen, C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy;
- L 2 is C1-C4 alkylene
- R 2 is phenyl, 5-10-membered nitrogen-containing heteroaryl or 4-10-membered heterocyclic group, preferably pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyrazinyl, pyrrolopyridyl , pyridodihydrofuranyl or pyrido1,3-dioxolane or indolyl, each of said phenyl, 5-10-membered nitrogen-containing heteroaryl and 4-10-membered heterocyclyl is optional ground is substituted with 1 or 2 substituents selected from C1-C6 alkoxy, halogen, C1-C6 alkyl, cyano, C3-C8 cycloalkyl-O- and halogenated C1-C6 alkoxy;
- R 0 is C1-C4 alkyl substituted by -NR 3 R 4 ; wherein, R 3 and R 4 are each independently selected from H, C1 optionally substituted with 1-6 substituents selected from hydroxy, cyano and halogen -C6 alkyl and optionally 1, 2 or 3 selected from halogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a 4-8-membered heterocyclic group substituted by substituents of R b and hydroxy, wherein R a and R b are each independently H or C1-C4 alkyl; or R 3 and R 4 together with the nitrogen atom to which they are attached form optionally by 1, 2 or 3 selected from halogen, C1-C6 alkyl, C3-C6 cycloalkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, hal
- Rc and Rd are each independently H or C1-C4 alkyl.
- Ring A is a C3-C6 cycloalkyl optionally surrounded by 1, 2 or 3 selected from halogen, C1-C4 alkyl and halogenated C1 Substituent substitution of -C4 alkyl;
- L 2 is C1-C4 alkylene
- R 2 is a 5-10-membered nitrogen-containing heteroaryl group or a 4-10-membered heterocyclic group, preferably pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyrazinyl, pyrrolopyridyl, pyrido Dihydrofuranyl or pyrido1,3-dioxolyl or indolyl, the 5-10-membered nitrogen-containing heteroaryl group or the 4-10-membered heterocyclic group are each optionally selected from 1 or 2 Substituents from C1-C6alkoxy, C1-C6alkyl, C3-C8cycloalkyl-O-, halogenated C1-C6alkoxy, halogen and cyano;
- R 0 is -NR 3 R 4 substituted C1-C4 alkyl, wherein R 3 and R 4 are each independently selected from H and optionally by 1, 2, 3, 4, 5 or 6 selected from hydroxyl, cyano A C1-C6 alkyl group substituted with a halogen substituent, or R3 and R4 together with the nitrogen atom to which they are attached form optionally replaced by 1, 2 or 3 groups selected from halogen, hydroxy, C1- C4 alkoxy and C1 -C4 alkyl-substituted 4-8-membered heterocyclic group, preferably, the 4-8-membered heterocyclic group is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, 2-piperidine oxazinone group, morpholino group, and
- Rc and Rd are each independently H or C1-C4 alkyl.
- a compound of formula III or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvate thereof , polymorphs, prodrugs or metabolites, characterized in that,
- L 2 is selected from bond, optionally substituted C1-C6 alkylene, optionally substituted C1-C6 alkylene-O-, optionally substituted C1-C6 alkylene-NH-, optionally substituted C1 -C6 alkylene-S- and optionally substituted C2-C4 alkenylene;
- R 0 is selected from H, C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, -C(O)NR 3 R 4 , -CH 2 OR 3 , - NR 3 R 4 substituted C1-C6 alkyl;
- R is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl;
- R 3 and R 4 are each independently selected from H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, optionally substituted 4-10 membered Heterocyclyl and optionally substituted 5-10 membered heteroaryl; alternatively, R and R together with the nitrogen atom to which they are attached form an optionally substituted 4-10 membered heterocyclyl or 5-10 membered heteroaryl ;
- X 6 is each independently selected from C, O, N, S,
- q is an integer of 1, 2 or 3
- R 7 is selected from F, Cl, cyano, hydroxy, C1-C6 alkyl, fluoro or chloro C1-C6 alkyl, hydroxy substituted C1-C6 alkyl, C1-C6 alkoxy, fluoro or chloro Substituted C1-C6 alkoxy, hydroxy-substituted C1-C6 alkyl and -NR a R b ; wherein, said R a and R b are each independently selected from H and C1-C6 alkyl,
- n is an integer of 0, 1, 2 or 3;
- Rc and Rd are each independently H or C1-C4 alkyl.
- R 0 is a C1-C6 alkyl group substituted by -NR 3 R 4 ; wherein R 3 and R 4 are each independently selected from H, optionally by 1, 2, 3, 4, 5 or 6 C1-C6 alkyl substituted with substituents selected from halogen, cyano, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a R b and hydroxy, or R 3 and R 4 together with the nitrogen atom to which it is attached forms azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, 2-piperazinone, morpholinyl, pyridyl, pyrrolyl, pyrazolyl , imidazoly
- R 0 is a C1-C6 alkyl substituted with -NR 3 R 4 , and wherein R 3 and R 4 together with the nitrogen atom to which they are attached form an azetidinyl group , pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl, iso Indolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl, qui
- R 0 is a C1-C6 alkyl substituted by -NR 3 R 4 , wherein R 3 and R 4 together with the nitrogen atom to which they are attached form an azetidinyl group, Pyrrolidinyl, piperidinyl, piperazinyl, 2-piperazinone, morpholinyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl , indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzis
- Rc and Rd are each independently H or methyl.
- L 2 is selected from a bond and a C1-C6 alkylene group, wherein the C1-C6 alkylene group is optionally surrounded by 1, 2 or 3 selected from halogen, C1 Substituent substitution of -C3 alkyl, C3-C5 cycloalkyl and hydroxy.
- R 2 is optionally replaced by 1, 2 or 3 selected from -NR a R b , cyano, C1-C6 alkyl, halogen, hydroxy, C1-C6 alkoxy base, halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkyl-O-, 6-14-membered aryl, 5-10-membered heteroaryl and cyano substituents; wherein, R a and R b are each independently H or C1-C6 alkyl; and wherein, the heteroaryl group is preferably a heteroaryl group containing 1 or 2 ring nitrogen atoms, preferably
- R 2 is selected from 6-14-membered aryl, 5-10-membered heteroaryl and 4-10-membered heterocyclic group, the 6-14-membered aryl, 5- 10-membered heteroaryl and 4-10-membered heterocyclyl are optionally surrounded by 1, 2 or 3 members selected from -NR a R b , cyano, C1-C6 alkyl, halogen, hydroxy, C1-C6 alkoxy , halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkyl-O-, 6-14-membered aryl, 5-10-membered heteroary
- R 2 is selected from phenyl, naphthyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl, Indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl, azetidine Alkyl, pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, pyranyl, pyridodihydrofuranyl, pyr
- L 2 is C1-C4 alkylene
- R 2 is 1 or 2 selected from C1-C6 alkoxy, halogen, C1-C6 alkyl, cyano, 6-14-membered aryl, 5-10-membered nitrogen-containing heteroaryl or 4-10-membered heterocyclic substituted by substituents of C3-C8 cycloalkyl-O- and halogenated C1-C6 alkoxy, preferably Phenyl, pyridyl, pyrazolyl, pyrrolopyridyl, pyridodihydrofuranyl, pyrido1,3-dioxocyclopentenyl or indolyl.
- R 0 is H or -NR 3 R 4 substituted C1-C4 alkyl group, wherein R 3 and R 4 are each independently selected from H, 4-6 membered heterocyclic group and C1-C6 alkyl optionally substituted with 1, 2, 3, 4 , 5 or 6 substituents selected from hydroxy, cyano and halogen, or R and R together with the nitrogen atom to which they are attached form any 4-6-membered heterocyclic group substituted by 1, 2 or 3 members selected from halogen, hydroxyl, C1-C4 alkoxy and C1-C4 alkyl; wherein, the 4-6-membered heterocyclic group preferably contains Oxygen and/or nitrogen heterocyclyl, preferably selected from oxetanyl,
- L 2 is C1-C4 alkylene
- R 2 is a 6-14-membered aryl group, a 5-10-membered nitrogen-containing heteroaryl group or a 4-10-membered heterocyclic group, preferably phenyl, pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyridine oxazinyl, indolyl, pyrrolopyridyl, pyridodihydrofuranyl or pyrido1,3-dioxolyl, the 6-14-membered aryl, 5-10-membered nitrogen-containing heteroaryl or 4-10-membered heterocyclic groups are each optionally replaced by 1 or 2 groups selected from C1-C6 alkoxy, C1-C4 alkyl, halogen, C3-C6 cycloalkyl-oxy, halogenated C1-C4 alkoxy Substituent substitution of cyano group and cyano group;
- R c and R d are each independently H or C1-C4 alkyl
- X 6 is C or O
- q 1 or 2;
- R 7 is selected from F, Cl, cyano, hydroxy, C1-C6 alkyl, fluoro or chloro C1-C6 alkyl, hydroxy substituted C1-C6 alkyl, C1-C6 alkoxy, fluoro or chloro Substituted C1-C6 alkoxy and hydroxy substituted C1-C6 alkyl.
- L 2 is C1-C4 alkylene
- R 2 is phenyl, 5-10-membered nitrogen-containing heteroaryl or 4-10-membered heterocyclic group, preferably pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyrazinyl, pyrrolopyridyl , pyridodihydrofuranyl or pyrido1,3-dioxolane or indolyl, each of said phenyl, 5-10-membered nitrogen-containing heteroaryl and 4-10-membered heterocyclyl is optional ground is substituted with 1 or 2 substituents selected from C1-C6 alkoxy, halogen, C1-C6 alkyl, cyano, C3-C8 cycloalkyl-O- and halogenated C1-C6 alkoxy;
- R 0 is C1-C4 alkyl substituted by -NR 3 R 4 ; wherein, R 3 and R 4 are each independently selected from H, C1 optionally substituted with 1-6 substituents selected from hydroxy, cyano and halogen -C6 alkyl and optionally 1, 2 or 3 selected from halogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a 4-8-membered heterocyclic group substituted by substituents of R b and hydroxy, wherein R a and R b are each independently H or C1-C4 alkyl; or R 3 and R 4 together with the nitrogen atom to which they are attached form optionally by 1, 2 or 3 selected from halogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy,
- R c and R d are each independently H or C1-C4 alkyl
- X 6 is C or O
- q 1 or 2;
- R 7 is selected from F, Cl, cyano, hydroxy, C1-C6 alkyl, fluoro or chloro C1-C6 alkyl, hydroxy substituted C1-C6 alkyl, C1-C6 alkoxy, fluoro or chloro Substituted C1-C6 alkoxy and hydroxy substituted C1-C6 alkyl.
- L 2 is C1-C4 alkylene
- R 2 is a 5-10-membered nitrogen-containing heteroaryl group or a 4-10-membered heterocyclic group, preferably pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyrazinyl, pyrrolopyridyl, pyrido Dihydrofuranyl or pyrido1,3-dioxolyl or indolyl, the 5-10-membered nitrogen-containing heteroaryl group or the 4-10-membered heterocyclic group are each optionally selected from 1 or 2 Substituents from C1-C6alkoxy, C1-C6alkyl, C3-C8cycloalkyl-O-, halogenated C1-C6alkoxy, halogen and cyano;
- R 0 is -NR 3 R 4 substituted C1-C4 alkyl, wherein R 3 and R 4 are each independently selected from H and optionally by 1, 2, 3, 4, 5 or 6 selected from hydroxyl, cyano C1-C6 alkyl substituted with a halogen substituent, or R3 and R4 together with the nitrogen atom to which they are attached form a 4 optionally substituted with 1, 2 or 3 selected from halogen, hydroxy and C1-C4 alkyl -8-membered heterocyclic group, preferably, the 4-8 membered heterocyclic group is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,
- R c and R d are each independently H or C1-C4 alkyl
- X 6 is C or O
- q 1 or 2;
- R 7 is selected from F, Cl, cyano, hydroxy, C1-C6 alkyl, fluoro or chloro C1-C6 alkyl, hydroxy substituted C1-C6 alkyl, C1-C6 alkoxy, fluoro or chloro Substituted C1-C6 alkoxy and hydroxy substituted C1-C6 alkyl.
- a compound of formula I or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution thereof, Solvate, Polymorph, Prodrug or Metabolite:
- Ring A is a substituted or unsubstituted 3-8 membered saturated carbocyclic ring or a substituted or unsubstituted 3-8 membered saturated heterocyclic ring containing 1-2 heteroatoms independently selected from N, O and S;
- X 3 is selected from CR 5 and N;
- X 5 is selected from N and CR 5 ;
- L 1 is selected from bond, optionally substituted C1-C6 alkylene, optionally substituted C1-C6 alkylene-O-, optionally substituted C1-C6 alkylene-NH-, optionally substituted C1 -C6 alkylene-S- and optionally substituted C2-C4 alkenylene;
- L 2 is selected from bond, optionally substituted C1-C6 alkylene, optionally substituted C1-C6 alkylene-O-, optionally substituted C1-C6 alkylene-NH-, optionally substituted C1 -C6 alkylene-S- and optionally substituted C2-C4 alkenylene;
- R 0 is selected from optionally substituted C1-C6 haloalkyl, -C(O)NR 3 R 4 , -CH 2 OR 3 and -NR 3 R 4 substituted C1-C6 alkyl;
- R 1 is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted amino and guanidino;
- R is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl;
- R 3 and R 4 are each independently selected from H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, optionally substituted 4-10 membered Heterocyclyl and optionally substituted 5-10 membered heteroaryl; alternatively, R and R together with the nitrogen atom to which they are attached form an optionally substituted 4-10 membered heterocyclyl or 5-10 membered heteroaryl ;
- R 5 is selected from H, halogen, C1-C6 alkyl, halogenated C1-C6 alkyl and C1-C6 alkoxy;
- R 6 is selected from H, C1-C6 alkyl, halogenated C1-C6 alkyl and C1-C6 alkoxy.
- ring A is C3-C8 cycloalkyl or 3-7 membered heterocyclyl.
- Ring A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl , piperazinyl, oxetanyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl and morpholinyl.
- Ring A is substituted with 1, 2 or 3 C1-C6 groups selected from halogen, hydroxy, cyano, C1-C6 alkyl, halogenated C1-C6 alkyl, hydroxy Substituents of alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy and -NR a R b are substituted; wherein said R a and R b are each independently selected from H and C1-C6 alkyl.
- Ring A is cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, oxetanyl, azetidine or tetrahydrofuranyl,
- Ring A is optionally surrounded by 1, 2 or 3 selected from F, Cl, Br, CF3 , CH3 , -OH, -OCH3 , -NH2 , - Substituent substitution of NHCH 3, -NH 2 (CH 3 ) 2 .
- R 0 is a C1-C6 alkyl group substituted by -NR 3 R 4 ; wherein R 3 and R 4 are each independently selected from H, optionally by 1, 2, 3, 4, 5 or 6 C1-C6 alkyl substituted with substituents selected from halogen, cyano, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a R b and hydroxy, or R 3 and R 4 together with the nitrogen atom to which it is attached forms azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, 2-piperazinone, morpholinyl, pyridyl, pyrrolyl, pyrazolyl , imidazo
- R 0 is a C1-C6 alkyl substituted with -NR 3 R 4 , and wherein R 3 and R 4 together with the nitrogen atom to which they are attached form an azetidinyl group , pyrrolidinyl, piperidinyl, piperazinyl, 2-piperazinone, morpholinyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazine base, indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl,
- R 0 is a C1-C6 alkyl substituted by -NR 3 R 4 , wherein R 3 and R 4 together with the nitrogen atom to which they are attached form an azetidinyl group, Pyrrolidinyl, piperidinyl, piperazinyl, 2-piperazinone, morpholinyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl , indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzis
- the compounds of formula I described in the present invention or their pharmaceutically acceptable salts, or their enantiomers, diastereomers, tautomers, isotopic substitutions, solvates,
- X 3 and/or X 5 are CR 5 .
- R 5 is selected from H and C1-C4 alkyl.
- X 4 is -(CH 2 ) n -, and n is 1 or 2; and wherein the -(CH 2 ) n - is optionally selected from 1 or 2 by 1 or 2 Substituents of halogen, hydroxy, amino, C1-C6 alkyl and halogenated C1-C6 alkyl are substituted.
- X3 and X5 are both CR5 ; and X4 is optionally substituted -( CH2 )-.
- L 1 is selected from C1-C6 alkylene, C1-C6 alkylene-O-, C1-C6 alkylene-NH-, C1-C6 alkylene- S- and C2-C4 alkenylene, the C1-C6 alkylene, C1-C6 alkylene-O-, C1-C6 alkylene-NH-, C1-C6 alkylene-S- and The C2-C4 alkenylene group may be optionally substituted with 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl and hydroxy.
- L 1 is selected from C1-C6 alkylene and C1-C6 alkylene-NH-, said C1-C6 alkylene and C1-C6 alkylene-NH - optionally substituted with 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl and hydroxy.
- R 1 is selected from optionally substituted C3-C8 cycloalkyl, optionally substituted 6-14-membered aryl, optionally substituted 5-10-membered heteroaryl and Optionally substituted 4-10 membered heterocyclyl, and each of said cycloalkyl, aryl, heteroaryl and heterocyclyl may be optionally Substituent substitution of -C6 alkyl, halogen, hydroxy, C1-C6 alkoxy, C1-C6 haloalkyl and cyano; wherein, the optionally substituted amino is -NR a R b , wherein R a and R b is each independently H or C1-C6 alkyl.
- R 1 is selected from optionally substituted phenyl, naphthylpyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazolyl Azinyl, pyridoimidazolyl, indolyl, isoindolyl, indazolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl, pyrrole Alkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, pyranyl, pyridodihydrofuranyl, pyr
- the L 1 is C1-C4 alkylene or C1-C4 alkylene-NH-
- R 1 is pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl or The pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl or Optionally substituted with 1 or 2 substituents selected from halogen, C1-C4 alkyl and -NR a R b , wherein R a and R b are each independently H or C1-C4 alkyl.
- L 2 is selected from a bond and a C1-C6 alkylene group, wherein the C1-C6 alkylene group is optionally surrounded by 1, 2 or 3 selected from halogen, C1 Substituent substitution of -C3 alkyl, C3-C5 cycloalkyl and hydroxy.
- R 2 is optionally replaced by 1, 2 or 3 selected from -NR a R b , cyano, C1-C6 alkyl, halogen, hydroxy, C1-C6 alkoxy base, halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkyl-O-, 6-14-membered aryl, 5-10-membered heteroaryl and cyano substituents; wherein, R a and R b are each independently H or C1-C6 alkyl; and wherein, the heteroaryl group is preferably a heteroaryl group containing 1 or 2 ring nitrogen atoms, preferably
- R 2 is selected from 6-14-membered aryl, 5-10-membered heteroaryl and 4-10-membered heterocyclic group
- the 6-14-membered aryl, 5- 10-membered heteroaryl and 4-10-membered heterocyclyl can be optionally surrounded by 1, 2 or 3 members selected from -NR a R b , cyano, C1-C6 alkyl, halogen, hydroxy, C1-C6 alkoxy base, halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkyl-O-, 6-14-membered aryl, 5-10-membered hetero
- R 2 is selected from phenyl, naphthyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl, Indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl, azetidine Alkyl, pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, pyranyl, pyridodihydrofuranyl, pyr
- L 2 is a C1-C4 alkylene group
- R 2 is a 6-14-membered aryl group, a 5-10-membered nitrogen-containing heteroaryl group or a 4-10-membered heterocyclic group
- the 6-14-membered aryl group, 5-10-membered nitrogen-containing heteroaryl group or 4-10-membered heterocyclic group is optionally replaced by 1 or 2 members selected from C1-C6 alkoxy, halogen, C1-C6 alkyl , cyano, C3-C8 cycloalkyl-O- and halogenated C1-C6 alkoxy substituents, preferably phenyl, pyridyl, pyrazolyl, pyrrolopyr
- ring A is a C3-C6 cycloalkyl or a 4-8 membered heterocyclyl, and the cycloalkyl or heterocyclyl is optionally selected from 1, 2 or 3 Substituted from substituents of halogen, C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy and halogenated C1-C4 alkoxy;
- X 3 and X 5 are both CH;
- X 4 is CH 2 ;
- L 1 is C1-C4 alkylene
- L 2 is C1-C4 alkylene
- R 2 is phenyl, 5-10-membered nitrogen-containing heteroaryl or 4-10-membered heterocyclic group, preferably pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyrazinyl, pyrrolopyridyl , pyridodihydrofuranyl or pyrido1,3-dioxolane or indolyl, each of said phenyl, 5-10-membered nitrogen-containing heteroaryl and 4-10-membered heterocyclyl is optional ground is substituted with 1 or 2 substituents selected from C1-C6 alkoxy, halogen, C1-C6 alkyl, cyano, C3-C8 cycloalkyl-O- and halogenated C1-C6 alkoxy;
- R 0 is C1-C4 alkyl substituted by -NR 3 R 4 ; wherein, R 3 and R 4 are each independently selected from H, C1 optionally substituted with 1-6 substituents selected from hydroxy, cyano and halogen -C6 alkyl and optionally 1, 2 or 3 selected from halogen, C1-C6 alkyl, C3-C6 cycloalkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1- 4-8-membered heterocyclic group substituted by substituents of C6 alkoxy, -NR a R b and hydroxy, wherein R a and R b are each independently H or C1-C4 alkyl; or R 3 and R 4 are their The attached nitrogen atoms are taken together to form optionally 1, 2 or 3 atoms selected from the group consisting of halogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-
- Ring A is a C3-C6 cycloalkyl optionally surrounded by 1, 2 or 3 selected from halogen, C1-C4 alkyl and halogenated C1 Substituent substitution of -C4 alkyl;
- X 3 and X 5 are both CH;
- X 4 is CH 2 ;
- L 1 is C1-C4 alkylene
- L 2 is C1-C4 alkylene
- R 2 is a 5-10-membered nitrogen-containing heteroaryl group or a 4-10-membered heterocyclic group, preferably pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyrazinyl, pyrrolopyridyl, pyrido Dihydrofuranyl or pyrido1,3-dioxolyl or indolyl, the 5-10-membered nitrogen-containing heteroaryl group or the 4-10-membered heterocyclic group are each optionally selected from 1 or 2 Substituents from C1-C6alkoxy, C1-C6alkyl, C3-C8cycloalkyl-O-, halogenated C1-C6alkoxy, halogen and cyano;
- R 0 is -NR 3 R 4 substituted C1-C4 alkyl, wherein R 3 and R 4 are each independently selected from H and optionally by 1, 2, 3, 4, 5 or 6 selected from hydroxyl, cyano A C1-C6 alkyl group substituted with a halogen substituent, or R3 and R4 together with the nitrogen atom to which they are attached form optionally replaced by 1, 2 or 3 groups selected from halogen, hydroxy, C1- C4 alkoxy and C1 -C4 alkyl substituted 4-8-membered heterocyclic group, preferably, the 4-8-membered heterocyclic group is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl ,
- a pharmaceutical composition which contains the compound described in this application, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, or isomer thereof.
- a compound described in this application or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, or isotopic substitution thereof , solvate, polymorph, prodrug or metabolite in the manufacture of a medicament for the treatment or prevention of WDR5-mediated diseases.
- WDR5-mediated diseases include Kabuki syndrome, and various solid and hematological tumors.
- the WDR5-mediated diseases include Noonan syndrome, Leopard syndrome, neuroblastoma, sarcoma, melanoma, articular chondroma, cholangiomas, leukemia, breast cancer, gastrointestinal stromal tumors, histiocytes lymphoma, lung cancer, esophageal cancer, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, cervical cancer, ovarian cancer, colon cancer, nasopharyngeal cancer, brain cancer, bone cancer, kidney cancer, oral cavity cancer cancer, head cancer, neuroblastoma, squamous cell carcinoma of the head and neck, anaplastic large cell lymphoma or glioblastoma, wherein the leukemia is preferably juvenile myelomonocytic leukemia, human myelomonocytic leukemia, Lung cancer is preferably non-small cell lung cancer, small cell lung cancer, lung squamous cell carcinoma, and lung
- the inventors prepared a novel heterocyclic compound compound represented by formula I, which can inhibit the growth of tumor cells by blocking the WDR5 protein-protein interaction.
- the compound of the present invention exhibits good biological activity and druggability, and has a good prospect for drug development. It can inhibit the WDR5 protein-protein interaction at a very low concentration (can be as low as ⁇ 100 nM/L).
- the inhibitory activity is quite excellent, so it can be used to treat diseases or conditions related to WDR5, such as tumors.
- reaction and purification can be carried out using the manufacturer's instructions for use of the kit, or in a manner well known in the art or as described in the present invention.
- the techniques and methods described above can generally be carried out according to conventional methods well known in the art from the descriptions in the various general and more specific documents cited and discussed in this specification.
- groups and their substituents can be selected by those skilled in the art to provide stable moieties and compounds.
- substituents When substituents are described by conventional chemical formulae written from left to right, the substituents also include the chemically equivalent substituents obtained when the structural formula is written from right to left. For example, -CH2O- is equivalent to -OCH2- .
- C1-C6 alkyl refers to an alkyl group as defined below having a total of 1 to 6 carbon atoms.
- the total number of carbon atoms in the simplified notation does not include carbons that may be present in the substituents of the group.
- halogen refers to fluorine, chlorine, bromine or iodine.
- Hydroxyalkyl refers to an alkyl group as defined below substituted with hydroxy (-OH).
- Niro refers to -NO2 .
- Cyano refers to -CN.
- Amino refers to -NH2 .
- Substituted amino refers to an amino group substituted with one or two alkyl, alkylcarbonyl, alkyl-substituted aminocarbonyl, aralkyl, heteroaralkyl as defined below, eg, monoalkylamino, Dialkylamino, alkylamido, aralkylamino, heteroaralkylamino, alkylaminocarbonylamino.
- Carboxyl refers to -COOH.
- alkyl as a group or part of another group (eg, as used in a halogen (eg, fluorine, chlorine, bromine, or iodine) substituted alkyl group, etc.), refers to fully saturated A straight or branched hydrocarbon chain radical consisting only of carbon atoms and hydrogen atoms, having, for example, 1 to 12 (preferably 1 to 8, more preferably 1 to 6) carbon atoms, and is bonded to the molecule by a single bond the rest of the connection.
- halogen eg, fluorine, chlorine, bromine, or iodine
- Alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2 - Dimethylpropyl, n-hexyl, heptyl, 2-methylhexyl, 3-methylhexyl, octyl, nonyl and decyl, etc. More preferred alkyl groups are C1-C4 alkyl groups.
- alkylene refers to a divalent alkyl group such as -( CH2 ) n- , wherein n is an integer from 1-12, preferably an integer from 1-6, more preferably an integer from 1-4.
- the divalent alkyl group can also be a straight chain or branched chain group, such as -CH( CH3 ) CH2-, -CH2CH ( CH3 ) CH2-, and the like.
- alkenyl as a group or part of another group means consisting only of carbon and hydrogen atoms, containing at least one double bond, having, for example, 2 to 20 (preferably 2 to 10) a straight or branched hydrocarbon chain group having 2 to 6, more preferably 2 to 4) carbon atoms and connected to the rest of the molecule by a single bond.
- Alkenyl groups include, but are not limited to, vinyl, propenyl, allyl, but-1-enyl, but-2-enyl, pent-1-enyl, pent-1,4-dienyl, and the like.
- alkynyl as a group or part of another group, means consisting only of carbon and hydrogen atoms, containing at least one triple bond, having, for example, 2 to 20 (preferably 2 to 10 a straight or branched hydrocarbon chain group having 2 to 6, more preferably 2 to 4) carbon atoms and connected to the rest of the molecule by a single bond.
- Alkynyl groups include, but are not limited to, ethynyl, propynyl, and the like.
- alkoxy as a group or part of another group means “alkyl-O-", as defined herein.
- Preferred alkoxy groups are C1-C6 alkoxy groups, more preferably C1-C4 alkoxy groups, including but not limited to methoxy, ethoxy and the like.
- cyclohydrocarbyl means a stable non-aromatic monocyclic or polycyclic hydrocarbon group (eg, alkyl, alkenyl, etc.) consisting only of carbon atoms and hydrogen atoms. or alkynyl), which may include fused ring systems, bridged ring systems or spiro ring systems, having 3 to 15 carbon atoms, preferably 3 to 10 carbon atoms, more preferably 3 to 8 carbon atoms, such as 3 , 4, 5, 6, 7 or 8 carbon atoms, and it is saturated or unsaturated and can be linked to the rest of the molecule by a single bond through any suitable carbon atom.
- cyclohydrocarbyl means a stable non-aromatic monocyclic or polycyclic hydrocarbon group (eg, alkyl, alkenyl, etc.) consisting only of carbon atoms and hydrogen atoms. or alkynyl), which may include fused ring systems, bridged ring systems or spiro ring systems, having
- carbon atoms in a cyclic hydrocarbon group may be optionally oxidized.
- cyclohydrocarbyl refers to a cycloalkyl group having 3-8 ring carbon atoms.
- cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclooctyl, 1H-indene base, 2,3-indenyl, 1,2,3,4-tetrahydro-naphthyl, 5,6,7,8-tetrahydro-naphthyl, 8,9-dihydro-7H-benzoyl Cyclohepten-6-yl, 6,7,8,9-tetrahydro-5H-benzocycloheptenyl, 5,6,7,8,9,10-hexahydro-benzocyclooctenyl, Fluorenyl, bicyclo[2.2.1]heptyl, 7,7-dimethyl-bicyclo[2.2.1]heptyl,
- heterocyclyl as part of a group or other group means from 2 to 14 carbon atoms (eg 2, 3, 4, 5, 6, 7, 8, 9, 10 , 11, 12, 13 or 14 carbon atoms) and a stable 3- to 20-membered non-aromatic cyclic group consisting of 1 to 6 heteroatoms selected from nitrogen, phosphorus, oxygen and sulfur.
- the heterocyclyl group may be a monocyclic, bicyclic, tricyclic or more ring ring system, which may include a fused ring system, a bridged ring system or a spiro ring system;
- the nitrogen, carbon, or sulfur atoms of a can be optionally oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclyl group can be partially or fully saturated.
- a heterocyclyl group can be attached to the rest of the molecule via a carbon atom or a heteroatom and through a single bond.
- heterocyclyl containing fused rings one or more of the rings may be aryl or heteroaryl as defined below, provided that the point of attachment to the rest of the molecule is a non-aromatic ring atom.
- the heterocyclyl group is preferably a stable 4- to 11-membered non-aromatic monocyclic, bicyclic, bridged or spirocyclic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur group, more preferably a stable 4- to 10-membered non-aromatic monocyclic, bicyclic, bridged or spirocyclic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur.
- the number of ring atoms of a heterocyclyl group is 4-9, 4-8, or 4-7. In some embodiments, the number of ring atoms in the heterocyclyl group is 3-8, preferably 3-7, more preferably 3-6.
- heterocyclyl groups include, but are not limited to: azetidinyl, pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, thiomorpholinyl, 2,7-diazepine Hetero-spiro[3.5]nonan-7-yl, 2-oxa-6-aza-spiro[3.3]heptan-6-yl, 2,5-diaza-bicyclo[2.2.1]heptane -2-yl, azetidinyl, pyranyl, tetrahydropyranyl, thiopyranyl, pyridodihydrofuranyl, pyrido1,3-dioxocyclopentenyl, tetrahydrofuranyl, oxa azinyl, dioxolane, tetrahydroisoquinolinyl, decahydroisoquinolinyl, imid
- aryl means having 6 to 18 carbon atoms, such as 6 to 14 carbon atoms (preferably having 6 to 10 carbon atoms, such as 6 , 7, 8, 9 or 10 carbon atoms) conjugated hydrocarbon ring system group.
- an aryl group can be a monocyclic, bicyclic, tricyclic or more ring system, and can also be fused to a cycloalkyl or heterocyclic group as defined above, provided that the aryl group is via The atoms on the aromatic ring are connected to the rest of the molecule by single bonds.
- aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthryl, fluorenyl, 2,3-dihydro-1H-isoindolyl, 2-benzoxazolinone, 2H-1, 4-benzoxazin-3(4H)-one-7-yl and the like.
- arylalkyl refers to an alkyl group as defined above substituted with an aryl group as defined above.
- heteroaryl as a group or part of another group means a ring having 1 to 15 carbon atoms (preferably 1 to 10 carbon atoms, eg 1, 2, 3, 4 , 5, 6, 7, 8, 9 or 10 carbon atoms) and 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur, a 5- to 16-membered, preferably 5-10 membered, conjugated ring system group.
- a heteroaryl group can be a monocyclic, bicyclic, tricyclic or more cyclic ring system, and can also be fused to a cycloalkyl or heterocyclyl group as defined above, provided that the heterocyclic group
- the aryl group is attached to the rest of the molecule by a single bond through an atom on the aromatic ring.
- a nitrogen, carbon or sulfur atom in a heteroaryl group can optionally be oxidized; the nitrogen atom can optionally be quaternized.
- a heteroaryl group is preferably a stable 5- to 12-membered aromatic group containing 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, more preferably 1 to 4 selected heteroatoms.
- heteroaryl groups include, but are not limited to, thienyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, Benzimidazolyl, benzopyrazolyl, indolyl, furanyl, pyrrolyl, triazolyl, tetrazolyl, triazinyl, indazinyl, isoindolyl, indazolyl, isoindazolyl , purinyl, quinolinyl, isoquinolinyl, diazanaphthyl, naphthyridinyl,
- heteroarylalkyl refers to an alkyl group, as defined above, substituted with a heteroaryl group, as defined above.
- substituents described in the claims and specification sections of the present invention include, but are not limited to, alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloepoxy, haloalkenyl, haloalkyne , cyano, cycloalkyl-O-, nitro, amino, optionally substituted amino, alkoxy, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted One or more of cycloalkyl and optionally substituted heterocyclyl.
- substituents include, but are not limited to, C1-C6 alkyl, haloalkyl, haloepoxy, cycloalkyl, amino, C1-C6 alkyl substituted amino, halogen, cyano, C3- One or more of C8 cycloalkyl-O-, aryl and heteroaryl.
- the number of substituents may be 1-5, such as 1-3, depending on the structure of the substituted group.
- phenyl may be substituted with 1-3 substituents selected from C1-C6 alkoxy, C3-C8 cycloalkyl-O-, halogen and amino.
- WDR5 refers to WD40 domain repeat family protein 5
- WD40 domain refers to the smallest conserved unit comprising approximately 40 amino acids (typically supported by glycine-histidine and tryptophan-aspartic acid).
- moiety refers to a specific fragment or functional group in a molecule.
- a chemical moiety is usually thought of as a chemical entity embedded or attached to a molecule.
- intermediate compound functional groups may need to be protected by suitable protecting groups.
- suitable protecting groups include trialkylsilyl or diarylalkylsilyl groups (eg tert-butyldimethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl) , tetrahydropyranyl, benzyl, etc.
- Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxycarbonyl and the like.
- Suitable thiol protecting groups include -C(O)-R" (wherein R" is alkyl, aryl or aralkyl), p-methoxybenzyl, trityl, and the like.
- Suitable carboxyl protecting groups include alkyl, aryl or aralkyl esters.
- Protecting groups can be introduced and removed according to standard techniques known to those skilled in the art and as described herein. The use of protecting groups is described in detail in Greene, T.W. and P.G.M. Wuts, Protective Groups in Organi Synthesis, (1999), 4th Ed., Wiley.
- the protecting group can also be a polymeric resin.
- the compound of formula I of the present invention has the following formula structure:
- Ring A is a substituted or unsubstituted 3-8 membered saturated or unsaturated carbocyclic ring, a substituted or unsubstituted 3-8 membered saturated or unsaturated heterocyclic ring, and the heterocyclic ring contains 1-2 independently selected from N, O and heteroatoms of S;
- X 3 is selected from CR 5 and N;
- X 5 is selected from N and CR 5 ;
- L 1 is selected from bond, optionally substituted C1-C6 alkylene, optionally substituted C1-C6 alkylene-O-, optionally substituted C1-C6 alkylene-NH-, optionally substituted C1 -C6 alkylene-S- and optionally substituted C2-C4 alkenylene;
- L 2 is selected from bond, optionally substituted C1-C6 alkylene, optionally substituted C1-C6 alkylene-O-, optionally substituted C1-C6 alkylene-NH-, optionally substituted C1 -C6 alkylene-S- and optionally substituted C2-C4 alkenylene;
- R 0 is selected from H, C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl and -NR 3 R 4 substituted C1-C6 alkyl;
- R 1 is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted amino and guanidino;
- R is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl;
- R 3 and R 4 are each independently selected from H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, optionally substituted 4-10 membered Heterocyclyl and optionally substituted 5-10 membered heteroaryl; alternatively, R and R together with the nitrogen atom to which they are attached form an optionally substituted 4-10 membered heterocyclyl or 5-10 membered heteroaryl ;
- R 5 is selected from H, halogen, C1-C6 alkyl, halogenated C1-C6 alkyl and C1-C6 alkoxy;
- R 6 is selected from H, C1-C6 alkyl, halogenated C1-C6 alkyl and C1-C6 alkoxy.
- ring A is a C3-C8 cycloalkyl group, such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; or, ring A is a 3-7 membered heterocyclic group, such as azacyclopropyl, nitrogen Heterocyclobutyl, pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl and the like.
- the groups of Ring A described herein include the C atom shared by Ring A and the ring containing X 4 .
- Ring A may be optionally substituted with 1, 2 or 3 groups selected from halogen, cyano, hydroxy, C1-C6 alkyl, halogenated C1-C6 alkyl, hydroxy substituted C1-C6 alkyl, C1- C6 alkoxy, halogenated C1-C6 alkoxy, hydroxy substituted C1-C6 alkyl, -NR a R b , -NR a R b substituted carbonyl, -NR a R b substituted C1-C6 alkyl , C1-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, optionally substituted 6-14-membered aryl, optionally substituted 5-10-membered heteroaryl, optionally substituted C3-C8 cycloalkyl, Optionally substituted 4-10 membered heteroaryl, optionally substituted 6-14 membered aryl substituted C1-C6 alkyl, optionally substituted 5-10
- the substituents may be 1, 2 or 3 selected from halogen , C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a R b , -NR a R b substituted carbonyl, -NR a R Substituents of b -substituted C1-C6 alkyl, C1-C6 alkylcarbonyl, and C1-C6 alkoxycarbonyl.
- the R a and R b are each independently selected from H and C1-C6 alkyl.
- the substituent may be on C or on N.
- Ring A is a C3-C6 cycloalkyl or 3-6 membered heterocyclyl optionally surrounded by 1, 2 or 3 groups selected from C1-C4 alkyl, halogenated C1-C4 alkyl , hydroxy-substituted C1-C4 alkyl, -NR a R b substituted carbonyl and -NR a R b substituted C1-C4 alkyl substituents, wherein, said R a and R b are each independently selected from H and C1-C4 alkyl.
- X 3 is CR 5 .
- R 5 is selected from H and C1-C4 alkyl.
- X 4 is -(CH 2 ) n -, and n is 1 or 2.
- the number of substituents may be 1 or 2, and the substituents may be selected from halogen, hydroxyl, amino, C1-C6 alkyl and halogenated C1 -C6 alkyl, preferably halogen and C1-C6 alkyl.
- L 1 is selected from bond, C1-C6 alkylene, C1-C6 alkylene-O-, C1-C6 alkylene-NH-, C1-C6 alkylene-S- and C2-C4 alkylene Alkenyl, more preferably C1-C6 alkyl or C1-C6 alkylene-NH-.
- L 1 may be optionally substituted, the substituents may be selected from halogen, C1-C4 alkyl and hydroxyl, and the number of substituents may be 1, 2 or 3. It is understood that when the C1-C6 alkyl and C1-C6 alkylene- are substituted with C1-C4 alkyl, a branched alkyl or branched alkylene may be formed.
- R 1 is selected from optionally substituted C3-C8 cycloalkyl, optionally substituted 6-14 membered aryl, optionally substituted 5-10 membered heteroaryl and optionally substituted 4-10 membered heteroaryl ring base.
- preferred 6-14 membered aryl groups include phenyl and naphthyl.
- the preferred 5-10-membered heteroaryl group is a heteroaryl group with one or more (such as within 4 or within 3) ring nitrogen atoms, especially a 5- or 6-membered nitrogen-containing heteroaryl group, Including, but not limited to, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl (such as triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl and 1,3 , 4-triazolyl), pyrimidinyl, pyrazinyl, triazinyl.
- Heteroaryl groups can also be fused rings including, but not limited to, indolyl, isoindolyl, indazolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, pyrrolopyridyl, benzene And isoxazolyl, quinolyl and so on.
- Preferred heteroaryl groups are pyridyl, pyrrolyl, imidazolyl and triazolyl, more preferably imidazolyl and pyridyl.
- R 1 is a heteroaryl group, it is attached to L 1 through a nitrogen atom on the heteroaryl ring.
- preferred 5-10 membered heterocyclic groups include but are not limited to pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, pyranyl, pyridodihydrofuranyl, pyridine 1,3-dioxolyl, tetrahydropyranyl, tetrahydrofuranyl, oxazinyl, tetrahydroisoquinolinyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, quinolinyl , thiazolidinyl, isothiazolidinyl, isoxazolidinyl, indoline, octahydroindolyl, octahydroisoindolyl, pyrrolidinyl, pyrazolidine, phthalimide Amino etc.
- the cycloalkyl group, aryl group, heteroaryl group and heterocyclic group can each be optionally substituted by 1, 2 or 3 substituents, and the preferred substituents can be selected from optionally substituted amino, Alkyl (such as C1-C6 alkyl), halogen, hydroxyl, alkoxy (such as C1-C6 alkoxy), haloalkyl (such as C1-C6 haloalkyl) and cyano, etc.; wherein, optionally substituted amino Can be -NR a R b , wherein R a and R b are each independently H or C1-C6 alkyl; more preferably, the substituents on the cycloalkyl, aryl, heteroaryl and heterocyclyl Can be independently the optionally substituted amino, halo, alkyl and cyano.
- R 1 is an optionally substituted amino group or a guanidino group
- the substituent on the amino group can be an aminocarbonyl group optionally substituted by an alkyl group, that is, NR a R b -CO-, wherein R a and R b are each independently H or C1-C6 alkyl.
- R1 is substituted amino, halogen, alkyl and/or cyano substituted 5- or 6 -membered nitrogen-containing heteroaryl, especially substituted amino, halogen, alkyl and/or cyano substituted imidazole pyrimidinyl, pyrimidinyl, triazolyl, pyridyl, pyrazinyl, pyrrolyl and pyrazolyl, etc., more preferably substituted amino, halogen, alkyl and/or cyano substituted imidazolyl and pyridyl, wherein , the substituted amino group is preferably -NR a R b , wherein R a and R b are each independently H or C1-C6 alkyl.
- Ring A is cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, oxetanyl, azepanyl or tetrahydrofuranyl, which is optionally substituted by 1 , 2 or 3 substituents selected from F, Cl, Br, CF 3 , CH 3 , -OH, -OCH 3 , -NH 2 , -NHCH 3 , -NH 2 (CH 3 ) 2 are substituted.
- the L 1 is C1-C4 alkylene or C1-C4 alkylene-NH-
- R 1 is optionally 1 or 2 selected from halogen, cyano, C1-C4 5- or 6-membered nitrogen-containing heteroaryl substituted by substituents of alkyl and -NR a R b , preferably pyridyl, pyrrolyl, pyrazolyl, imidazolyl, imidazolone, pyridopyrrolyl, oxazolone group, oxazolidinone group, triazolyl group, pyrimidinyl group, pyrazinyl group, triazinyl group, wherein R a and R b are each independently H or C1-C4 alkyl group.
- the alkylene group may be a straight or branched chain alkylene group.
- L 2 may be selected from bonds, C3-C5 cycloalkyl and C1-C6 alkylene.
- L 2 may be optionally substituted with a substituent selected from halogen, C1-C3 alkyl, C3-C5 cycloalkyl and hydroxy, and the number of substituents may be 1, 2 or 3.
- Preferred L 2 is optionally substituted C1-C4 alkylene.
- the alkylene group may be a straight or branched chain alkylene group.
- R 2 is selected from optionally substituted 6-14 membered aryl, optionally substituted 5-10 membered heteroaryl and optionally substituted 4-10 membered heterocyclyl, more preferably optionally substituted mono Cyclic or bicyclic aryl, monocyclic or bicyclic heteroaromatic or monocyclic or bicyclic heterocyclyl.
- the aryl group is preferably phenyl or naphthyl.
- the heteroaryl group is preferably a heteroaryl group with one or more (such as within 4 or 3) ring nitrogen atoms, especially a 5-membered or 6-membered nitrogen-containing heteroaryl group, including but not limited to pyridyl, pyrrole base, pyrazolyl, imidazolyl, triazolyl (such as triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl and 1,3,4-triazolyl), Pyrimidyl, pyrazinyl, triazinyl.
- the heteroaryl group can also be a fused ring, including but not limited to indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl , pyrrolopyridyl, benzisoxazolyl, quinolyl, etc.
- Preferred heteroaryl groups are pyridyl, pyrazolyl, pyrrolopyridyl, or indolyl.
- the heterocyclic group is preferably azetidinyl, pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, pyranyl, pyridodihydrofuranyl, Pyrido-1,3-dioxocyclopentenyl, tetrahydropyranyl, tetrahydrofuranyl, oxazinyl, tetrahydroisoquinolinyl, chromanyl, decahydroisoquinolinyl, imidazolinyl , imidazolidinyl, 6,7-dihydro-5H-cyclopentane[c]pyridine, quinazolidinyl, thiazolidinyl, isothiazolidinyl, isoxazolidinyl, indoline, octahydro Indolyl, octahydroisoindolyl,
- the substituents on R 2 may be 1, 2 or 3, preferably selected from optionally substituted amino, cyano, C1-C6 alkyl, halogen, hydroxyl, C1-C6 alkoxy, halogenated C1 -C6 alkyl, halogenated C1-C6 alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkyl-O-, 6-14-membered aryl (such as phenyl), 5-10-membered heteroaryl (preferably a heteroaryl group containing 1 or 2 ring nitrogen atoms, such as pyrazolyl, imidazolyl, pyridyl, pyrazinyl, piperazinyl, etc.), 4-10 membered heterocyclic group (such as oxetane) group, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl,
- substituents on R 2 are C1-C6 alkoxy, halogen, C1-C6 alkyl, cyano, C3-C8 cycloalkyl-O- and halogenated C1-C6 alkoxy.
- the substituents on R 2 include at least C1-C6 alkoxy, halogenated C1-C6 alkoxy or C3-C8 cycloalkyloxy.
- the number of substituents on R 2 is 2, preferably at least one of the substituents is C1-C6 alkoxy, halogenated C1-C6 alkoxy or C3-C8 cycloalkyloxy.
- the C1-C6 alkoxy, halo-C1-C6 alkoxy or C3-C8 cycloalkyloxy is located in the meta position of the C to which R 2 is attached to L 2 .
- R 2 is optionally surrounded by 1 or 2 groups selected from C1-C6 alkoxy, halogen, C1-C6 alkyl, cyano, C3-C8 cycloalkyl-O- and halogenated C1-C6 alkoxy Substituents of radicals substituted phenyl.
- R 2 is optionally surrounded by 1 or 2 groups selected from C1-C6 alkoxy, halogen, C1-C6 alkyl, cyano, C3-C8 cycloalkyl-O- and halogenated C1-C6 alkoxy 5-10-membered nitrogen-containing heteroaryl substituted by the substituent of the base (such as pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyrazinyl, pyrrolopyridyl, or indolyl, etc.) or 4 -10-membered heterocyclic group, such as pyridodihydrofuranyl and pyrido1,3-dioxolyl, etc.
- the base such as pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyrazinyl, pyrrolopyridyl, or ind
- L 2 is a C1-C4 alkylene group
- R 2 is a group consisting of 1 or 2 groups selected from C1-C6 alkoxy, halogen, C1-C6 alkyl, cyano, C3-C8 cycloalkane 6-14-membered aryl (such as phenyl) or 5-10-membered nitrogen-containing heteroaryl (such as pyridyl, pyrazolyl, pyrrolo) substituted by substituents of base-O- and halogenated C1-C6 alkoxy pyridyl, or indolyl) or 4-10 membered heterocyclyl (eg, pyridodihydrofuranyl and pyrido1,3-dioxolyl).
- R 0 is H.
- R 0 is -NR 3 R 4 substituted C1-C6 alkyl, wherein R 3 and R 4 are each independently selected from H, optionally substituted C1-C6 alkyl, optionally substituted 4 -10 membered heterocyclyl and optionally substituted 5-10 membered heteroaryl.
- the C1-C6 alkyl group may be optionally replaced by 1, 2, 3, 4, 5 or 6 selected from halogen, cyano, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a Substituent substitution of R b and hydroxy, wherein R a and R b are each independently H or C1-C4 alkyl.
- the 4-10 membered heterocyclic groups include but are not limited to nitrogen- and/or oxygen-containing heterocyclic groups, such as oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, Piperazinyl, tetrahydropyranyl, morpholinyl, etc.
- the 5-10-membered heteroaryl groups include, but are not limited to, 5-10-membered nitrogen-containing and/or oxygen-containing heteroaryl groups, such as pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazine base, triazinyl, indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl and quinoline Base et al.
- 5-10-membered nitrogen-containing and/or oxygen-containing heteroaryl groups such as pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazine base, triazinyl, indolyl, isoindolyl, indazolyl, benzopyr
- the 4-10-membered heterocyclic group and the 5-10-membered heteroaryl group may each be optionally surrounded by 1, 2 or 3 groups selected from halogen, cyano, C1-C6 alkyl, halogenated C1-C6 alkyl, Substituent substitution of C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a R b and hydroxy, wherein R a and R b are each independently H or C1-C4 alkyl.
- R3 and R4 are not both said optionally substituted 4-10 membered heterocyclyl or said optionally substituted 5-10 membered heteroaryl or both.
- R3 and R4 together with the nitrogen atom to which they are attached form an optionally substituted 4-10 membered heterocyclyl or 5-10 membered heteroaryl.
- the 4-10 membered heterocyclic group includes, but is not limited to, nitrogen- and/or oxygen-containing heterocyclic groups, such as azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and the like.
- the 5-10-membered heteroaryl groups include, but are not limited to, 5-10-membered nitrogen-containing and/or oxygen-containing heteroaryl groups, such as pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazine base, triazinyl, indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl and quinoline Base et al.
- 5-10-membered nitrogen-containing and/or oxygen-containing heteroaryl groups such as pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazine base, triazinyl, indolyl, isoindolyl, indazolyl, benzopyr
- the 4-10-membered heterocyclic group and the 5-10-membered heteroaryl group may each be optionally replaced by 1, 2 or 3 groups selected from halogen, cyano, sulfo, C1-C6 alkylsulfonyl, C1-C6 Alkoxysulfonyl, C1-C6 alkylcarbonyl, halogenated C1-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, halogenated C1-C6 alkoxycarbonyl, C1-C6 alkyl, halogenated C1- Substituent substitution of C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a R b and hydroxy, wherein R a and R b are each independently H or C1-C4 alkyl.
- R 0 is -NR 3 R 4 substituted C1-C4 alkyl, wherein R 3 and R 4 are each independently selected from H, optionally substituted C1-C6 alkyl and optionally substituted 4-8-membered heterocyclic group, or R 3 and R 4 together with the nitrogen atom to which they are attached form an optionally substituted 4-8-membered heterocyclic group; further preferably, the C1-C6 alkyl group is optionally replaced by 1 -6 substituents selected from hydroxy, cyano and halogen, each of said 4-8 membered heterocyclyl groups is optionally substituted with 1, 2 or 3 substituents selected from halogen, C1-C6 alkyl, halogenated C1- C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, sulfo, C1-C6 alkylsulfonyl, C1-C6 alkoxysulfonyl,
- Ring A is a C3-C6 cycloalkyl or 4-8 membered heterocyclyl, which may be optionally selected from 1, 2 or 3 Halogen, C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy, -NR a R b substituted carbonyl and -NR a R b substituted C1- C4 alkyl substituted; X 3 and X 5 are both CH; X 4 is CH 2 ; L 1 is C1-C4 alkylene; R 1 is optionally 1 or 2 selected from halogen, C1-C4 alkyl and -5- or 6-membered nitrogen-containing heteroaryl substituted by the substituent of NR a R b , preferably pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyra
- Ring A is a C3-C6 cycloalkyl, which may be optionally surrounded by 1, 2, or 3 groups selected from halogen, C1-C4 alkyl, and halogenated C1- Substituents substituted for C4 alkyl; X 3 and X 5 are both CH; X 4 is CH 2 ; L 1 is C1-C4 alkylene; R 1 is 1 or 2 selected from C1-C4 alkyl and - 5 or 6-membered nitrogen-containing heteroaryl substituted by the substituent of NR a R b , preferably pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl, R a and R b are each independently H or C1-C4 alkyl; L 2 is C1-C4 alkylene; R 2 is 5-10-membered nitrogen-containing heteroaryl
- the compound of formula I has the structure shown in formula II below:
- Ring A, R 0 , L 2 and R 2 are each as described in any of the embodiments herein, and R c and R d are each independently H or C1-C6 alkyl.
- ring A is a C3-C6 cycloalkyl group or a 4-10-membered heterocyclic group, and the C3-C6 cycloalkyl group or a 4-10-membered heterocyclic group can be optionally replaced by 1, 2 or 3 selected from halogen, C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy, -NR a R b substituted carbonyl and -NR a R b -substituted C1-C4 alkyl substituted, wherein R a and R b are each independently H or C1-C4 alkyl; R 0 is -NR 3 R 4 substituted C
- ring A is a C3-C6 cycloalkyl group, and the cycloalkyl group may be optionally surrounded by 1, 2 or 3 groups selected from halogen, C1-C4 alkyl and halogenated C1-C4 alkane Substituent substitution of the base;
- L 2 is a C1-C4 alkylene group;
- R 2 is a 5-10-membered nitrogen-containing heteroaryl group, such as pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyrazinyl or Indolyl, the 5-10-membered nitrogen-containing heteroaryl can be optionally substituted by 1 or 2 substituents selected from C1-C6 alkoxy, halogen and cyano;
- R 0 is -NR 3 R 4 substituted C1-C4 alkyl group, wherein, R 3 and R 4 are each independently selected from H and C1-C6 alkyl group
- ring A is C3-C optionally substituted by a substituent selected from C1-C4 alkyl, -NR a R b substituted carbonyl and -NR a R b substituted C1-C4 alkyl substituents.
- C6 cycloalkyl or C4-C6 heterocyclic group containing 1 nitrogen or 1 O preferably cyclopropyl, cyclobutyl, oxetanyl or azetidine, the cyclopropyl, cyclobutyl Butyl, oxetanyl or azetidine, the cyclopropyl, cyclobutyl, oxetanyl or azetidine, the cyclopropyl, cyclobutyl, oxetan Butyl or azetidine is optionally substituted by C1-C4 alkyl, -NR a R b substituted carbonyl and -NR a R b substituted C1-C4 alkyl substituent; R 0 is H or - C1-C4 alkyl substituted by NR 3 R 4 , wherein R 3 and R 4 are each independently selected from H, 4-6 membered heterocyclyl and optionally by 1, 2, 3, 4, 5
- the compound of formula I has the structure shown in formula III below:
- Ring A, R 0 , L 2 and R 2 are each as described in any of the embodiments herein, and R c and R d are each independently H or C1-C4 alkyl.
- X 6 is each independently selected from C, O, N, S, and q is an integer of 1, 2 or 3.
- X 6 is C.
- q is 1 or 2.
- R 7 is selected from F, Cl, cyano, hydroxy, C1-C6 alkyl, fluoro or chloro C1-C6 alkyl, hydroxy-substituted C1-C6 alkyl, C1-C6 alkoxy, fluoro substituted or chloro-substituted C1-C6 alkoxy, hydroxy substituted C1-C6 alkyl, -NR a R b , -NR a R b substituted carbonyl, -NR a R b substituted C1-C6 alkyl, C1- C6 alkylcarbonyl, C1-C6 alkoxycarbonyl; wherein, the R a and R b are each independently selected from H and C1-C6 alkyl, and m is an integer of 0, 1, 2 or 3. Preferably, m is 0 or 2.
- a compound of formula I or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution thereof, Solvate, Polymorph, Prodrug or Metabolite:
- Ring A is a substituted or unsubstituted 3-8 membered saturated carbocyclic ring or a substituted or unsubstituted 3-8 membered saturated heterocyclic ring containing 1-2 heteroatoms independently selected from N, O and S;
- X 3 is selected from CR 5 and N;
- X 5 is selected from N and CR 5 ;
- L 1 is selected from bond, optionally substituted C1-C6 alkylene, optionally substituted C1-C6 alkylene-O-, optionally substituted C1-C6 alkylene-NH-, optionally substituted C1 -C6 alkylene-S- and optionally substituted C2-C4 alkenylene;
- L 2 is selected from bond, optionally substituted C1-C6 alkylene, optionally substituted C1-C6 alkylene-O-, optionally substituted C1-C6 alkylene-NH-, optionally substituted C1 -C6 alkylene-S- and optionally substituted C2-C4 alkenylene;
- R 0 is selected from optionally substituted C1-C6 haloalkyl, -C(O)NR 3 R 4 , -CH 2 OR 3 and -NR 3 R 4 substituted C1-C6 alkyl;
- R 1 is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted amino and guanidino;
- R is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl;
- R 3 and R 4 are each independently selected from H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, optionally substituted 4-10-membered Heterocyclyl and optionally substituted 5-10 membered heteroaryl; alternatively, R and R together with the nitrogen atom to which they are attached form an optionally substituted 4-10 membered heterocyclyl or 5-10 membered heteroaryl ;
- R 5 is selected from H, halogen, C1-C6 alkyl, halogenated C1-C6 alkyl and C1-C6 alkoxy;
- R 6 is selected from H, C1-C6 alkyl, halogenated C1-C6 alkyl and C1-C6 alkoxy.
- ring A is C3-C8 cycloalkyl or 3-7 membered heterocyclyl.
- Ring A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl , piperazinyl, oxetanyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl and morpholinyl.
- ring A is substituted with 1, 2 or 3 C1-C6 groups selected from halogen, hydroxy, cyano, C1-C6 alkyl, halogenated C1-C6 alkyl, hydroxy Substituents of alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy and -NR a R b are substituted; wherein said R a and R b are each independently selected from H and C1-C6 alkyl.
- Ring A is cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, oxetanyl, azetidine or tetrahydrofuranyl,
- Ring A is optionally surrounded by 1, 2 or 3 selected from F, Cl, Br, CF3 , CH3 , -OH, -OCH3 , -NH2 , - Substituent substitution of NHCH 3, -NH 2 (CH 3 ) 2 .
- R 0 is a C1-C6 alkyl group substituted by -NR 3 R 4 ; wherein R 3 and R 4 are each independently selected from H, optionally by 1, 2, 3, 4, 5 or 6 C1-C6 alkyl substituted with a substituent selected from halogen, cyano, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a R b and hydroxy, or R 3 and R 4 together with the nitrogen atom to which it is attached forms azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, 2-piperazinone, morpholinyl, pyridyl, pyrrolyl, pyrazolyl , imid
- R 0 is a C1-C6 alkyl substituted with -NR 3 R 4 , and wherein R 3 and R 4 together with the nitrogen atom to which they are attached form an azetidinyl group , pyrrolidinyl, piperidinyl, piperazinyl, 2-piperazinone, morpholinyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazine base, indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl,
- R 0 is a C1-C6 alkyl substituted by -NR 3 R 4 , wherein R 3 and R 4 together with the nitrogen atom to which they are attached form an azetidinyl group, Pyrrolidinyl, piperidinyl, piperazinyl, 2-piperazinone, morpholinyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl , indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzis
- the compounds of formula I described in the present invention or their pharmaceutically acceptable salts, or their enantiomers, diastereomers, tautomers, isotopic substitutions, solvates,
- X 3 and/or X 5 are CR 5 .
- R 5 is selected from H and C1-C4 alkyl.
- X 4 is -(CH 2 ) n -, and n is 1 or 2; and wherein the -(CH 2 ) n - is optionally selected from 1 or 2 by 1 or 2 Substituents of halogen, hydroxy, amino, C1-C6 alkyl and halogenated C1-C6 alkyl are substituted.
- X3 and X5 are both CR5 ; and X4 is optionally substituted -( CH2 )-.
- L 1 is selected from C1-C6 alkylene, C1-C6 alkylene-O-, C1-C6 alkylene-NH-, C1-C6 alkylene- S- and C2-C4 alkenylene, the C1-C6 alkylene, C1-C6 alkylene-O-, C1-C6 alkylene-NH-, C1-C6 alkylene-S- and The C2-C4 alkenylene group may be optionally substituted with 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl and hydroxy.
- L 1 is selected from C1-C6 alkylene and C1-C6 alkylene-NH-, said C1-C6 alkylene and C1-C6 alkylene-NH - optionally substituted with 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl and hydroxy.
- R 1 is selected from optionally substituted C3-C8 cycloalkyl, optionally substituted 6-14-membered aryl, optionally substituted 5-10-membered heteroaryl and Optionally substituted 4-10 membered heterocyclyl, and each of said cycloalkyl, aryl, heteroaryl and heterocyclyl may be optionally Substituent substitution of -C6 alkyl, halogen, hydroxy, C1-C6 alkoxy, C1-C6 haloalkyl and cyano; wherein, the optionally substituted amino is -NR a R b , wherein R a and R b is each independently H or C1-C6 alkyl.
- R 1 is selected from optionally substituted phenyl, naphthylpyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazolyl Azinyl, pyridoimidazolyl, indolyl, isoindolyl, indazolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl, pyrrole Alkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, pyranyl, pyridodihydrofuranyl, pyr
- the L 1 is C1-C4 alkylene or C1-C4 alkylene-NH-
- R 1 is pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl or The pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl or Optionally substituted with 1 or 2 substituents selected from halogen, C1-C4 alkyl and -NR a R b , wherein R a and R b are each independently H or C1-C4 alkyl.
- L 2 is selected from a bond and a C1-C6 alkylene group, wherein the C1-C6 alkylene group is optionally surrounded by 1, 2 or 3 selected from halogen, C1 Substituent substitution of -C3 alkyl, C3-C5 cycloalkyl and hydroxy.
- R 2 is optionally replaced by 1, 2 or 3 selected from -NR a R b , cyano, C1-C6 alkyl, halogen, hydroxy, C1-C6 alkoxy base, halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkyl-O-, 6-14-membered aryl, 5-10-membered heteroaryl and cyano substituents; wherein, R a and R b are each independently H or C1-C6 alkyl; and wherein, the heteroaryl group is preferably a heteroaryl group containing 1 or 2 ring nitrogen atoms, preferably
- R 2 is selected from 6-14-membered aryl, 5-10-membered heteroaryl and 4-10-membered heterocyclic group
- the 6-14-membered aryl, 5- 10-membered heteroaryl and 4-10-membered heterocyclyl can be optionally surrounded by 1, 2 or 3 members selected from -NR a R b , cyano, C1-C6 alkyl, halogen, hydroxy, C1-C6 alkoxy base, halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkyl-O-, 6-14-membered aryl, 5-10-membered hetero
- R 2 is selected from phenyl, naphthyl, pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl, Indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl, azetidine Alkyl, pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, pyranyl, pyridodihydrofuranyl, pyr
- L 2 is a C1-C4 alkylene group
- R 2 is a 6-14-membered aryl group, a 5-10-membered nitrogen-containing heteroaryl group or a 4-10-membered heterocyclic group
- the 6-14-membered aryl group, 5-10-membered nitrogen-containing heteroaryl group or 4-10-membered heterocyclic group is optionally replaced by 1 or 2 members selected from C1-C6 alkoxy, halogen, C1-C6 alkyl , cyano, C3-C8 cycloalkyl-O- and halogenated C1-C6 alkoxy substituents, preferably phenyl, pyridyl, pyrazolyl, pyrrolopyr
- ring A is a C3-C6 cycloalkyl or a 4-8 membered heterocyclyl, and the cycloalkyl or heterocyclyl is optionally selected from 1, 2 or 3 Substituted from substituents of halogen, C1-C4 alkyl, halogenated C1-C4 alkyl, C1-C4 alkoxy and halogenated C1-C4 alkoxy;
- X 3 and X 5 are both CH;
- X 4 is CH 2 ;
- L 1 is C1-C4 alkylene
- L 2 is C1-C4 alkylene
- R 2 is phenyl, 5-10-membered nitrogen-containing heteroaryl or 4-10-membered heterocyclic group, preferably pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyrazinyl, pyrrolopyridyl , pyridodihydrofuranyl or pyrido1,3-dioxolane or indolyl, each of said phenyl, 5-10-membered nitrogen-containing heteroaryl and 4-10-membered heterocyclic group is optional ground is substituted with 1 or 2 substituents selected from C1-C6 alkoxy, halogen, C1-C6 alkyl, cyano, C3-C8 cycloalkyl-O- and halogenated C1-C6 alkoxy;
- R 0 is C1-C4 alkyl substituted by -NR 3 R 4 ; wherein, R 3 and R 4 are each independently selected from H, C1 optionally substituted with 1-6 substituents selected from hydroxy, cyano and halogen -C6 alkyl and optionally 1, 2 or 3 selected from halogen, C1-C6 alkyl, C3-C6 cycloalkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1- 4-8-membered heterocyclic group substituted by substituents of C6 alkoxy, -NR a R b and hydroxy, wherein R a and R b are each independently H or C1-C4 alkyl; or R 3 and R 4 are their The attached nitrogen atoms are taken together to form optionally 1, 2 or 3 atoms selected from the group consisting of halogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-
- Ring A is a C3-C6 cycloalkyl optionally surrounded by 1, 2 or 3 selected from halogen, C1-C4 alkyl and halogenated C1 Substituent substitution of -C4 alkyl;
- X 3 and X 5 are both CH;
- X 4 is CH 2 ;
- L 1 is C1-C4 alkylene
- L 2 is C1-C4 alkylene
- R 2 is a 5-10-membered nitrogen-containing heteroaryl group or a 4-10-membered heterocyclic group, preferably pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyrazinyl, pyrrolopyridyl, pyrido Dihydrofuranyl or pyrido1,3-dioxolyl or indolyl, the 5-10-membered nitrogen-containing heteroaryl group or the 4-10-membered heterocyclic group are each optionally selected from 1 or 2 Substituents from C1-C6alkoxy, C1-C6alkyl, C3-C8cycloalkyl-O-, halogenated C1-C6alkoxy, halogen and cyano;
- R 0 is -NR 3 R 4 substituted C1-C4 alkyl, wherein R 3 and R 4 are each independently selected from H and optionally by 1, 2, 3, 4, 5 or 6 selected from hydroxyl, cyano A C1-C6 alkyl group substituted with a halogen substituent, or R3 and R4 together with the nitrogen atom to which they are attached form optionally replaced by 1, 2 or 3 groups selected from halogen, hydroxy, C1- C4 alkoxy and C1 -C4 alkyl substituted 4-8-membered heterocyclic group, preferably, the 4-8-membered heterocyclic group is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl ,
- Exemplary compounds of formula I of the present invention include, but are not limited to, the following compounds and their pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, isotopic substitutions, solvates, poly Crystal form, prodrug or metabolite:
- Embodiment 1 A compound of formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvate, polymorph thereof Substances, prodrugs or metabolites:
- Ring A is a substituted or unsubstituted 3-8 membered saturated or unsaturated carbocyclic ring or a substituted or unsubstituted 3-8 membered saturated or unsaturated heterocyclic ring, the heterocyclic ring contains 1-2 independently selected from N, O and heteroatoms of S;
- X 3 is selected from CR 5 and N;
- X 5 is selected from N and CR 5 ;
- L 1 is selected from bond, optionally substituted C1-C6 alkylene, optionally substituted C1-C6 alkylene-O-, optionally substituted C1-C6 alkylene-NH-, optionally substituted C1 -C6 alkylene-S- and optionally substituted C2-C4 alkenylene;
- L 2 is selected from bond, optionally substituted C1-C6 alkylene, optionally substituted C1-C6 alkylene-O-, optionally substituted C1-C6 alkylene-NH-, optionally substituted C1 -C6 alkylene-S- and optionally substituted C2-C4 alkenylene;
- R 0 is selected from H, C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl and -NR 3 R 4 substituted C1-C6 alkyl;
- R 1 is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted amino and guanidino;
- R is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl;
- R 3 and R 4 are each independently selected from H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, optionally substituted 4-10 membered Heterocyclyl and optionally substituted 5-10 membered heteroaryl; alternatively, R and R together with the nitrogen atom to which they are attached form an optionally substituted 4-10 membered heterocyclyl or 5-10 membered heteroaryl ;
- R 5 is selected from H, halogen, C1-C6 alkyl, halogenated C1-C6 alkyl and C1-C6 alkoxy;
- R 6 is selected from H, C1-C6 alkyl, halogenated C1-C6 alkyl and C1-C6 alkoxy.
- Embodiment 2 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, characterized in that Ring A is C3-C8 cycloalkyl or 3-7 membered heterocyclic group, preferably selected from cyclopropyl, cyclobutyl, cyclopentyl, Cyclohexyl, aziridyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl and morpholine base;
- Ring A is optionally substituted with 1, 2 or 3 groups selected from halogen, hydroxy, cyano, C1-C6 alkyl, halogenated C1-C6 alkyl, hydroxy substituted C1-C6 alkyl, C1-C6 alkyl Alkoxy, halogenated C1-C6 alkoxy, -NR a R b , -NR a R b substituted carbonyl, -NR a R b substituted C1-C6 alkyl, C1-C6 alkyl carbonyl, C1 -C6 alkoxycarbonyl, optionally substituted 6-14 membered aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 4-10 membered heterocyclyl, optionally substituted C3-C8 ring Alkyl, optionally substituted 6-14 membered aryl substituted C1-C6 alkyl, optionally substituted 5-10 membered heteroaryl substituted C1-C6 substituted C
- Embodiment 3 The compound of formula I according to embodiment 1 or 2, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution thereof , solvate, polymorph, prodrug or metabolite, wherein ring A is cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, oxetanyl, azetidine or tetrahydrofuranyl,
- Ring A is optionally surrounded by 1, 2 or 3 rings selected from F, Cl, Br, CF3 , CH3 , -OH, -OCH3 , -NH2 , -NHCH3 , -NH2 ( CH3 ) 2 is substituted with the substituent.
- Embodiment 4 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, characterized in that,
- X 3 is CR 5 , and R 5 is selected from H and C1-C4 alkyl; and/or
- X 4 is -(CH 2 ) n -, and n is 1 or 2; wherein, the -(CH 2 ) n - is optionally selected from halogen, hydroxyl, amino, C1-C6 alkyl and halogen by 1 or 2 Substituents substituted for C1-C6 alkyl groups.
- Embodiment 5 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, wherein L is selected from C1 -C6 sub-substituents optionally substituted with 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl and hydroxy Alkyl, C1-C6 alkylene-O-, C1-C6 alkylene-NH-, C1-C6 alkylene-S- and C2-C4 alkenylene, preferably selected from optionally 1, 2 or C1-C6 alkylene or C1-C6 alkylene-NH- substituted with 3 substituents selected from halogen, C1-C4 alkyl and hydroxy.
- L is selected from C1 -C6 sub-substituents optionally substituted with 1, 2 or 3 substituents selected from hal
- Embodiment 6 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, characterized in that R 1 is selected from optionally substituted C3-C8 cycloalkyl, optionally substituted 6-14-membered aryl, optionally substituted 5-10 membered heteroaryl and optionally substituted 4-10 membered heterocyclyl;
- the 6-14-membered aryl group is phenyl or naphthyl
- the 5-10-membered heteroaryl group is selected from pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyridyl Azinyl, triazinyl, indolyl, isoindolyl, indazolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl and quinolinyl, preferably pyridine base, pyrrolyl, imidazolyl and triazolyl;
- the 4-10 membered heterocyclic group is selected from pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, pyranyl, pyrido Dihydrofuranyl, pyrido1,3-dioxocyclopenten
- each of the alkoxy, aryl, heteroaryl and heterocyclyl groups may be optionally replaced by 1, 2 or 3 groups selected from optionally substituted amino, C1-C6 alkyl, halogen, hydroxy, C1 Substituent substitution of -C6 alkoxy, C1-C6 haloalkyl and cyano; wherein, the optionally substituted amino is -NR a R b , wherein R a and R b are each independently H or C1-C6 alkyl.
- Embodiment 7 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, characterized in that L 1 is C1-C4 alkylene or C1-C4 alkylene-NH-, R 1 is optionally selected from 1 or 2 5- or 6-membered nitrogen-containing heteroaryl substituted from halogen, C1-C4 alkyl and substituents of -NR a R b , the 5- or 6-membered nitrogen-containing heteroaryl is preferably pyridyl, pyrrolyl, pyrazole group, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl or triazinyl, wherein R a and R b are each independently H or C1-C4 alkyl.
- Embodiment 8 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, wherein L is selected from a bond and a C1 - C6 alkylene group, wherein the C1-C6 alkylene group is optionally surrounded by 1, 2 or 3 Substituents selected from halogen, C1-C3 alkyl, C3-C5 cycloalkyl and hydroxy are substituted.
- Embodiment 9 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, characterized in that R 2 is selected from optionally substituted 6-14-membered aryl, optionally substituted 5-10-membered heteroaryl, and optionally substituted 4- 10-membered heterocyclic group;
- the 6-14-membered aryl group is phenyl or naphthyl;
- the 5-10-membered heteroaryl group is selected from pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, pyridyl Azinyl, triazinyl, indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl and quinoline Linyl, preferably pyridyl, pyrrolopyridyl, pyrazolyl or indolyl;
- the 4-10-membered heterocyclic group is selected from azetidinyl, pyrrolidinyl, morpholinyl, piperazinyl, Homopiperazinyl, piperidinyl, pyranyl,
- R 2 is optionally replaced by 1, 2 or 3 optionally substituted amino, cyano, C1-C6 alkyl, halogen, hydroxy, C1-C6 alkoxy, halogenated C1-C6 alkyl , halogenated C1-C6 alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkyl-O-, 6-14-membered aryl, 5-10-membered heteroaryl and cyano substituents; wherein , the optionally substituted amino group is -NR a R b , wherein R a and R b are each independently H or C1-C6 alkyl; wherein, the heteroaryl group preferably contains 1 or 2 ring nitrogen atoms
- the heteroaryl group is preferably selected from pyrazolyl, imidazolyl, pyridyl, pyrazinyl and piperazinyl.
- Embodiment 10 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof
- L 2 is a C1-C4 alkylene group
- R 2 is 1 or 2 selected from C1-C6 alkoxy, halogen, C1-C6 alkane 6-14-membered aryl, 5-10-membered nitrogen-containing heteroaryl or 4-10-membered heteroaryl
- the cyclic group is preferably phenyl, pyridyl, pyrazolyl, pyrrolopyridyl, pyridodihydrofuranyl, pyrido1,3-dioxolyl or indolyl.
- Embodiment 11 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, characterized in that R 0 is H or -NR 3 R 4 substituted C1-C6 alkyl; wherein, R 3 and R 4 are each independently selected from H, optionally C1-substituted with 1, 2, 3, 4, 5 or 6 substituents selected from halogen, cyano, C1-C6alkoxy, halogenated C1-C6alkoxy, -NR a R b and hydroxy C6 alkyl, or R3 and R4 together with the nitrogen atom to which they are attached form optionally substituted 4-10 membered heterocyclyl and optionally substituted 5-10 membered heteroaryl, wherein each of R a and R b independently H or C1-C4 alkyl;
- the 4-10 membered heterocyclic group is preferably a nitrogen and/or oxygen-containing heterocyclic group, preferably selected from oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidine pyridyl, piperazinyl, tetrahydropyranyl and morpholinyl;
- the 5-10-membered heteroaryl group is a 5-10-membered nitrogen-containing and/or oxa-heteroaryl group, preferably selected from pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, Pyrazinyl, triazinyl, indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl and quinolinyl;
- the 4-10-membered heterocyclic group and the 5-10-membered heteroaryl group are each optionally replaced by 1, 2 or 3 groups selected from halogen, cyano, C1-C6 alkyl, halogenated C1-C6 alkane substituted by substituents of radicals, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a R b and hydroxy, wherein R a and R b are each independently H or C1-C4 alkyl.
- Embodiment 12 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, characterized in that R 0 is a C1-C6 alkyl substituted with -NR 3 R 4 , wherein R 3 and R 4 together with the nitrogen atom to which they are attached form an optional Substituted 4-10 membered heterocyclyl or 5-10 membered heteroaryl;
- the 4-10 membered heterocyclic group is a nitrogen- and/or oxygen-containing heterocyclic group, preferably selected from oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidine group, piperazinyl, tetrahydropyranyl and morpholinyl;
- the 5-10-membered heteroaryl group is a 5-10-membered nitrogen-containing and/or oxa-heteroaryl group, preferably selected from pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, Pyrazinyl, triazinyl, indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl and quinolinyl;
- the 4-10-membered heterocyclic group and the 5-10-membered heteroaryl group are each optionally replaced by 1, 2 or 3 groups selected from halogen, cyano, C1-C6 alkyl, halogenated C1-C6 alkane substituted by substituents of radicals, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a R b and hydroxy, wherein R a and R b are each independently H or C1-C4 alkyl.
- Embodiment 13 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, characterized in that R 0 is a C1-C6 alkyl substituted with -NR 3 R 4 , wherein R 3 and R 4 together with the nitrogen atom to which they are attached form an optional Substituted 4-10 membered heterocyclyl or 5-10 membered heteroaryl;
- the 4-10 membered heterocyclic group is a nitrogen- and/or oxygen-containing heterocyclic group, preferably selected from oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidine group, piperazinyl, tetrahydropyranyl and morpholinyl;
- the 5-10-membered heteroaryl group is a 5-10-membered nitrogen-containing and/or oxa-heteroaryl group, preferably selected from pyridyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, pyrimidinyl, Pyrazinyl, triazinyl, indolyl, isoindolyl, indazolyl, benzopyrrolyl, benzimidazolyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl and quinolinyl;
- the 4-10-membered heterocyclic group and the 5-10-membered heteroaryl group are each optionally replaced by 1, 2 or 3 groups selected from halogen, cyano, C1-C6 alkyl, halogenated C1-C6 alkane base, C1-C6 alkoxy, halogenated C1-C6 alkoxy, sulfo, C1-C6 alkylsulfonyl, C1-C6 alkoxysulfonyl, C1-C6 alkylcarbonyl, halogenated C1-C6 Substituent substitution of alkylcarbonyl, C1-C6 alkoxycarbonyl, halogenated C1-C6 alkoxycarbonyl, -NR a R b and hydroxy, wherein R a and R b are each independently H or C1-C4 alkane base.
- Embodiment 14 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, characterized in that,
- Ring A is a C3-C6 cycloalkyl group or a 4-8 membered heterocyclyl group, the cycloalkyl or heterocyclyl group is optionally surrounded by 1, 2 or 3 groups selected from halogen, C1-C4 alkyl, halogenated C1 -C4 alkyl, C1-C4 alkoxy, halogenated C1-C4 alkoxy, -NR a R b substituted carbonyl and -NR a R b substituted C1-C4 alkyl substituted; wherein R a and R b is each independently H or C1-C4 alkyl;
- X 3 and X 5 are both CH;
- X 4 is CH 2 ;
- L 1 is C1-C4 alkylene
- R 1 is a 5- or 6-membered nitrogen-containing heteroaryl optionally substituted by 1 or 2 substituents selected from halogen, C1-C4 alkyl and -NR a R b , preferably pyridyl, pyrrolyl, pyrazole base, imidazolyl, triazolyl, pyrimidinyl, pyrazinyl, triazinyl; wherein, R a and R b are each independently H or C1-C4 alkyl;
- L 2 is C1-C4 alkylene
- R 2 is phenyl, 5-10-membered nitrogen-containing heteroaryl or 4-10-membered heterocyclic group, preferably pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyrazinyl, pyrrolopyridyl , pyridodihydrofuranyl or pyrido1,3-dioxolane or indolyl, each of said phenyl, 5-10-membered nitrogen-containing heteroaryl and 4-10-membered heterocyclyl is optional ground is substituted with 1 or 2 substituents selected from C1-C6 alkoxy, halogen, C1-C6 alkyl, cyano, C3-C8 cycloalkyl-O- and halogenated C1-C6 alkoxy;
- R 0 is C1-C4 alkyl substituted by -NR 3 R 4 ; wherein, R 3 and R 4 are each independently selected from H, C1 optionally substituted with 1-6 substituents selected from hydroxy, cyano and halogen -C6 alkyl and optionally 1, 2 or 3 selected from halogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, -NR a 4-8-membered heterocyclic group substituted by substituents of R b and hydroxy, wherein R a and R b are each independently H or C1-C4 alkyl; or R 3 and R 4 together with the nitrogen atom to which they are attached form optionally by 1, 2 or 3 selected from halogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy,
- Embodiment 15 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, characterized in that,
- Ring A is a C3-C6 cycloalkyl optionally substituted with 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl and halo-C1-C4 alkyl;
- X 3 and X 5 are both CH;
- X 4 is CH 2 ;
- L 1 is C1-C4 alkylene
- R 1 is a 5- or 6-membered nitrogen-containing heteroaryl substituted by 1 or 2 substituents selected from C1-C4 alkyl and -NR a R b , preferably pyridyl, pyrrolyl, pyrazolyl, imidazolyl , triazolyl, pyrimidinyl, pyrazinyl, triazinyl; wherein, R a and R b are each independently H or C1-C4 alkyl;
- L 2 is C1-C4 alkylene
- R 2 is a 5-10-membered nitrogen-containing heteroaryl group or a 4-10-membered heterocyclic group, preferably pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyrazinyl, pyrrolopyridyl, pyrido Dihydrofuranyl or pyrido1,3-dioxolyl or indolyl, the 5-10-membered nitrogen-containing heteroaryl group or the 4-10-membered heterocyclic group are each optionally selected from 1 or 2 Substituents from C1-C6alkoxy, C1-C6alkyl, C3-C8cycloalkyl-O-, halogenated C1-C6alkoxy, halogen and cyano;
- R 0 is -NR 3 R 4 substituted C1-C4 alkyl, wherein R 3 and R 4 are each independently selected from H and optionally by 1, 2, 3, 4, 5 or 6 selected from hydroxyl, cyano C1-C6 alkyl substituted with a halogen substituent, or R3 and R4 together with the nitrogen atom to which they are attached form a 4 optionally substituted with 1, 2 or 3 selected from halogen, hydroxy and C1-C4 alkyl -8-membered heterocyclic group, preferably, the 4-8 membered heterocyclic group is selected from oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, Tetrahydropyranyl and morpholinyl.
- Embodiment 16 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, characterized in that the compound of formula I has the structure shown in the following formula II:
- Ring A is as described in Embodiment 1, 2, 3, 14 or 15;
- R 0 is as described in Embodiment 11, 12, 13, 14 or 15;
- L 2 is as described in Embodiment 8,
- 10, 14 or 15 R is as described in Embodiment 9 , 10, 14 or 15;
- Rc and Rd are each independently H or C1-C4 alkyl.
- Embodiment 17 The compound of formula I according to Embodiment 16, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, characterized in that in formula II:
- Ring A is a C3-C6 ring optionally substituted with a substituent selected from F, Cl, hydroxy, C1-C4 alkyl, -NR a R b substituted carbonyl, and -NR a R b substituted C1-C4 alkyl group Alkyl or C4-C6 heterocyclyl containing 1 nitrogen or 1 O, preferably C1-C4 alkyl optionally substituted by C1-C4 alkyl, -NR a R b substituted carbonyl and -NR a R b substituted C1-C4 alkane cyclopropyl, cyclobutyl, oxetanyl or azetidine substituted by the substituent of the group; wherein, R a and R b are each independently H or C1-C4 alkyl;
- R 0 is a C1-C4 alkyl substituted by H or -NR 3 R 4 , wherein R 3 and R 4 are each independently selected from H, 4-6 membered heterocyclyl and optionally 1, 2, 3, 4, C1-C6 alkyl substituted with 5 or 6 substituents selected from hydroxy, cyano and halogen, or R3 and R4 taken together with the nitrogen atom to which they are attached form optionally substituted by 1, 2 or 3 substituents selected from halogen, 4-6-membered heterocyclic group substituted by hydroxyl and C1-C4 alkyl; wherein, the 4-6-membered heterocyclic group is preferably an oxygen- and/or nitrogen-containing heterocyclic group, preferably selected from oxetanyl , azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl and morpholinyl;
- L 2 is C1-C4 alkylene
- R 2 is a 6-14-membered aryl group, a 5-10-membered nitrogen-containing heteroaryl group or a 4-10-membered heterocyclic group, preferably phenyl, pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl, pyridine oxazinyl, indolyl, pyrrolopyridyl, pyridodihydrofuranyl or pyrido1,3-dioxolyl, the 6-14-membered aryl, 5-10-membered nitrogen-containing heteroaryl or 4-10-membered heterocyclic groups are each optionally replaced by 1 or 2 groups selected from C1-C6 alkoxy, C1-C4 alkyl, halogen, C3-C6 cycloalkyl-oxy, halogenated C1-C4 alkoxy Substituent substitution of cyano group and cyano group;
- Rc and Rd are each independently H or C1-C4 alkyl.
- Embodiment 18 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, characterized in that the compound of formula I has the structure shown in the following formula III:
- X 6 is each independently selected from C, O, N, S,
- q is an integer of 1, 2 or 3
- R 7 is selected from F, Cl, cyano, hydroxy, C1-C6 alkyl, fluoro or chloro C1-C6 alkyl, hydroxy substituted C1-C6 alkyl, C1-C6 alkoxy, fluoro or chloro Substituted C1-C6 alkoxy, hydroxy substituted C1-C6 alkyl, -NR a R b , -NR a R b substituted carbonyl, -NR a R b substituted C1-C6 alkyl, C1-C6 alkyl Carbonyl, C1-C6 alkoxycarbonyl; wherein, the R a and R b are each independently selected from H and C1-C6 alkyl,
- n is an integer of 0, 1, 2 or 3.
- Embodiment 19 The compound of formula I according to Embodiment 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution, solvent thereof compound, polymorph, prodrug or metabolite, characterized in that the compound is selected from:
- Embodiment 20 A pharmaceutical composition comprising the compound of any one of Embodiments 1-16, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, Tautomers, isotopic substitutions, solvates, polymorphs, prodrugs or metabolites, and pharmaceutically acceptable carriers or excipients.
- Embodiment 21 The compound of any one of Embodiments 1-19, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, isotopic substitution thereof Use of a compound, solvate, polymorph, prodrug or metabolite in the manufacture of a medicament for the treatment or prevention of WDR5-mediated diseases.
- Embodiment 22 The use according to Embodiment 21, wherein the WDR5-mediated diseases include Kabuki syndrome, and various solid tumors and hematological tumors; preferably, the solid tumors and hematological tumors are selected from the group consisting of: Southern syndrome, Leopard syndrome, neuroblastoma, sarcoma, melanoma, articular chondroma, cholangiomas, leukemia, breast cancer, gastrointestinal stromal tumor, histiocytic lymphoma, lung cancer, esophageal cancer, pancreatic cancer, Breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, cervical cancer, ovarian cancer, bowel cancer, nasopharyngeal cancer, brain cancer, bone cancer, kidney cancer, oral cancer, head cancer, neuroblastoma, head and neck cancer Squamous cell carcinoma, anaplastic large cell lymphoma or glioblastoma, wherein the leukemia is preferably juvenile myelomono
- the present invention includes pharmaceutically acceptable salts of compounds of formula I.
- pharmaceutically acceptable salt includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
- “Pharmaceutically acceptable acid addition salts” refer to salts formed with inorganic or organic acids that retain the biological effectiveness of the free base without other adverse effects.
- Inorganic acid salts include but are not limited to hydrochloride, hydrobromide, sulfate, nitrate, phosphate, etc.; organic acid salts include but are not limited to formate, acetate, 2,2-dichloroacetate , trifluoroacetate, propionate, caproate, caprylate, caprate, undecylenate, glycolate, gluconate, lactate, sebacate, hexamethylene Acid, glutarate, malonate, oxalate, maleate, succinate, fumarate, tartrate, citrate, palmitate, stearate, oleate , cinnamate, laurate, malate, glutamate, pyroglutamate, aspartate, benzoate, mesylate, benzenesulfonate, p-tol
- “Pharmaceutically acceptable base addition salts” refers to salts formed with inorganic or organic bases that retain the biological effectiveness of the free acid without other adverse effects. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Preferred inorganic salts are ammonium, sodium, potassium, calcium and magnesium salts.
- Salts derived from organic bases include, but are not limited to, the following salts: primary, secondary and tertiary amines, substituted amines, including natural substituted amines, cyclic amines, and basic ion exchange resins , such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, bicyclic Hexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperazine pyridine, N-ethylpiperidine, polyamine resin, etc.
- Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicycl
- the present invention also includes isomers of the compounds of formula I, including stereoisomers, enantiomers or tautomers.
- stereoisomers refer to compounds composed of the same atoms, bonded by the same bonds, but having different three-dimensional structures.
- the present invention encompasses various stereoisomers and mixtures thereof.
- “Tautomer” refers to an isomer formed by the transfer of a proton from one atom of a molecule to another atom of the same molecule. All tautomeric forms of the compounds of the present invention are also intended to be included within the scope of the present invention.
- the compounds of the present invention may contain one or more chiral carbon atoms, and thus may give rise to enantiomeric, diastereomeric, and other stereoisomeric forms.
- Each chiral carbon atom can be defined as (R)- or (S)- based on stereochemistry.
- the present invention is intended to include all possible isomers, as well as their racemates and optically pure forms.
- the compounds of the present invention can be prepared by selecting racemates, diastereomers or enantiomers as starting materials or intermediates.
- Optically active isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques such as crystallization and chiral chromatography.
- the compounds of the present invention are intended to include both E- and Z-geometric isomers.
- the present invention also includes all suitable isotopic variations of the compounds of the present invention, pharmaceutically acceptable salts or isomers thereof.
- Isotopic variants of the compounds of the present invention, pharmaceutically acceptable salts or isomers thereof are defined as those in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from that often found in nature .
- Isotopes that can be incorporated into the compounds of the present invention, pharmaceutically acceptable salts or isomers thereof include, but are not limited to, isotopes of H, C, N and O, such as 2 H, 3 H, 11 C, 13 C, 14C , 15N , 17O , 18O , 35S , 18F , 36Cl and 125I .
- Isotopic variations of the compounds of the present invention, pharmaceutically acceptable salts or isomers thereof can be prepared by conventional techniques using appropriate isotopic variations with appropriate reagents.
- the compounds of Formula Ha of the present invention can be prepared by the methods shown in the following schemes:
- intermediate IIa-1 is reduced to obtain intermediate IIa-2; IIa-2 is obtained by amine transesterification to obtain IIa-3; IIa-3 is obtained by acid-catalyzed cyclization to obtain IIa-4;
- the ester compound IIa-5 is formed; the aromatic ring of IIa-5 is halogenated to obtain IIa-6; the ester group of IIa-6 is reduced to form IIa-7; the hydroxyl group of IIa-7 is further halogenated to form IIa-8;
- IIa-8 IIa-9 is obtained after alkylation with imidazolamine; IIa-9 is obtained by catalytic coupling with boronic acid derivatives to obtain IIa-10; IIa-10 is alkylated with R 2 -L 2 -Br to form IIa-11; IIa -11 Deprotection gives compounds of formula IIa.
- the reaction conditions for each step are shown in the reaction scheme.
- the catalytic cyclization reaction of IIa-3 to IIa-4 is used to construct the aromatic spiro intermediate of formula IIa-4.
- the reaction is carried out under the catalysis of an acid (preferably trifluoromethanesulfonic acid) in a halogenated alkane (preferably dichloromethane) at low temperature or room temperature.
- an acid preferably trifluoromethanesulfonic acid
- a halogenated alkane preferably dichloromethane
- IIa-8 can react with imidazole compounds to introduce the imidazole group on the right to obtain IIa-9.
- alkali and phase transfer catalyst preferably cesium carbonate, tetrabutylammonium iodide
- Catalytic coupling reaction between IIa-9 and boronic acid compound to introduce R 0 substituent can be carried out in the presence of water and organic solvent (such as alcohol or ether solvent, preferably dioxane).
- organic solvent such as alcohol or ether solvent, preferably dioxane
- IIa-10 is obtained in the presence of a base (eg, sodium carbonate) and a catalyst such as a palladium-based catalyst (eg, Pd(dppf)Cl2 ) under heating conditions.
- Reaction of IIa-10 with a halide under the condition of a base introduces the R2 - L2- group.
- the solvent for the alkylation reaction may be an organic solvent, preferably tetrahydrofuran, DMF or NMP.
- the above scheme also includes the step of removing the Boc protecting group.
- the deprotection reaction can be carried out in a conventional manner.
- the general method of the compound of the formula IIa can be adopted, and different raw materials can be changed to obtain different compounds.
- the preparation method usually includes the above-mentioned steps of catalytic ring closure, catalytic coupling, reductive halogenation and alkylation substitution reactions.
- WDR5 belongs to the WD40 domain repeat protein family (WD40-repeat protein).
- WD40 is an important structural domain consisting of about 40 amino acid residues.
- the WDR domain contains a ring-shaped seven-leaf ⁇ -propeller domain. Each contains the conserved serine-histidine (SH) and tryptophan-aspartic acid (WD) sequences.
- the WDR5 protein contains a central cavity formed by a 7-lobed ⁇ -helix that runs up and down.
- the WDR5 protein mainly plays a regulatory role through a deep arginine binding pocket, that is, the WIN site forms a core catalytic complex with MLL1, and forms the core catalytic complex of MWRAD (MLL1, WDR5, RbBP5, ASH2L and DYP-30) with other proteins. , catalyzes histone H3 methylation, activates gene transcription and participates in epigenetic regulation.
- the MLL family protein complex which is widespread in eukaryotes, is an important class of histone methyltransferases that catalyze the methylation of histone H3K4, either by catalyzing the methylation of H3K4 and/or by recruiting other transcription-related proteins to interact with Mediators, which activate transcription, play a crucial role during development. Mutations in these proteins, including genomic translocations where they fuse with other transcription factors, can cause a variety of diseases, such as mixed lineage leukemia (MLL), lymphoma, and Kabuki syndrome.
- MLL mixed lineage leukemia
- Using WDR5 as a drug target compounds designed for the WIN pocket where WDR5 binds to histones and MLL1 can reduce the expression of genes downstream of WDR5 and treat MLL rearrangement-dependent leukemia.
- the TP53 gene is the most frequently mutated gene in tumors, and TP53 mutations occur in 50% of human cancers.
- the high frequency of missense mutations and the high expression level of mutant p53 (mp53) protein in cancer cells promote mp53 protein to have new functions (“gain of function” (GOF)), and also actively promote cancer development and progression.
- GAF gain of function
- the growth of tumor cells driven by mutations in the p53 gene depends on the binding of WDR5 to MLL. MLL, MOZ and histone modifications are all regulated by the expression of GOF p53.
- Inhibitors at the WDR5WIN locus can effectively block the growth of breast cancer cell lines and leukemia cells driven by mutations in the p53 gene.
- MYC is a class of oncoproteins with transcription factor functions, which are overexpressed in most malignant tumors. MYC can bind to the regulatory sequences of thousands of target genes, regulate target gene expression, and affect processes such as cell growth, proliferation, metabolism, genome stability, and apoptosis. Earlier studies have found that the extensive binding of MYC to chromatin also depends on the interaction of WDR5, and that MYC binds to the hydrophobic cleft on the surface of WDR5 through its evolutionarily conserved "MYC box IIIb" sequence, which plays an important role in tumorigenesis in vivo. Blocking the interaction of MYC with WDR5 inhibits the ability of MYC to drive carcinogenesis. Inhibitors targeting the WDR5WIN site can be used as targeted therapies for MYC-driven tumors.
- WDR5 is highly expressed in a variety of solid tumors, and there is a certain correlation with poor tumor prognosis. On the one hand, it is due to the regulatory effect of WDR5 on EMT.
- Epithelial-mesenchymal transition refers to the biological process by which epithelial cells are transformed into cells with a mesenchymal phenotype through a specific program. EMT is an important biological process for epithelial cell-derived malignant tumor cells to acquire the ability to migrate and invade. WDR5 can directly regulate the TGF ⁇ 1 signaling pathway, thereby participating in tumor cell ETM and migration.
- WDR5 inhibitor does not have obvious killing effect, but can enhance the sensitivity of cells to PTX by reducing the level of TGF ⁇ 1 and inhibit the ability of tumor metastasis. This also suggests the potential of WDR5 inhibitors in combination therapy. WDR5 can also mediate the expression of multiple EMT signature molecules such as N-cadherin, ZNF407, HOXA9, SNAIL1 and VIMENTIN.
- EMT signature molecules such as N-cadherin, ZNF407, HOXA9, SNAIL1 and VIMENTIN.
- the researchers also found that while WDR5 regulates the expression of tumor-related signaling molecules, it is also regulated by multiple upstream signaling pathways or molecules.
- PI3K/AKT-mediated upregulation of WDR5 promotes colorectal cancer metastasis, while in gastric cancer, inducible expression of cyclin D1 upregulates WDR5 and promotes tumorigenesis.
- WDR5 protein-protein interaction inhibitors can be used to treat a variety of diseases, including Kabuki syndrome, and various solid and hematological tumors, including but not limited to Noonan syndrome, Leopard syndrome, neuroblastoma, Sarcoma, melanoma, articular chondroma, cholangiomas, leukemia (such as juvenile myelomonocytic leukemia, human myelomonocytic leukemia, etc.), breast cancer, gastrointestinal stromal tumor, histiocytic lymphoma, lung cancer (such as non-small cell lung cancer, small cell lung cancer, lung squamous cell carcinoma, lung adenocarcinoma, etc.), esophageal cancer, pancreatic cancer,
- the compounds of formula I, pharmaceutically acceptable salts and isomers thereof of the present invention are inhibitors of WDR5, which can inhibit the binding of WDR5 to MLL1 or MYC, and can also inhibit the activity of WDR5 itself. Therefore, the compounds of formula I, pharmaceutically acceptable salts and isomers thereof of the present invention can be used for the treatment or prevention of WDR5-mediated diseases.
- WDR5-mediated disease refers to a disease in which WDR5 is involved in the occurrence and/or development of the disease, and the purpose of alleviation, treatment and/or prevention can be achieved by inhibiting the expression and/or activity of WDR5.
- WDR5-mediated diseases include but are not limited to the Kabuki syndrome described above, as well as various solid tumors and hematological tumors, especially including MLL rearrangement-dependent leukemia (such as human myelomonocytic leukemia), MYC driven tumors and breast cancer, etc.
- MYC-driven tumors refer to tumors caused by MYC activity.
- the compounds of formula I, pharmaceutically acceptable salts and isomers thereof of the present invention can also be used to inhibit epithelial-mesenchymal transition (EMT), thereby inhibiting the metastasis of epithelial-derived malignant tumor cells. Therefore, "WDR5-mediated disease" as described in this application also includes the metastasis of cancer, especially the metastasis of malignant tumor of epithelial cell origin.
- the present invention provides a method of treating or preventing the WDR5-mediated diseases described herein, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, pharmaceutically acceptable salts and isomers thereof of the present invention Or a pharmaceutical composition containing the compound of formula I of the present invention, its pharmaceutically acceptable salts and isomers.
- Subject or “individual” as used herein refers to mammals, particularly primates, and more particularly humans.
- preventing and preventing include reducing the likelihood of the occurrence or exacerbation of a disease or disorder in a patient; the terms also include: preventing the occurrence of a disease or disorder in mammals, particularly when such mammals are susceptible to When you have the disease or condition, but have not been diagnosed with the disease or condition.
- "Treat” and other similar synonyms include the following meanings: (i) inhibiting a disease or disorder, ie, arresting its progression; (ii) alleviating a disease or disorder, ie, causing regression of the state of the disease or disorder; or (iii) alleviating the Symptoms caused by a disease or condition.
- an “effective amount” for use in therapy is the amount of a composition comprising a compound of Formula I disclosed herein, a pharmaceutically acceptable salt or isomer thereof, required to provide clinically significant relief of the condition.
- the dosage can be determined according to factors such as the subject's age, sex, disease and its severity. An effective amount appropriate in any individual case can be determined using techniques such as dose escalation assays.
- administering refers to methods capable of delivering a compound or composition to the desired site of biological action.
- Administration methods well known in the art can be used in the present invention. These methods include, but are not limited to, the oral route, the duodenal route, parenteral injection (including intrapulmonary, intranasal, intrathecal, intravenous, subcutaneous, intraperitoneal, intramuscular, intraarterial injection or infusion), Topical and rectal administration.
- a compound of formula I of the present invention, a pharmaceutically acceptable salt or isomer thereof, or a medicament containing a compound of formula I of the present invention, a pharmaceutically acceptable salt or isomer thereof, is administered orally combination.
- the compound of formula I of the present invention, its pharmaceutically acceptable salts and isomers or the pharmaceutical composition containing the compound of formula I of the present invention, its pharmaceutically acceptable salts and isomers can be combined with other pharmacologically active compounds
- the compounds are used in combination, especially in the treatment of cancer.
- the compounds of formula I, pharmaceutically acceptable salts and isomers thereof of the present invention or pharmaceutical compositions containing the compounds of formula I, pharmaceutically acceptable salts and isomers thereof of the present invention may be combined with one or more Simultaneous, sequential or separate administration of a combination of multiple drugs selected from the group consisting of chemotherapeutic agents, such as mitotic inhibitors, such as taxanes, vinca alkaloids, paclitaxel, docetaxel, vincristine, vinblastine, Vinorelbine or vinorelbine, other anticancer agents such as cisplatin, 5-fluorouracil or 5-fluoro-2-4(1H,3H)-pyrimidinedione (5FU), flutamide or gemcitabine, etc.
- chemotherapeutic agents such as mitotic inhibitors, such as taxanes, vinca alkaloids, paclitaxel, docetaxel, vincristine, vinblastine, Vinorelbine or vinorelbine
- other anticancer agents
- the inventive compounds of formula I, pharmaceutically acceptable salts and isomers thereof of the present invention or pharmaceutical compositions comprising the inventive compounds of formula I, pharmaceutically acceptable salts and isomers thereof also It can be used for cancer treatment together with tumor immunotherapy drugs known in the art, such as anti-PD1 antibodies.
- tumor immunotherapy drugs known in the art, such as anti-PD1 antibodies.
- the compound of formula I of the present invention, its pharmaceutically acceptable salts and isomers or the pharmaceutical composition containing the compound of formula I of the present invention, its pharmaceutically acceptable salts and isomers can also be combined with conventional radiotherapy use.
- combination refers to drug therapy obtained by mixing or combining more than one active ingredient, which includes fixed and non-fixed active ingredients Combination, or the combination of two or more different treatments.
- fixed combination refers to the simultaneous administration to a patient of at least one compound described herein and at least one synergistic agent in the form of a single entity or single dosage form.
- unfixed combination refers to the simultaneous administration, co-administration, or sequential administration of at least one compound described herein and at least one synergistic formulation at variable intervals to a patient as separate entities. These also apply to cocktail therapy, eg the administration of three or more active ingredients.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula I of the present invention, a pharmaceutically acceptable salt or isomer thereof, and a pharmaceutically acceptable carrier or excipient.
- pharmaceutical composition refers to a compound of formula I of the present invention, a pharmaceutically acceptable salt or isomer thereof, and a compound generally accepted in the art for the delivery of biologically active compounds to mammals (eg, humans) preparation of the medium.
- the medium includes a pharmaceutically acceptable carrier.
- the purpose of the pharmaceutical composition is to facilitate the administration of the organism, facilitate the absorption of the active ingredient and then exert the biological activity.
- pharmaceutically acceptable refers to a substance (eg, a carrier or diluent) that does not affect the biological activity or properties of a compound of formula I of the present invention, a pharmaceutically acceptable salt or isomer thereof, and is relatively non-toxic , that is, the substance can be administered to an individual without causing an adverse biological response or interacting in an undesired manner with any of the components contained in the composition.
- “Pharmaceutically acceptable carrier or excipient” includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, Diluents, preservatives, dyes/colorants, flavors, surfactants, wetting agents, dispersing agents, suspending agents, stabilizers, isotonic agents, solvents or emulsifiers.
- the active ingredient of the pharmaceutical composition of the present invention may contain, in addition to the compound of formula I of the present invention, a pharmaceutically acceptable salt or isomer thereof, other known anticancer agents, including but not Limited to taxanes, vinca alkaloids, paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine, vinflunine, cisplatin, 5-fluorouracil, 5-fluoro-2-4(1H , 3H)-pyrimidinedione (5FU), flutamide and gemcitabine, etc.
- other known anticancer agents including but not Limited to taxanes, vinca alkaloids, paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine, vinflunine, cisplatin, 5-fluorouracil, 5-fluoro-2-4(1H , 3H)-pyrimidinedione (5FU), flutamide and gemcitabine, etc.
- the present invention relates to compounds of formula I of the present invention, pharmaceutically acceptable salts and isomers thereof, or pharmaceutical compositions comprising compounds of formula I of the present invention, pharmaceutically acceptable salts and isomers thereof, in the treatment or prophylaxis herein
- the present invention also provides compounds of formula I according to the present invention, pharmaceutically acceptable salts and isomers thereof or containing compounds of formula I according to the present invention, for use in the treatment or prevention of WDR5-mediated diseases described herein Pharmaceutical compositions of the above acceptable salts and isomers.
- the starting materials used in the following examples can be purchased from chemical vendors such as Aldrich, TCI, Alfa Aesar, Bidder, Anegi, etc., or can be synthesized by known methods.
- the ice bath refers to -5°C to 0°C
- the room temperature refers to 10°C to 30°C
- the reflux temperature generally refers to the reflux temperature of the solvent under normal pressure.
- the reaction overnight generally refers to a time of 8-15 hours.
- the specific operating temperature is not limited, and all are carried out at room temperature.
- the separation and purification of intermediates and final products are carried out by normal-phase or reversed-phase chromatographic column separation or other suitable methods.
- the normal phase flash chromatography column uses ethyl acetate and n-hexane or methanol and dichloromethane as mobile phases.
- Reversed-phase preparative high pressure liquid chromatography (HPLC) was performed on a C18 column with UV detection at 214 nm and 254 nm with mobile phases A (water and 0.1% formic acid), B (acetonitrile) or mobile phase A (water and 0.1% carbonic acid) ammonium hydrogen), B (acetonitrile).
- LCMS instrument pump: Agilent 1260;
- UV detector Agilent 1260 DAD Mass Spectrometer API 3000;
- Step 1 -78°C, under argon protection, to a solution of 2-bromo-5-fluoropyridine (A1-1, 102 g, 580.0 mmol) in tetrahydrofuran (1.0 L) was added dropwise LDA (2M, tetrahydrofuran solution, 434 mL, 868.0 mmol). After reacting at this temperature for 1 hour, triisopropyl borate (163 g, 870.0 mmol) was added, and the mixture was reacted at this temperature for 30 minutes, and then the temperature was raised to room temperature and reacted for 16 hours.
- reaction solution was cooled to 0°C, an aqueous solution of sodium hydroxide (4M, 2.5L) was added, and the temperature was warmed to room temperature and stirred for 1 hour.
- the aqueous phase was separated and the pH was adjusted to 3 with 6M aqueous hydrochloric acid. Extract with ethyl acetate (3*1.5L), wash the organic phase with saturated brine, dry, filter, and concentrate to dryness to give crude (2-bromo-5-fluoropyridin-4-yl)boronic acid (A1-2, 114.5 g, yield : 89.9%).
- Step 2 To the suspension of (2-bromo-5-fluoropyridin-4-yl)boronic acid (A1-2, 114.5 g, 520.9 mmol) in dichloromethane (1.5 L) was added hydrogen peroxide (30%) at 0°C aq., 177.1 g, 1562.7 mmol). After the addition was completed, the temperature was raised to room temperature for 16 hours.
- reaction solution was concentrated to remove the solvent, water (500 mL) and ethyl acetate (1.0 L) were added, the layers were separated, the aqueous phase was extracted with ethyl acetate (2*1.0 L), the organic phases were combined, and concentrated to dryness to obtain crude 2-bromo -5-Fluoropyridin-4-ol (A1-3, 96 g, yield: 96.0%).
- Step 3 To a solution of 2-bromo-5-fluoropyridin-4-ol (A1-3, 96g, 500mmol) in DMF (600mL) was added potassium carbonate (138.1g, 1000mmol) and iodoethane (234g, 1500mmol) . The reaction was carried out at room temperature for 16 hours. The reaction solution was poured into saturated brine, extracted with ethyl acetate (2*1000mL), the organic phase was washed with water (3*1500mL) and saturated brine (2*1500mL) successively, dried, filtered, concentrated to dryness under reduced pressure, and the mixture was filtered through a column. Purification by chromatography gave 2-bromo-4-ethoxy-5-fluoropyridine (A1-4, 85 g, yield: 77.3%) as a colorless liquid.
- Step 4 Under argon protection, 2-bromo-4-ethoxy-5-fluoropyridine (A1-4, 42 g, 190.9 mmol) and tributyl(1-ethoxyvinyl)stannane (103.4 g , 286.4 mmol) in 1,4-dioxane (1,4-dioxane) was added tetrakistriphenylphosphine palladium (7.3 g, 0.03 mmol). The temperature was raised to 100°C for 16 hours. The solvent was removed by concentration under reduced pressure, diluted with ethyl acetate (800 mL), saturated aqueous potassium fluoride solution was added, and the mixture was stirred at room temperature for 1 hour.
- reaction solution was separated into layers, the aqueous phase was extracted with dichloromethane (2*1000 mL), the organic phases were combined, washed with saturated brine, dried, filtered, concentrated to dryness under reduced pressure, and purified by column chromatography to obtain A1-5 (32.5 g, collected rate: 93.0%).
- Step 5 Dissolve 1-(5-fluoro-4-ethoxypyridin-2-yl)ethan-1-one (A1-5, 28.4 g, 155.0 mmol) in ethanol (560 mL), cool to 0°C , sodium borohydride (5.85 g, 155.0 mmol) was added in three portions. After the addition was completed, the reaction was kept at 0°C for 10 minutes, and then the temperature was raised to room temperature for overnight reaction.
- reaction solution was poured into ice water, extracted with dichloromethane (4*1000 mL), the organic phases were combined, washed with saturated brine, dried, filtered, concentrated to dryness under reduced pressure, and purified by column chromatography to obtain a pale yellow oil 1-( 5-Fluoro-4-ethoxypyridin-2-yl)ethan-1-ol (A1-6, 25 g, yield: 87.1%).
- Step 6 1-(5-Fluoro-4-ethoxypyridin-2-yl)ethane-1-ol (A1-6, 24.2 g, 130.7 mmol) and triphenyl
- a solution of phosphorus (61.7 g, 235.2 mmol) in tetrahydrofuran (500 mL) was added dropwise a solution of carbon tetrabromide (65.0 g, 196.0 mmol) in tetrahydrofuran (100 mL).
- the reaction was kept at 0°C for 10 minutes, and the temperature was raised to room temperature for overnight reaction.
- the reaction solution was filtered, the filter cake was washed with tetrahydrofuran, the filtrate was concentrated to dryness under reduced pressure, and purified by column chromatography to obtain light yellow oil A1 (24 g, yield: 74.1%).
- Step 1 Add sodium methoxide (5.5 g, 101.7 mmol) to a methanol (200 mL) solution of 4,6-dichloronicotinonitrile (A2-1, 16.0 g, 92.5 mmol) at 0°C under argon protection. After adding 0°C and reacting for 20 minutes, the temperature was raised to room temperature for 3 hours.
- Step 2 under argon protection, 6-chloro-4-methoxynicotinonitrile (A2-2, 11 g, 65.2 mmol) and tributyl(1-ethoxyvinyl)stannane (35.3 g, 97.8 mmol) were added ) in 1,4-dioxane was added tetrakistriphenylphosphine palladium (3.78 g, 3.26 mmol). The temperature was raised to 100°C for 16 hours. The solvent was removed by concentration under reduced pressure, diluted with ethyl acetate (300 mL), saturated aqueous potassium fluoride solution was added, and the mixture was stirred at room temperature for 1 hour.
- Step 3 Dissolve 6-(1-ethoxyvinyl)-4-methoxynicotinonitrile (A2-3, 14g, 65.2mmol) in tetrahydrofuran (200mL) and add aqueous hydrochloric acid (2M, 130mL, 260mmol), The reaction was carried out at room temperature for 60 minutes.
- Step 4 To a solution of 6-acetyl-4-methoxynicotinonitrile (A2-4, 8.5 g, 47.75 mmol) in methanol (50 mL) was added sodium borohydride (2.7 g, 71.63 mmol) in an ice-water bath. The reaction was carried out at 0°C for 60 minutes. The reaction was quenched with ice water. Concentrate under reduced pressure to remove most of the methanol solvent.
- Step 5 6-(1-hydroxyethyl)-4-methoxynicotinonitrile (A2-5, 5.6 g, 31.46 mmol) and carbon tetrabromide (15.63 g, 47.19 mmol) were added under argon protection at 0°C ) in dichloromethane (120 mL) was added a solution of triphenylphosphine (12.36 g, 47.19 mmol) in dichloromethane (30 mL). The reaction was stirred at 0°C for 60 minutes.
- Step 1 To a solution of 4,6-dichloronicotinonitrile (A2-1, 20.0 g, 115.6 mmol) in tetrahydrofuran (400 mL) was added sodium ethoxide ethanol solution (20%, 101.3 g) at 0°C under argon protection. , 121.4 mmol). After adding 0°C and reacting for 10 minutes, the temperature was raised to room temperature for 2 hours.
- Step 2 Under argon protection, 6-chloro-4-ethylnicotinonitrile (A3-2, 16.5 g, 90.36 mmol) and tributyl(1-ethoxyethylene) tin (49.0 g, 135.54 mmol) were added ) in 1,4-dioxane (300 mL) was added tetrakistriphenylphosphine palladium (5.2 g, 4.52 mmol). The temperature was raised to 100°C for 16 hours. Concentrate under reduced pressure to remove the solvent, dilute with ethyl acetate (150 mL), add saturated potassium fluoride aqueous solution, stir at room temperature for 1 hour, and separate the layers.
- aqueous phase is extracted with ethyl acetate (200 mL), the organic phases are combined, washed with saturated brine, and dried. , filtered, and the filtrate was concentrated to dryness under reduced pressure. The residue was dissolved in tetrahydrofuran (100 mL) and aqueous hydrochloric acid (2M, 120 mL, 240 mmol) was added. The reaction was carried out at room temperature for 1 hour.
- Step 3 To a methanol (400 mL) solution of 6-acetyl-4-ethoxynicotinonitrile (A3-3, 16.6 g, 87.28 mmol) was added sodium borohydride (3.3 g, 87.28 mmol) at 0°C. The reaction was carried out at 0°C for 1 hour. The reaction was quenched with ice water. Concentrate under reduced pressure to remove most of the methanol solvent.
- Step 4 To 4-ethoxy-6-(1-hydroxyethyl)nicotinonitrile (A3-4, 12.3 g, 63.99 mmol) and triphenylphosphine (33.6 g, 127.98 mmol) at 0°C under argon mmol) in tetrahydrofuran (400 mL) was added carbon tetrabromide (31.8 g, 95.98 mmol). After 5 minutes of reaction at 0°C, the reaction was stirred at room temperature for 16 hours.
- Step 1 Add 1-(6-fluoro-5-methoxypyridin-3-yl)ethan-1-one (A4-1, 3.0 g, 17.73 mmol) in methanol (30 mL) solution under ice-water bath Sodium borohydride (671 mg, 17.73 mmol). The reaction was stirred at room temperature for 60 minutes. The reaction solution was quenched by adding ice water.
- Step 2 1-(6-Fluoro-5-methoxypyridin-3-yl)ethan-1-ol (A4-2, 2.6 g, 15.19 mmol) in dichloromethane ( 40 mL) solution was added triphenylphosphine (6.0 g, 22.78 mmol) and NBS (4.1 g, 22.78 mmol). The reaction was stirred at room temperature for 5 hours.
- reaction solution was diluted with dichloromethane (100 mL), washed with saturated brine (3*100 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was subjected to silica gel chromatography (0 to 20% gradient of ethyl acetate: Petroleum ether) was purified to obtain solid A4 (2.5 g, yield: 70%).
- Step 1 To a solution of 2-bromo-5-fluoropyridin-4-ol (A5-1, 6.0 g, 31.3 mmol) in DMF (50 mL) was added potassium carbonate (10.8 g, 78.2 mmol) and methyl iodide (11.0 g) , 77.5 mmol). The reaction was carried out at room temperature for 16 hours. The reaction solution was diluted with water (50mL), extracted with ethyl acetate (2*150mL), the organic phase was washed with water (3*200mL) and saturated brine (2*200mL), dried, filtered, the filtrate was concentrated to dryness under reduced pressure, and the filtrate was concentrated to dryness under reduced pressure. Chromatographic purification gave white solid A5-2 (2.6 g, yield: 40.4%).
- Step 2 Under argon protection, 2-bromo-5-fluoro-4-methoxypyridine (A5-2, 2.6 g, 12.6 mmol) and tributyl(1-ethoxyvinyl)stannane (6.8 g, 18.9 mmol) in dioxane solution was added tetrakistriphenylphosphine palladium (1.0 g, 0.87 mmol), the temperature was raised to 100°C, and the reaction was carried out for 16 hours. The solvent was removed by concentration under reduced pressure, diluted with ethyl acetate (100 mL), saturated aqueous potassium fluoride solution was added, and the mixture was stirred at room temperature for 1 hour.
- reaction solution was diluted with ethyl acetate (100 mL), washed with saturated sodium bicarbonate and saturated brine successively, dried, filtered, concentrated to dryness under reduced pressure, and purified by column chromatography to obtain white solid A5-3 (1.8 g, yield: 84.3%).
- Step 3 1-(5-fluoro-4-methoxypyridin-2-yl)ethanone (A5-3, 12.9 g, 76.3 mmol) in methanol (100 mL) solution was divided into methanol (100 mL) at 0°C under argon protection. Sodium borohydride (5.75 g, 152.5 mmol) was added in batches. The reaction was stirred at room temperature for 1 hour.
- Step 4 Triphenylphosphine (2.14g, 8.18mmol), NBS (1.25g, 7.01 g) were successively added to a solution of A5-4 (1.0g, 5.84mmol) in dichloromethane (10mL) at 0°C under argon protection mmol). The reaction was stirred at room temperature for 18 hours.
- Step 1 To A8-1 (1.0 g, 6.40 mmol) and potassium carbonate (2.66 g, 19.21 mmol) in DMF (10 mL) was added iodoethane (5.0 g, 32.02 mmol) dropwise. Heat to 50°C and stir the reaction for 5 hours. The reaction solution was diluted with ethyl acetate (30 mL), washed with saturated brine (3*50 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and chromatographed on silica gel (0 to 30% gradient of ethyl acetate: petroleum ether) Purification gave white solid A8-2 (1.1 g, yield: 93.2%).
- Step 2 To A8-2 (1.0 g, 5.43 mmol) in tetrahydrofuran (15 mL) was added dropwise lithium borohydride (2.0 M in THF, 5.4 mL, 10.86 mmol). Heat to 40°C and stir the reaction overnight. The reaction was quenched by adding sodium sulfate decahydrate (3.0 g), filtered, and the filtrate was concentrated under reduced pressure, and purified by silica gel chromatography (0 to 50% gradient of ethyl acetate: petroleum ether) to give A8-3 (580 mg, obtained as a colorless oil). rate: 68.4%).
- Step 1 [1,1'-bis(diphenylphosphino)ferrocene]di Palladium chloride (321 mg, 0.44 mmol) and DIPEA (1.69 g, 13.17 mmol). After replacing the air with carbon monoxide, the mixture was heated to 100°C and reacted for 12 hours. It was diluted with ethyl acetate (400 mL), saturated brine was added, and the mixture was stirred at room temperature for 1 hour.
- Step 2 To a solution of A13-1 (206 mg, 1 mmol) in methanol (10 mL) was added sodium borohydride (75.6 mg, 2 mmol) under an ice-water bath. The reaction was carried out at 0°C for 60 minutes. The reaction was quenched with ice water. Concentrate under reduced pressure to remove most of the methanol solvent.
- Step 3 To a solution of A13-2 (80 mg, 0.45 mmol) in dichloromethane (10 mL) was added thionyl chloride (107 mg, 0.9 mmol) under an ice-water bath. The reaction was carried out at 0°C for 60 minutes.
- Step 1 -75°C, under argon protection, to A1-4 (2.70g, 12.27mmol) in anhydrous tetrahydrofuran (40mL) was added dropwise n-BuLi (1.6M in hexane, 11.5ml, 18.41mmol), -75 The reaction was carried out at °C for 15 minutes. Anhydrous DMF (1.42 ml, 2.05 mmol) was added. React at -75°C for 15 minutes. Add water to quench, extract with ethyl acetate (3*60 mL), combine the organic phases, wash with water, dry, filter, concentrate, and purified by column chromatography to obtain A14-1 (915 mg, yield: 44.1%).
- Step 2 To a solution of A14-1 (1.0 g, 5.91 mmol) in ethanol (20 mL) was added sodium borohydride (671 mg, 17.74 mmol) at 0°C under argon protection. The reaction was carried out at room temperature for 3 hours. The reaction was quenched with saturated aqueous ammonium chloride solution, water was added, extracted with ethyl acetate, dried, concentrated, and purified by column chromatography to obtain A14-2 (690 mg, yield: 68.2%).
- Step 3 To a solution of A14-2 (250 mg, 1.46 mmol) in acetonitrile (10 mL) was added thionyl chloride (0.32 ml, 4.39 mmol) dropwise. The reaction was carried out at room temperature for 1 hour. Distilled under reduced pressure, added dichloromethane, washed with sodium bicarbonate, dried, concentrated, and purified by column chromatography to obtain Intermediate A14 (240 mg, yield: 86.6%).
- Step 3 A15-3 (1.0 g, 5.61 mmol) was mixed with trimethylsilyl chloride (10 mL) and stirred at room temperature for 60 minutes. The reaction solution was poured into ice water. Extracted with ethyl acetate (2*50 mL), the organic phases were combined, washed with saturated aqueous sodium chloride solution (100 mL), dried over anhydrous sodium sulfate and concentrated to obtain Intermediate A15 (1.1 g, yield: 100%). used directly in the next step.
- Step 1 To a solution of A16-1 (600 mg, 4.0 mmol) in ethanol (60 mL) was added sodium borohydride (453 mg, 12.0 mmol) at 0°C. The reaction was stirred at room temperature for 12 hours. The reaction solution was poured into ice water (50 mL), extracted with dichloromethane (2*50 mL), the organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated to dryness under reduced pressure, and subjected to column chromatography Purification gave A16-2 as a colorless oil (450 mg, yield: 74.0%).
- Step 1 under argon protection, to A1-3 (4.59g, 23.91mmol) in N,N-dimethylformamide (135mL) solution under ice-water bath was slowly added sodium hydrogen (60% dispersed in oil, 2.87 g) g, 71.75 mmol). Continue stirring for 10 minutes after the addition is complete. Chlorodifluoroacetic acid (4.66 g, 35.85 mmol) was then added dropwise. React overnight at 70°C.
- Step 2 Compound A17-1 (622mg, 2.57mmol), tributyl(1-ethoxyethylene)tin (1.39g, 3.85mmol), and tetrakis(triphenylphosphorus)palladium (149mg) were added to the dry flask in turn , 0.13 mmol), 1,4-dioxane (40 mL). After the addition, the reaction was carried out at 100°C overnight under nitrogen protection. The reaction solution was concentrated, dissolved in ethyl acetate (20 mL), a saturated aqueous potassium fluoride solution (15 mL) was added, and the mixture was stirred at room temperature for 1 hour.
- Step 3 Trifluoroacetic acid (6 mL) was added dropwise to a solution of A17-2 (590 mg, 2.53 mmol) in dichloromethane (20 mL) under an ice-water bath. React overnight at room temperature. The reaction solution was placed in an ice bath and stirred, and sodium bicarbonate solution was added to adjust to weakly alkaline, water (15 mL) was added for layering, and extraction was performed. The aqueous phase was washed with dichloromethane (2*15 mL). (2*15mL) washed, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by silica gel chromatography to obtain colorless liquid A17-3 (308 mg, yield: 59.3%).
- Step 4 To a solution of A17-3 (308 mg, 1.50 mmol) in methanol (10 mL) was slowly added sodium borohydride (114 mg, 3.0 mmol) under an ice-water bath. After the addition, the reaction was carried out at room temperature overnight. The reaction solution was quenched by adding water (20mL), extracted with ethyl acetate (3*20mL), the organic phases were combined, washed with saturated brine (2*15mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, Prep-TLC Purification gave A17-4 as a colorless oil (295 mg, yield: 94.8%).
- Step 5 Under nitrogen protection, a solution of carbon tetrabromide (180 mg, 0.54 mmol) was added dropwise to a solution of A17-4 (75 mg, 0.36 mmol) and triphenylphosphorus (171 mg, 0.65 mmol) in tetrahydrofuran (4 mL) under an ice-water bath. A solution in tetrahydrofuran (1 mL). React overnight at room temperature.
- Step 1 The synthetic method of reference Tetrahedron Letters (2008), 49(44), 6368-6370 generates A18-1 from A1-3 in one step.
- Step 2 Referring to the synthetic route of intermediate A17, intermediate A18 is generated from intermediate A18-1 through a four-step reaction.
- Step 1 To a solution of A19-1 (2.0 g, 13.14 mmol) in acetonitrile/acetone (40 mL/10 mL) was added phosphorus pentoxide (9.3 g, 65.72 mmol). Heated to 75°C and reacted for 3 hours. Phosphorus pentoxide (4.67 g*4, 131.50 mmol) was added in batches every 4 hours. The reaction was continued for 48 hours.
- Step 3 A19-3 (490 mg, 2.52 mmol) was mixed with trimethylchlorosilane (5 mL) and stirred at room temperature for 1 hour. The reaction solution was poured into ice water, extracted with ethyl acetate (2*20 mL), the organic phases were combined, washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate and concentrated to obtain A19 (500 mg, yield: 93.2%).
- Step 4 Trifluoromethanesulfonic acid (30.4 mL, 344.91 mmol) was slowly added dropwise to a solution of B1-5 (27.8 g, 68.77 mmol) in dichloromethane (500 mL) at 0°C under argon protection. The reaction was stirred at 0°C for 1 hour.
- Step 5 To 7'-bromo-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one (B1-6, 10.72g, 42.52 mmol) in methanol (20 mL) and DMSO (20 mL) was added Pd(dppf)Cl 2 ⁇ CH 2 Cl 2 (3.32 g, 4.07 mmol) and N,N-diisopropylethylamine (21.1 mL, 128.13 mmol). After replacing the air with CO three times, the temperature was raised to 90° C. and reacted for 16 hours.
- Step 6 Add 1'-ketoketo-2',3'-dihydro-1'H-spiro[cyclopropane-1,4 to the mixed solution of concentrated sulfuric acid (20 mL) and glacial acetic acid (20 mL) at 0°C '-Isoquinoline]-7'-carboxylate methyl ester (B1-7, 4.0 g, 17.3 mmol). After stirring for 20 minutes, a solution of 1,3-dibromo-5,5-dimethylhydantoin (4.9 g, 17.3 mmol) in glacial acetic acid (20 mL) was added dropwise to the reaction solution. The reaction was carried out at room temperature for 5 hours.
- Step 7 To 5'-bromo-1'-keto-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-7'-carboxylic acid methyl ester ( To a solution of B1-8, 3.1 g, 10 mmol) in tetrahydrofuran (50 mL) and water (50 mL) was added lithium hydroxide monohydrate (800 mg, 20 mmol). The reaction was carried out at room temperature for 14 hours. LCMS showed 80% product. The solvent tetrahydrofuran was removed under reduced pressure.
- Step 8 To 5'-bromo-1'-keto-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-7'-carboxylic acid at 0°C To a solution of (B1-9, 2.2 g, 7.4 mmol) and triethylamine (2.24 g, 22.2 mmol) in dichloromethane (30 mL) was added isobutyl chloroformate (2.02 g, 14.8 mmol). The reaction was stirred at room temperature for 2 hours. The reaction solution was poured into ice water and stirred at room temperature for 1 hour.
- Step 9 To a solution of B1-10 (1.65 g, 4.2 mmol) in tetrahydrofuran (30 mL) was added sodium borohydride (472 mg, 12.5 mmol) at 0°C. The reaction was carried out at room temperature for 2 hours. The reaction was quenched by the addition of methanol (10 mL). The reaction solution was poured into ice water and stirred at room temperature for 0.5 hour.
- Step 10 Add thionyl chloride (127 mg, 1.068 mmol) to a solution of B1-11 (100 mg, 0.356 mmol) in acetonitrile (20 mL) at 0°C, and react at room temperature for 6 hours. The reaction solution was spin-dried to obtain the crude product 5'-bromo-7'-(chloromethyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1 ⁇ -ketone (B1, 110 mg, yield: 100%).
- Step 1 To a solution of B2-1 (25 g, 127.52 mmol) in DMF (500 mL) was added sodium hydride (60% in mineral oil, 20.4 g, 510.07 mmol) in portions at 0°C under argon. The reaction was carried out at 0°C for 30 minutes. A solution of 1,3-dibromopropane (19.42 mL, 191.28 mmol) in DMF (50 mL) was added dropwise. The reaction was carried out at room temperature for 1 hour. Quench with ice water.
- Step 5 To a solution of B2-5 (1.8 g, 6.77 mmol) in methanol (10 mL) and DMSO (30 mL) was added N,N-diisopropylethylamine (3.3 mL, 20.30 mmol) and [1,1' - Bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (552 mg, 0.677 mmol). After replacing the air with CO three times, the temperature was raised to 90° C. and reacted for 16 hours.
- Step 6 To the mixed solution of B2-6 (1.3g, 5.3mmol) in concentrated sulfuric acid (10mL) and glacial acetic acid (10mL) at 0°C, 1,3-dibromo-5,5-dimethyl was slowly added dropwise Hydantoin (3.0 g, 10.6 mmol) in glacial acetic acid (10 mL). The reaction was carried out at room temperature for 16 hours. The reaction was quenched with ice water, extracted with ethyl acetate (3*50 mL), the organic phases were combined, dried, filtered, concentrated, and purified by column chromatography to obtain B2-7 (1.2 g, yield: 69.8%).
- Step 7 Lithium borohydride (2M in THF, 9.3 mL, 18.51 mmol) was added dropwise to a mixed solution of B2-7 (1.2 g, 3.70 mmol) in THF (10 mL) and ethanol (2 mL) at 0°C. The reaction was carried out at room temperature for 10 minutes and then heated to 45°C for 2 hours. The reaction was quenched with ice water. Extracted with ethyl acetate (3*50 mL), combined the organic phases, dried, filtered, concentrated, and purified by column chromatography to obtain B2-8 (580 mg, yield: 52.7%).
- Step 8 To a solution of B2-8 (200 mg, 0.675 mmol) in acetonitrile (10 mL) was added dropwise thionyl chloride (0.15 mL, 2.03 mmol) at 0°C. The reaction was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure to obtain B2 (215 mg, 0.675 mmol), and the crude product was directly used in the next step.
- Step 2 To a solution of B10-2 (21 g, 82.32 mmol) in tetrahydrofuran (300 mL) was added (trifluoromethyl)trimethylsilane (93.6 g, 658.54 mmol) and sodium iodide (7.4 g, 49.39 mmol). The reaction was carried out in a stuffy tank at 110°C for 14 hours.
- Step 4 To a solution of B10-4 (31.8 g, 114.78 mmol) in DMA (600 mL) was added DIPEA (89.0 g, 688.66 mmol) and HATU (52.37 g, 137.73 mmol). Stir at room temperature for 30 minutes. Ammonium chloride (18.42 g, 344.33 mmol) was added. After stirring at room temperature for 30 minutes, the reaction solution was heated to 60°C for 16 hours. After cooling to room temperature, add ethyl acetate (1.5L) to dilute, wash with water (3*1L), and wash with saturated aqueous sodium chloride solution (1L).
- Step 8 To a solution of B10-8 (7.8 g, 27.07 mmol) in methanol (80 mL) and dimethyl sulfoxide (160 mL) was added DIPEA (10.5 g, 81.22 mmol) and [1,1'-bis(diphenylene)] phosphino)ferrocene]palladium dichloride (1.98 g, 2.71 mmol). After replacing the air with carbon monoxide, the reaction was carried out at 90°C for 8 hours.
- Step 9 Add 1,3-dibromo-1,3,5-triazine-2,4,6-triazine to a solution of B10-9 (3 g, 11.23 mmol) in acetic acid (30 mL) and concentrated sulfuric acid (60 mL) Ketone (8 g, 28.07 mmol). The reaction was carried out at room temperature for 3 hours.
- Step eleven To a solution of B10-11 in dichloromethane (6 mL) was added thionyl chloride (375 mg, 3.14 mmol) dropwise. The reaction was carried out at room temperature for 5 hours. After monitoring that the reaction was not completed, thionyl chloride (750 mg, 6.28 mmol) was added, and the reaction was continued for 16 hours.
- Step 1 To a solution of B11-1 (50 g, 255.03 mmol) in DMF (1 L) was added sodium hydride (60% in oil, 22.4 g, 561.08 mmol) in portions under ice-water bath. Stir at room temperature for 1 hour. 1,3-Dibromo-2,2-dimethoxypropane (73.5 g, 280.54 mmol) was added dropwise. Heated to 60°C for 16 hours.
- reaction solution was cooled to room temperature, poured into ice water, extracted with ethyl acetate (2*700mL), the organic phases were combined, washed with water (3*500mL), washed with saturated aqueous sodium chloride solution (2*700mL), and dried over anhydrous sodium sulfate After concentration. The residue was dissolved in petroleum ether and filtered to obtain B11-2 (55 g, yield: 72.8%).
- Step 3 B11-3 (30 g, 120.0 mmol) was dissolved in dichloromethane (300 mL) and methanol (0.3 mL). After stirring for 10 minutes, DAST (92 mL, 319.8 mmol) was added dropwise under an ice-water bath. The reaction was carried out at room temperature for 3 hours.
- Step 6 Trifluoromethanesulfonic acid (32.7 mL, 369.82 mmol) was added dropwise to a solution of B11-7 (24.0 g, 52.83 mmol) in dichloromethane (300 mL) under an ice-water bath. The reaction was carried out at room temperature for 3 hours. The reaction solution was poured into ice water, dichloromethane (500 mL) was added, the organic phase was washed with water (2*500 mL), washed with saturated aqueous sodium chloride solution (2*500 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was dissolved in petroleum ether/dichloromethane (10/1), and filtered to obtain B11-8 (8.3 g, yield: 51.9%).
- Step 7 To B11-8 (7.5 g, 24.82 mmol) in methanol (25 mL) and dimethyl sulfoxide (100 mL) was added DIPEA (9.6 g, 74.47 mmol) and [1,1'-bis(diphenyl) phosphine)ferrocene]palladium dichloride (1.27 g, 1.74 mmol). The carbon monoxide environment was reacted at 90°C for 4 hours.
- Step 1 2-nitro-1H-imidazole (C1-1, 9000 mg, 79.8 mmol) was added to anhydrous tetrahydrofuran (270 mL), and sodium hydrogen (60%, 3.5 g, 87.5 mmol) was added under ice bath. The reaction was carried out at 0°C for 0.5 hours under argon protection. After dropwise addition of (2-(chloromethoxy)ethyl)trimethylsilicon (14.6 g, 87.6 mmol), the mixture was reacted at 0°C for 2 hours.
- Step 2 Add 2-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole 14-2 (C1-2, 14.3 g, 58.8 mmol) to in absolute ethanol (420 mL). The hydrogen was replaced three times, and the reaction was carried out at room temperature for 16 hours under the protection of hydrogen. The reaction solution was filtered, and the filtrate was concentrated to obtain crude 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-amine. The crude 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-amine was dissolved in dichloromethane (300 mL).
- Step 3 (1-(((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)carbamic acid tert-butyl ester (C1-3, 9.6g, 30.7 mmol) was added to anhydrous tetrahydrofuran (300 mL). Cool to 0 °C, add sodium hydrogen (60%, 1.5 g, 37.5 mmol). Under argon protection, react at 0 °C for 15 minutes, and dropwise add iodomethane (6.5 g, 45.8 mmol). mmol). Reaction at 0 °C for 3 hours.
- Step 4 tert-butylmethyl (1-(((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)carbamate (C1-4, 8.2g , 25.0 mmol) was added to anhydrous tetrahydrofuran (200 mL), and a solution of tetrabutylamine fluoride in tetrahydrofuran (1 M, 125 mL, 125 mmol) was added. The reaction was carried out at 80° C. for 1 hour under argon protection. The reaction solution was concentrated, and the crude product was subjected to column chromatography.
- Step 1 To a solution (4 mL) of 1-ethylpiperazine (460 mg, 4 mmol) in tetrahydrofuran (20 mL) was added potassium bromomethyl trifluoroborate (200 mg, 1 mmol). After replacing the air with nitrogen, the reaction was carried out at 80°C for 3 hours. The reaction solution was spin-dried to obtain crude product. The obtained crude product was dissolved in acetone (20 mL), potassium bicarbonate (100 mg, 1 mmol) was added, and the suspension was stirred at room temperature for 1 hour. After filtration, the filtrate was concentrated to dryness under reduced pressure to obtain a white solid ((4-ethylpiperazin-1-yl)methyl)potassium trifluoroborate (D57, 250 mg, yield: 100%).
- Step 1 To tert-butyl (1H-imidazol-2-yl)(methyl)carbamate (C1, 197 mg, 1 mmol), tetrabutylammonium iodide (369 mg, 1 mmol) and cesium carbonate (650 mg) at 0°C , 2mmol) in DMF (45mL) was added 5'-bromo-7'-(chloromethyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline Lino]-1'-one (B1, 302 mg, 1 mmol). The reaction was carried out at 80°C for 5 hours.
- Step 2 To tert-butyl(1-(((5'-bromo-1'-one-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline] -7'-yl)methyl)-1H-imidazol-2-yl)(methyl)carbamate (1-1, 230 mg, 0.5 mmol) and N,N-dimethylaminomethyltrifluoroboronic acid To a mixed solution of potassium (1-2, 165 mg, 1 mmol) in dioxane (dioxane, 6 mL) and water (2 mL) was added Pd(dppf)Cl 2 (37 mg, 0.05 mmol), K 2 CO 3 (138 mg, 1 mmol).
- Step 3 Add tert-butyl(1-((5'-(((dimethylamino)methyl)-1'-keto-2',3'-dihydro-1'H-spiro at 0°C [Cyclopropane-1,4'-isoquinoline]-7'-(methyl)-1H-imidazol-2-yl)(methyl)carbamate (1-3, 100 mg, 0.228 mmol) in DMF To the solution (15 mL) was added NaH (60% in mineral oil, 30 mg, 0.72 mmol). Stir at 0°C for 20 min. Add 2-(1-bromoethyl)-4-ethoxy-5-fluoropyridine ( A1, 90 mg, 0.363 mmol).
- reaction was stirred at room temperature for 2 hours.
- the reaction solution was poured into ice water (20 mL), extracted with dichloromethane (2*50 mL), the organic phases were combined, washed with saturated brine (100 mL), and dried over anhydrous sodium sulfate.
- Step 4 To tert-butyl(1-((5'-((dimethylamino)methyl)-2'-(1-(4-ethoxy-5-fluoropyridin-2-yl) at 0°C )ethyl)-1'-one-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinolin]-7'-yl)methyl)-1H-imidazole To a solution of -2-yl)(methyl)carbamate (1-4, 90 mg, 0.148 mmol) in dichloromethane (10 mL) was added trifluoroacetic acid (4 mL). The reaction was stirred at room temperature for 2 hours.
- reaction solution was poured into ice water (30 mL) and neutralized to pH 7 with saturated aqueous sodium bicarbonate solution.
- Dichloromethane (2*100mL) was extracted, the organic phases were combined, washed with saturated brine (100mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated to dryness under reduced pressure, and separated and purified by high performance liquid chromatography (SunFire Prep C18OBD 10um, acetonitrile/water system) to give a white solid, which was then passed through SFC (column type: Mobile phase: redistilled grade EtOH and Supercritical CO 2 ; wavelength: 214 nm) to separate compound 1 (formate, 16 mg, yield: 19.5%) and compound 1' (formate, 18 mg, yield: 22%).
- SFC columnumn type: Mobile phase: redistilled grade EtOH and Supercritical CO 2 ; wavelength: 214 nm
- the following compounds can be synthesized by the same method or an improved method by referring to the synthesis method of compound 1 in Example 1, using the corresponding intermediate.
- Step 1 Under argon protection, tert-butyl(1-((5'-(((dimethylamino)methyl)-1'-one-2',3'-dihydro-1 'H-spiro[cyclopropane-1,4'-isoquinoline]-7'-(methyl)-1H-imidazol-2-yl)(methyl)carbamate (1-3, 80 mg, 0.18 mmol) in DMF (10 mL) was added NaH (60% in mineral oil, 21 mg, 0.55 mmol). Stir at 0°C for 20 min.
- Step 2 To tert-butyl(1-((2'-(1-(5-cyano-4-methoxypyridin-2-yl)ethyl)-5'-((dimethyl Amino)methyl)-1'-one 2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinolin]-7'-yl)methyl)-1H-imidazole To a solution of -2-yl)(methyl)carbamate (2-1, 30 mg, 0.05 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (2 mL). The reaction was stirred at room temperature for 2 hours.
- Step 1 0°C, under argon protection, to tert-butyl(1-((5'-(((dimethylamino)methyl)-1'-one-2',3'-dihydro-1' H-spiro[cyclopropane-1,4'-isoquinoline]-7'-(methyl)-1H-imidazol-2-yl)(methyl)carbamate (1-3, 80 mg, 0.18 mmol ) in DMF (10 mL) was added NaH (60% in mineral oil, 21 mg, 0.55 mmol). Stir at 0°C for 20 min.
- Step 2 To tert-butyl(1-((2'-(1-(5-cyano-4-ethoxypyridin-2-yl)ethyl)-5)-((dimethyl) at 0°C (ylamino)methyl)-1'-one 2',3'-dihydro-1'H-spiro[cyclopropan-1,4'-isoquinolin]-7'-yl)methyl)-1H- To a solution of imidazol-2-yl)(methyl)carbamate (3-1, 45 mg, 0.073 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (1 mL). The reaction was stirred at room temperature for 2 hours.
- Step 1 To tert-butyl(1-(((5'-bromo-1'-one-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline] -7'-yl)methyl]-1H-imidazol-2-yl)(methyl)carbamate (1-1, 46 mg, 0.1 mmol) and 1-((trifluoroboranyl)methyl) To a solution of pyrrolidine potassium salt (D75, 38.4 mg, 0.2 mmol) in water (1 mL) and dioxane (4 mL) was added 1,1-bis(diphenylphosphino)pyridinium palladium dichloride (7.3 mg) , 0.01 mmol) and potassium carbonate (26.8 mg, 0.2 mmol).
- Step 2 To tert-butylmethyl (1-((1'-keto-5'-(pyrrolidin-1-ylmethyl)-2',3'-dihydro-1'H-spiro at 0°C [Cyclopropan-1,4'-isoquinolin]-7'-yl)methyl)-1H-imidazol-2-yl)carbamate (6-2, 30 mg, 0.064 mmol) in N,N- To a solution of dimethylformamide (10 mL) was added sodium hydride (60% in mineral oil, 10 mg, 0.204 mmol). Stir at 0°C for 20 minutes.
- Step 3 To tert-butyl(1-((2'-(1-(4-ethoxy-5-fluoropyridin-2-yl)ethyl)-1)-one 5'-( Pyrrolidin-1-ylmethyl)-2',3'-dihydro-1'H-spiro[cyclopropan-1,4'-isoquinolin]-7'-yl)methyl)-1H-imidazole To a solution of -2-yl)(methyl)carbamate (6-3, 20 mg, 0.0316 mmol) in dichloromethane (4 mL) was added trifluoroacetic acid (1 mL). The reaction was stirred at room temperature for 2 hours.
- Step 1 To a solution of B2 (215 mg, 0.675 mmol) in DMF (10 mL) at 0°C was added cesium carbonate (445 mg, 1.369 mmol) and tetrabutylamine iodide (253 mg, 0.685 mmol). After 20 minutes of reaction at 0°C, a solution of (1H-imidazol-2-yl)(methyl)carbamate C1 (270 mg, 1.369 mmol) in DMF (2 mL) was added. The reaction was carried out at 80°C for 3 hours. The reaction was complete as monitored by LCMS.
- Step 2 under argon protection, 23-1 (180 mg, 0.379 mmol) and N,N-dimethyl-1-(trifluoro-14-boranyl)methanamine potassium salt 1-2 (125 mg, 0.757 mmol), potassium carbonate (105 mg, 0.757 mmol) in dioxane (6 mL) and water (2 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride Dichloromethane complex (62 mg, 0.076 mmol). The reaction was microwaved at 115°C for 1.5 hours under argon protection. The reaction was complete as monitored by LCMS.
- Step 3 To a solution of 23-2 (33 mg, 0.072 mmol) in dry DMF (8 mL) was added sodium hydride (60% in oil, 13 mg, 0.325 mmol) at 0°C under nitrogen protection. After stirring was continued for 30 minutes at 0°C, a solution of A3 (30 mg, 0.118 mmol) in DMF (2 mL) was added dropwise. The reaction solution was kept at 0°C for 20 minutes.
- Step 4 To a solution of 23-3 (25 mg, 0.040 mmol) in dichloromethane (10 mL) was added dropwise trifluoroacetic acid (2.5 mL). The reaction was carried out at room temperature for 1 hour. The reaction solution was concentrated to remove trifluoroacetic acid, the residue was diluted with dichloromethane (50 mL), the organic phase was washed successively with saturated sodium bicarbonate (50 mL) and saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated To dryness, the residue was purified by high performance liquid chromatography (SunFire Prep C18OBD 10um, acetonitrile/water system) to obtain the racemic product, and then passed through SFC (column type: Mobile phase: redistilled grade EtOH and Supercritical CO 2 ; wavelength: 214 nm; system: Waters SFC 150) was purified to obtain chiral compounds 23 (9 mg, yield: 42.9%) and 23' (8.8
- the following compounds can be synthesized by the same method or an improved method by referring to the synthesis method of compound 23 in Example 5, using the corresponding intermediate.
- Step 2 To a solution of 70-1 (513 mg, 1.13 mmol) in dry DMF (15 mL) was added sodium hydride (60% in oil, 200 mg, 5 mmol) at 0°C under nitrogen protection. The reaction was kept at 0°C for 30 minutes. A solution of Al (330 mg, 1.33 mmol) in DMF (5 mL) was added dropwise. The reaction was kept at 0°C for 30 minutes.
- Step 3 Lithium borohydride (2M in tetrahydrofuran, 1.2 mL, 2.4 mmol) was added dropwise to a solution of compound 70-2 (500 mg, 0.80 mmol) in dry tetrahydrofuran (30 mL) at 0°C under nitrogen protection. After keeping the temperature at 0°C for 5 minutes, the temperature was raised to 25°C, and the reaction was incubated overnight. The reaction solution was poured into water, extracted with dichloromethane (3*80 mL), the organic phases were combined, washed with saturated brine (150 mL), dried over anhydrous sodium sulfate, filtered, concentrated to dryness, and the residue was dissolved in methanol (50 mL).
- Step 4 Triethylamine (104 mg, 1.03 mmol) was added to a solution of compound 70-3 (50 mg, 0.086 mmol) in dichloromethane (5 mL) at 0°C under nitrogen protection, followed by dropwise addition of methanesulfonyl chloride (80 mg, 0.70 mmol). ) in dichloromethane (4 mL). After the addition was completed, the temperature was raised to 25°C after the reaction was kept at 0°C for 5 minutes, and the reaction was maintained for 1 hour.
- reaction solution was poured into water, extracted with dichloromethane (2*50 mL), the organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain a colorless oil 70-4 (crude, 60 mg).
- Step 6 To a solution of 70-6 (50 mg, 0.074 mmol) in dichloromethane (10 mL) was added dropwise trifluoroacetic acid (2.5 mL). The reaction was carried out at room temperature for 1 hour. The reaction solution was concentrated to remove trifluoroacetic acid, the residue was diluted with dichloromethane (50 mL), washed successively with saturated sodium bicarbonate (50 mL) and saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness , the residue was separated and purified by high performance liquid chromatography to obtain a light yellow solid, which was separated and purified by SFC to obtain 2'-((S)-1-(4-ethoxy-5-fluoropyridin-2-yl)ethyl )-5'-((3-methyl-3,6-diazabicyclo[3.1.1]heptan-6-yl)methyl)-7'-((2-(methylamino)- 1
- Step 1 Dess-Martin oxidant (190 mg, 0.45 mmol) was added to a solution of 70-3 (200 mg, 0.35 mmol) in dichloromethane (10 mL) at 0°C under nitrogen protection. After the addition was completed, the reaction was kept at 0°C for 2 hours. The reaction solution was poured into water, extracted with dichloromethane (2*60 mL), the organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated to dryness under reduced pressure, and purified by column chromatography to obtain white Solid 41-1 (200 mg, yield: 100%).
- Step 2 To a solution of 41-1 (50 mg, 0.086 mmol) in dichloroethane (10 mL) was added methylamine tetrahydrofuran solution (2 mL, 4 mmol) under nitrogen protection. React overnight at room temperature. The reaction solution was cooled to 0°C. Sodium cyanoborohydride (10 mg, 0.17 mmol) was added. The temperature was raised to room temperature for 2 hours.
- Step 4 To a solution of 41-3 (5 mg, 0.007 mmol) in dichloromethane (5 mL) was added dropwise trifluoroacetic acid (1 mL). The reaction was carried out at room temperature for 1 hour. The reaction solution was concentrated to remove trifluoroacetic acid. The residue was diluted with dichloromethane (50 mL), washed successively with saturated sodium bicarbonate (50 mL) and saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated to dryness under reduced pressure, and the residue was subjected to HPLC Chromatographic separation and purification gave the diformate salt of white compound 41 (0.26 mg, yield: 5.3%).
- Step 1 Referring to the synthesis process of 1-1, the intermediate 88-1 was synthesized in one step using B10 as the starting compound.
- Step 2 Add sodium hydride (60% in oil, 40 mg, 1.01 mmol) to a solution of 88-1 (125 mg, 0.25 mmol) in DMF (5 mL) at 0°C under argon. Stir at 0°C for 0.5 hours. A solution of Al (187 mg, 0.75 mmol) in DMF (2 mL) was added dropwise. After the addition, the reaction was continued for 3 minutes. TLC showed the reaction was complete.
- Step 4 To a solution of 88-3 (65 mg, 0.10 mmol) in dichloromethane (4 mL) was added dropwise trifluoroacetic acid (1 mL). The reaction was carried out at room temperature for 3 hours. The reaction solution was poured into ice water, extracted with dichloromethane (20 mL), concentrated and separated and purified by high performance liquid chromatography to obtain two diastereomers 5'-((dimethylamino)methyl)-2'-( 1-(4-Ethoxy-5-fluoropyridin-2-yl)ethyl)-2,2-difluoro-7'-((2-(methylamino)-1H)imidazol-1-yl)methyl base)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinolin]-1'-one (compound 88: 6 mg, yield: 10.9% and compound 89: 7 mg, yield: 12.8%).
- Compound 88 (300 mg) was separated and purified by SFC to obtain two white solid compounds 90 (75.11 mg, yield: 25.0%) and compound 91 (78.88 mg, yield: 26.3%).
- the absolute configuration of compound 90 and compound 91 can be obtained from XRD single crystal diffraction data, or can be obtained from the co-crystal structure analysis of compound and WDR5 protein.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (85)
- 一种式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物:式中,环A为取代或未取代的3-8元饱和或不饱和碳环或取代或未取代的3-8元饱和或不饱和杂环,所述杂环含有1-2个独立选自N、O和S的杂原子;X 3选自CR 5和N;X 4选自任选取代的-(CH 2) n-、-C(=O)-和NR 6,其中,n为1、2或3;X 5选自N和CR 5;L 1选自键、任选取代的C1-C6亚烷基、任选取代的C1-C6亚烷基-O-、任选取代的C1-C6亚烷基-NH-、任选取代的C1-C6亚烷基-S-和任选取代的C2-C4亚链烯基;L 2选自键、任选取代的C1-C6亚烷基、任选取代的C1-C6亚烷基-O-、任选取代的C1-C6亚烷基-NH-、任选取代的C1-C6亚烷基-S-和任选取代的C2-C4亚链烯基;R 0选自H、C1-C6烷基、任选取代的C1-C6烷氧基、任选取代的C1-C6卤代烷基、-C(O)NR 3R 4、-CH 2OR 3和-NR 3R 4取代的C1-C6烷基;R 1选自任选取代的环烷基、任选取代的芳基、任选取代的杂芳基、任选取代的杂环基、任选取代的氨基和胍基;R 2选自任选取代的环烷基、任选取代的芳基、任选取代的杂芳基和任选取代的杂环基;R 3和R 4各自独立选自H、任选取代的C1-C6烷基、任选取代的C1-C6烷氧基、任选取代的C1-C6卤代烷基、任选取代的4-10元杂环基和任选取代的5-10元杂芳 基;或者,R 3和R 4与其所连接的氮原子一起形成任选取代的4-10元杂环基或5-10元杂芳基;R 5选自H、卤素、C1-C6烷基、卤代C1-C6烷基和C1-C6烷氧基;R 6选自H、C1-C6烷基、卤代C1-C6烷基和C1-C6烷氧基。
- 如权利要求1所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A为C3-C8环烷基或3-7元杂环基。
- 如权利要求1或2所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A选自环丙基、环丁基、环戊基、环己基、氮杂环丙基、氮杂环丁基、吡咯烷基、哌啶基、哌嗪基、氧杂环丙基、氧杂环丁基、四氢呋喃基、四氢吡喃基和吗啉基。
- 如权利要求1至3之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A被1、2或3个选自卤素、羟基、氰基、C1-C6烷基、卤代C1-C6烷基、羟基取代的C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b、-NR aR b取代的羰基、-NR aR b取代的C1-C6烷基、C1-C6烷基羰基、C1-C6烷氧基羰基、任选取代的6-14元芳基、任选取代的5-10元杂芳基、任选取代的4-10元杂环基、任选取代的C3-C8环烷基、任选取代的6-14元芳基取代的C1-C6烷基、任选取代的5-10元杂芳基取代的C1-C6烷基、任选取代的4-10元杂环基取代的C1-C6烷基、和任选取代的C3-C8环烷基取代的C1-C6烷基的取代基取代;其中,所述6-14元芳基、5-10元杂芳基、4-10元杂环基和C3-C8环烷基被取代时,取代基为1、2或3个选自卤素、C1-C6烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b、-NR aR b取代的羰基、-NR aR b取代的C1-C6烷基、C1-C6烷基羰基、C1-C6烷氧基羰基的取代基;并且其中,所述R a和R b各自独立选自H和C1-C6烷基。
- 如权利要求1至4之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A为环丙基、环丁基、环戊基、氮杂环丁基、氧杂环丁基、氮杂环戊基或四氢呋喃基。
- 如权利要求1至5之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A任选地被1、2或3个选自F、Cl、Br、CF 3、CH 3、-OH、-OCH 3、-NH 2、-NHCH 3,-NH 2(CH 3) 2的取代基取代。
- 如权利要求1至6之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 0为-NR 3R 4取代的C1-C6烷基;其中,R 3和R 4各自独立选自H,任选被1、2、3、4、5或6个选自卤素、氰基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代的C1-C6烷基,或者R 3和R 4与其所连接的氮原子一起形成氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 所述氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 各自任选地被1、2或3个选自卤素、氰基、C1-C6烷基、C3-C6环烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、磺基、C1-C6烷基磺酰基、C1-C6烷氧基磺酰基、C1-C6烷基羰基、羟基和卤代C1-C6烷基羰基的取代基取代,其中,R a和R b各自独立为H或C1-C4烷基。
- 如权利要求1至7之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 0为-NR 3R 4取代的C1-C6烷基,并且其中,R 3和R 4与其所连接的氮原子一起形成氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 所述氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 各自任选地被1、2或3个选自卤素、氰基、C1-C6烷基、C3-C6环烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、磺基、C1-C6烷基磺酰基、C1-C6烷氧基磺酰基、C1-C6烷基羰基、卤代C1-C6烷基羰基、C1-C6烷氧基羰基、卤代C1-C6烷氧基羰基、-NR aR b和羟基的取代基取代,其中,R a和R b各自独立为H或C1-C4烷基。
- 如权利要求1至8之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 0为-NR 3R 4取代的C1-C6烷基,其中,R 3和R 4与其所连接的氮原子一起形成氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 所述氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 各自任选地被1、2或3个选自卤素、氰基、C1-C6烷基、C3-C6环烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代;其中,R a和R b各自独立为H或C1-C4烷基。
- 如权利要求1至9之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,X 3和/或X 5为CR 5。
- 如权利要求1至10之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 5选自H和C1-C4烷基。
- 如权利要求1至11之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,X 4为-(CH 2) n-,n为1或2;并且其中,所述-(CH 2) n-任选被1或2个选自卤素、羟基、氨基、C1-C6烷基和卤代C1-C6烷基的取代基取代。
- 如权利要求1至12之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,L 1选自C1-C6亚烷基、C1-C6亚烷基-O-、C1-C6亚烷基-NH-、C1-C6亚烷基-S-和C2-C4亚链烯基,所述C1-C6亚烷基、C1-C6亚烷基-O-、C1-C6亚烷基-NH-、C1-C6亚烷基-S-和C2-C4亚链烯基任选被1、2或3个选自卤素、C1-C4烷基和羟基的取代基取代。
- 如权利要求1至13之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,L 1选自C1-C6亚烷基或C1-C6亚烷基-NH-,所述C1-C6亚烷基或C1-C6亚烷基-NH-任选被1、2或3个选自卤素、C1-C4烷基和羟基的取代基取代。
- 如权利要求1至14之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 1选自任选取代的C3-C8环烷基、任选取代的6-14元芳基、任选取代的5-10元杂芳基和任选取代的4-10元杂环基,并且所述环烷基、芳基、杂芳基和杂环基各自可任选地被1、2或3个选自任选取代的氨基、C1-C6烷基、卤素、羟基、C1-C6烷氧基、C1-C6卤代烷基和氰基的取代基取代;其中,所述任选取代的氨基是-NR aR b,其中,R a和R b各自独立为H或C1-C6烷基。
- 如权利要求1至15之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 1选自任选取代的苯基、萘基、吡啶基、吡咯基、吡唑基、咪唑基、咪唑酮基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并咪唑基、吡啶并吡咯基、吡啶并咪唑基、苯并三唑基、噁唑酮基、噁唑烷酮基、苯并噁唑基、苯并异噁唑基、喹啉基、吡咯烷基、吗啉基、哌嗪基、高哌嗪基、哌啶基、吡喃基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基、四氢吡喃基、四氢呋喃基、噁嗪基、四氢异喹啉基、十氢异喹啉基、咪唑啉基、咪唑烷基、喹嗪基、噻唑烷基、异噻唑烷基、异噁唑烷基、二氢吲哚基、八氢吲哚基、八氢异吲哚基、吡咯烷基、吡唑烷基、邻苯二甲酰亚氨基、
- 如权利要求1至17之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,L 2选自键、C3-C5环烷基和C1-C6亚烷基,其中,所述C3-C5环烷基、C1-C6亚烷基任选地被1、2或3个选自卤素、C1-C3烷基、C3-C5环烷基和羟基的取代基取代。
- 如权利要求1至18之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 2任选地被1、2或3个选自-NR aR b、氰基、C1-C6烷基、卤素、羟基、C1-C6烷氧基、卤代C1-C6烷基、卤代C1-C6烷氧基、C3-C8环烷基、C3-C8环烷基-O-、6-14元芳基和5-10元杂芳基的取代基取代;其中,R a和R b各自独立为H或C1-C6烷基;并且其中,所述杂芳基优选为含有1或2个环氮原子的杂芳基,优选选自吡唑基、咪唑基、吡啶基、吡嗪基和哌嗪基。
- 如权利要求1至19之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 2选自6-14元芳基、5-10元杂芳基和4-10元杂环基,所述的6-14元芳基、5-10元杂芳基和4-10元杂环基可任选地被1、2或3个选自-NR aR b、氰基、C1-C6烷基、卤素、羟基、C1-C6烷氧基、卤代C1-C6烷基、卤代C1-C6烷氧基、C3-C8环烷基、C3-C8环烷基-O-、6-14元芳基和5-10元杂芳基的取代基取代。
- 如权利要求1至20之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 2选自苯基、萘基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、杂氮环丁烷基、吡咯烷基、吗啉基、哌嗪基、高哌嗪基、哌啶基、吡喃基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基、四氢吡喃基、四氢呋喃基、噁嗪基、四氢异喹啉基、苯并二氢呋喃基、十氢异喹啉基、咪唑啉基、咪唑烷基、6,7-二氢-5H-环戊烷[c]吡啶、喹嗪基、噻唑烷基、异噻唑烷基、异噁唑烷基、二氢吲哚基、八氢吲哚基、八氢异吲哚基、吡咯烷基、吡唑烷基、 所述苯基、萘基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、杂氮环丁烷基、吡咯烷基、吗啉基、哌嗪基、高哌嗪基、哌啶基、吡喃基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基、四氢吡喃基、四氢呋喃基、噁嗪基、四氢异喹啉基、苯并二氢呋喃基、十氢异喹啉基、咪唑啉基、咪唑烷基、6,7-二氢-5H-环戊烷[c]吡啶、喹嗪基、噻唑烷基、异噻唑烷基、异噁唑烷基、二氢吲哚基、八氢吲哚基、八氢异吲哚基、吡咯烷基、吡唑烷基、 任选地被1、2或3个选自-NR aR b、氰基、C1-C6烷基、卤素、羟基、C1-C6烷氧基、卤代C1-C6烷基、卤代C1-C6烷氧基、C3-C8环烷基、C3-C8环烷基-O-、6-14元芳基和5-10元杂芳基的其取代基取代。
- 如权利要求1至21之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,L 2为C1-C4亚烷基,R 2为6-14元芳基、5-10元含氮杂芳基或4-10元杂环基,所述6-14元芳基、5-10元含氮杂芳基或4-10元杂环基任选被1或2个选自C1-C6烷氧基、卤素、C1-C6烷基、氰基、C3-C8环烷基-O-和卤代C1-C6烷氧基的取代基取代;R 2优选为苯基、吡啶基、吡唑基、吡咯并吡啶基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基、吲哚基、 所 述苯基、吡啶基、吡唑基、吡咯并吡啶基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基、 任选被1或2个选自C1-C6烷氧基、卤素、C1-C6烷基、氰基、C3-C8环烷基-O-和卤代C1-C6烷氧基的取代基取代。
- 如权利要求1所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A为C3-C6环烷基或4-8元杂环基,所述环烷基或杂环基任选地被1、2或3个选自卤素、C1-C4烷基、卤代C1-C4烷基、C1-C4烷氧基、卤代C1-C4烷氧基的取代基取代;X 3和X 5均为CH;X 4为CH 2;L 1为C1-C4亚烷基;R 1为任选被1或2个选自卤素、C1-C4烷基和-NR aR b的取代基取代的5或6元含氮杂芳基,所述5或6元含氮杂芳基优选为吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基或 其中,R a和R b各自独立为H或C1-C4烷基;L 2为C1-C4亚烷基;R 2为苯基、5-10元含氮杂芳基或4-10元杂环基,优选为吡啶基、嘧啶基、吡唑基、吡咯基、咪唑基、吡嗪基、吡咯并吡啶基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基或吲哚基,所述苯基、5-10元含氮杂芳基和4-10元杂环基各自任选地被1或2个选自C1-C6烷氧基、卤素、C1-C6烷基、氰基、C3-C8环烷基-O-和卤代C1-C6烷氧基的取代基取代;R 0为-NR 3R 4取代的C1-C4烷基;其中,R 3和R 4各自独立选自H,任选被1-6个选自羟基、氰基和卤素的取代基取代的C1-C6烷基和任选被1、2或3个选自卤素、C1-C6烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代的4-8元杂环基,其中,R a和R b各自独立为H或C1-C4烷基;或R 3和R 4与其所连接的氮原子一起形成任选被1、2或3个选自卤素、C1-C6烷 基、C3-C6环烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代的4-8元杂环基,其中,R a和R b各自独立为H或C1-C4烷基;优选地,所述4-8元杂环基各自独立选自氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、吗啉基、
- 如权利要求1所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A为C3-C6环烷基,所述环烷基任选地被1、2或3个选自卤素、C1-C4烷基和卤代C1-C4烷基的取代基取代;X 3和X 5均为CH;X 4为CH 2;L 1为C1-C4亚烷基;R 1为任选被1或2个选自C1-C4烷基和-NR aR b的取代基取代的5或6元含氮杂芳基,优选为吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基或 其中,R a和R b各自独立为H或C1-C4烷基;L 2为C1-C4亚烷基;R 2为5-10元含氮杂芳基或4-10元杂环基,优选为吡啶基、嘧啶基、吡唑基、吡咯基、咪唑基、吡嗪基、吡咯并吡啶基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基或吲哚基,所述5-10元含氮杂芳基或4-10元杂环基各自任选被1或2个选自C1-C6烷氧基、C1-C6烷基、C3-C8环烷基-O-、卤代C1-C6烷氧基、卤素和氰基的取代基取代;
- 式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物:其中,环A为取代或未取代的3-8元饱和或不饱和碳环或取代或未取代的3-8元饱和或不饱和杂环,所述杂环含有1-2个独立选自N、O和S的杂原子;L 2选自键、任选取代的C1-C6亚烷基、任选取代的C1-C6亚烷基-O-、任选取代的C1-C6亚烷基-NH-、任选取代的C1-C6亚烷基-S-和任选取代的C2-C4亚链烯基;R 0选自H、C1-C6烷基、任选取代的C1-C6烷氧基、任选取代的C1-C6卤代烷基、-C(O)NR 3R 4、-CH 2OR 3、-NR 3R 4取代的C1-C6烷基;R 2选自任选取代的环烷基、任选取代的芳基、任选取代的杂芳基和任选取代的杂环基;R 3和R 4各自独立选自H、任选取代的C1-C6烷基、任选取代的C1-C6烷氧基、任选取代的C1-C6卤代烷基、任选取代的4-10元杂环基和任选取代的5-10元杂芳基;或者,R 3和R 4与其所连接的氮原子一起形成任选取代的4-10元杂环基或5-10元杂芳基;并且R c和R d各自独立为H或C1-C4烷基。
- 如权利要求25所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A为C3-C8环烷基或3-7元杂环基。
- 如权利要求25或26所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A选自环丙基、环丁基、环戊基、环己基、氮杂环丙基、氮杂环丁基、吡咯烷基、哌啶基、哌嗪基、氧杂环丙基、氧杂环丁基、四氢呋喃基、四氢吡喃基和吗啉基。
- 如权利要求25至27之一所述的式II化合物,或其药学上可接受的盐,或 其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A被1、2或3个选自卤素、羟基、氰基、C1-C6烷基、卤代C1-C6烷基、羟基取代的C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b、C1-C6烷基羰基和C1-C6烷氧基羰基的取代基取代,所述R a和R b各自独立选自H和C1-C6烷基。
- 如权利要求25至28之一所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A为环丙基、环丁基、环戊基、环己烷、氮杂环丁基、氧杂环丁基、氮杂环戊基、四氢呋喃基或氧杂环己烷。
- 如权利要求25至29之一所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A任选地被1、2或3个选自F、Cl、Br、CF 3、CH 3、-OH、-OCH 3、-NH 2、-NHCH 3,-NH 2(CH 3) 2的取代基取代。
- 如权利要求25至30之一所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 0为-NR 3R 4取代的C1-C6烷基;其中,R 3和R 4各自独立选自H,任选被1、2、3、4、5或6个选自卤素、氰基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代的C1-C6烷基,或者R 3和R 4与其所连接的氮原子一起形成氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 所述氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 各自任选地被1、2或3个选自卤素、氰基、C1-C6烷基、C3-C6环烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、磺基、C1-C6烷基磺酰基、C1-C6烷氧基磺酰基、C1-C6烷基羰基、卤代C1-C6烷基羰基、C1-C6烷氧基羰基、卤代C1-C6烷氧基羰基、-NR aR b和羟基的取代基的取代基取代,其中,R a和R b各自独立为H或C1-C4烷基。
- 如权利要求25至31之一所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 0为-NR 3R 4取代的C1-C6烷基,并且其中,R 3和R 4与其所连接的氮原子一起形成氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 所述氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 各自任选地被1、2或3个选自卤素、氰基、C1-C6烷基、C3-C6环烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、磺基、C1-C6烷基磺酰基、C1-C6烷氧基磺酰基、C1-C6烷基羰基、卤代C1-C6烷基羰基、C1-C6烷氧基羰基、卤代C1-C6烷氧基羰基、-NR aR b和羟基的取代基取代;其中,R a和R b各自独立为H或C1-C4烷基。
- 如权利要求25至32之一所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 0为-NR 3R 4取代的C1-C6烷基,其中,R 3和R 4与其所连接的氮原子一起形成氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 所述氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 各自任选地被1、2或3个选自卤素、氰基、C1-C6烷基、C3-C6环烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代;其中,R a和R b各自独立为H或C1-C4烷基。
- 如权利要求25至33之一所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、 前药或代谢产物,其特征在于,R c和R d各自独立为H或甲基。
- 如权利要求25至34所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,L 2选自键和C1-C6亚烷基,其中,所述C1-C6亚烷基任选地被1、2或3个选自卤素、C1-C3烷基、C3-C5环烷基和羟基的取代基取代。
- 如权利要求25至35之一所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 2任选地被1、2或3个选自-NR aR b、氰基、C1-C6烷基、卤素、羟基、C1-C6烷氧基、卤代C1-C6烷基、卤代C1-C6烷氧基、C3-C8环烷基、C3-C8环烷基-O-、6-14元芳基、5-10元杂芳基和氰基的取代基取代;其中,R a和R b各自独立为H或C1-C6烷基;并且其中,所述杂芳基优选为含有1或2个环氮原子的杂芳基,优选选自吡唑基、咪唑基、吡啶基、吡嗪基和哌嗪基。
- 如权利要求25至36之一所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 2选自6-14元芳基、5-10元杂芳基和4-10元杂环基,所述6-14元芳基、5-10元杂芳基和4-10元杂环基任选地被1、2或3个选自-NR aR b、氰基、C1-C6烷基、卤素、羟基、C1-C6烷氧基、卤代C1-C6烷基、卤代C1-C6烷氧基、C3-C8环烷基、C3-C8环烷基-O-、6-14元芳基、5-10元杂芳基和氰基的取代基取代。
- 如权利要求25至37之一所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 2选自苯基、萘基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、杂氮环丁烷基、吡咯烷基、吗啉基、哌嗪基、高哌嗪基、哌啶基、吡喃基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基、四氢吡喃基、四氢呋喃基、噁嗪基、四氢异喹啉基、苯并二氢呋喃基、十氢异喹啉基、咪唑啉基、咪唑烷基、6,7-二氢-5H-环戊烷[c]吡啶、喹嗪基、噻唑烷基、异噻唑烷基、异噁唑烷基、二氢吲哚基、八氢吲哚基、八氢异吲哚基、吡咯烷基、吡唑烷基、 所述苯基、萘基、吡啶基、吡咯 基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、杂氮环丁烷基、吡咯烷基、吗啉基、哌嗪基、高哌嗪基、哌啶基、吡喃基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基、四氢吡喃基、四氢呋喃基、噁嗪基、四氢异喹啉基、苯并二氢呋喃基、十氢异喹啉基、咪唑啉基、咪唑烷基、6,7-二氢-5H-环戊烷[c]吡啶、喹嗪基、噻唑烷基、异噻唑烷基、异噁唑烷基、二氢吲哚基、八氢吲哚基、八氢异吲哚基、吡咯烷基、吡唑烷基、 任选地被1、2或3个选自-NR aR b、氰基、C1-C6烷基、卤素、羟基、C1-C6烷氧基、卤代C1-C6烷基、卤代C1-C6烷氧基、C3-C8环烷基、C3-C8环烷基-O-、6-14元芳基、5-10元杂芳基和氰基的取代基取代。
- 如权利要求25至38所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,L 2为C1-C4亚烷基,R 2为苯基、吡啶基、吡唑基、吡咯并吡啶基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基或吲哚基,所述苯基、吡啶基、吡唑基、吡咯并吡啶基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基或吲哚基被1或2个选自C1-C6烷氧基、卤素、C1-C6烷基、氰基、C3-C8环烷基-O-和卤代C1-C6烷氧基的取代基取代。
- 如权利要求25所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于:环A为任选被选自F、Cl、羟基或C1-C4烷基的取代基取代的C3-C6环烷基或含1个氮或1个O的C4-C6杂环基,优选为任选被F或C1-C4烷基取代的环丙基、环丁基、氧杂环丁基或氮杂环丁基;R 0为H或-NR 3R 4取代的C1-C4烷基,其中,R 3和R 4各自独立选自H、4-6元杂环基和任选被1、2、3、4、5或6个选自羟基、氰基和卤素的取代基取代的C1-C6烷基,或R 3和R 4与其所连接的氮原子一起形成任选被1、2或3个选自卤素、羟基、C1-C4烷氧基、C3-C6环烷基和C1-C4烷基取代的4-6元杂环基;其中,所述4-6元杂环基优选为仅含氮的杂环基或含氧和氮的杂环基,优选选自氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、L 2为C1-C4亚烷基;R 2为6-14元芳基、5-10元含氮杂芳基或4-10元杂环基,优选为苯基、吡啶基、嘧啶基、吡唑基、吡咯基、咪唑基、吡嗪基、吲哚基、吡咯并吡啶基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基、 所述6-14元芳基、5-10元含氮杂芳基或4-10元杂环基各自任选被1或2个选自C1-C6烷氧基、C1-C4烷基、卤素、C3-C6环烷基-氧基、卤代C1-C4烷氧基和氰基的取代基取代;R c和R d各自独立为H或C1-C4烷基。
- 如权利要求25所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A为C3-C6环烷基或4-8元杂环基,所述环烷基或杂环基任选地被1、2或3个选自卤素、C1-C4烷基、卤代C1-C4烷基、C1-C4烷氧基、卤代C1-C4烷氧基的取代基取代;L 2为C1-C4亚烷基;R 2为苯基、5-10元含氮杂芳基或4-10元杂环基,优选为吡啶基、嘧啶基、吡唑基、吡咯基、咪唑基、吡嗪基、吡咯并吡啶基、吡啶并二氢呋喃基或吡啶并1,3-二氧环戊烯基或吲哚基,所述苯基、5-10元含氮杂芳基和4-10元杂环基各自任选地被1或2个选自C1-C6烷氧基、卤素、C1-C6烷基、氰基、C3-C8环烷基-O-和卤代C1-C6烷氧基的取代基取代;R 0为-NR 3R 4取代的C1-C4烷基;其中,R 3和R 4各自独立选自H,任选被1-6个选自羟基、氰基和卤素的取代基取代的C1-C6烷基和任选被1、2或3个选自卤素、C1-C6烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代的4-8元杂环基,其中,R a和R b各自独立为H或C1-C4烷基;或R 3和R 4与其所连接的氮原子一起形成任选被1、2或3个选自卤素、C1-C6烷基、C3-C6环烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代的4-8元杂环基,其中,R a和R b各自独立为H或C1-C4烷基;优选地,所述4-8元杂环基各自独立选自氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、 并且R c和R d各自独立为H或C1-C4烷基。
- 如权利要求25所述的式II化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A为C3-C6环烷基,所述环烷基任选地被1、2或3个选自卤素、C1-C4烷基和卤代C1-C4烷基的取代基取代;L 2为C1-C4亚烷基;R 2为5-10元含氮杂芳基或4-10元杂环基,优选为吡啶基、嘧啶基、吡唑基、吡咯基、咪唑基、吡嗪基、吡咯并吡啶基、吡啶并二氢呋喃基或吡啶并1,3-二氧环戊烯基或吲哚基,所述5-10元含氮杂芳基或4-10元杂环基各自任选被1或2个选自C1-C6烷氧基、C1-C6烷基、C3-C8环烷基-O-、卤代C1-C6烷氧基、卤素和氰基的取代基取代;R 0为-NR 3R 4取代的C1-C4烷基,其中,R 3和R 4各自独立选自H和任选被1、2、3、4、5或6个选自羟基、氰基和卤素的取代基取代的C1-C6烷基,或R 3和R 4与其所连接的氮原子一起形成任选被1、2或3个选自卤素、羟基、C1-C4烷氧基和C1-C4烷基取代的4-8元杂环基,优选地,所述4-8元杂环基选自氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、 并且R c和R d各自独立为H或C1-C4烷基。
- 式III化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,其中,L 2选自键、任选取代的C1-C6亚烷基、任选取代的C1-C6亚烷基-O-、任选取代的C1-C6亚烷基-NH-、任选取代的C1-C6亚烷基-S-和任选取代的C2-C4亚链烯基;R 0选自H、C1-C6烷基、任选取代的C1-C6烷氧基、任选取代的C1-C6卤代烷基、-C(O)NR 3R 4、-CH 2OR 3和-NR 3R 4取代的C1-C6烷基;R 2选自任选取代的环烷基、任选取代的芳基、任选取代的杂芳基和任选取代的杂环基;R 3和R 4各自独立选自H、任选取代的C1-C6烷基、任选取代的C1-C6烷氧基、任选取代的C1-C6卤代烷基、任选取代的4-10元杂环基和任选取代的5-10元杂芳基;或者,R 3和R 4与其所连接的氮原子一起形成任选取代的4-10元杂环基或5-10元杂芳基;X 6各自独立选自C、O、N、S,q为1、2或3的整数,R 7选自F、Cl、氰基、羟基、C1-C6烷基、氟代或氯代C1-C6烷基、羟基取代的C1-C6烷基、C1-C6烷氧基、氟代或氯代C1-C6烷氧基、羟基取代的C1-C6烷基和-NR aR b;其中,所述R a和R b各自独立选自H和C1-C6烷基,m为0、1、2或3的整数;并且R c和R d各自独立为H或C1-C4烷基。
- 如权利要求43所述的式III化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 0为-NR 3R 4取代的C1-C6烷基;其中,R 3和R 4各自独立选自H,任选被1、2、3、4、5或6个选自卤素、氰基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代的C1-C6烷基,或者R 3和R 4与其所连接的氮原子一起形成氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 所述氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 各自任选地被1、2或3个选自卤素、氰基、C1-C6烷基、卤代C1-C6烷基、C3-C6环烷基、C1-C6烷氧基、卤代C1-C6烷氧基、磺基、C1-C6烷基磺酰基、C1-C6烷氧基磺酰基、C1-C6烷基羰基、卤代C1-C6烷基羰基、C1-C6烷氧基羰基、卤代C1-C6烷氧基羰 基、-NR aR b和羟基的取代基取代,其中,R a和R b各自独立为H或C1-C4烷基。
- 如权利要求43至44之一所述的式III化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 0为-NR 3R 4取代的C1-C6烷基,并且其中,R 3和R 4与其所连接的氮原子一起形成氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 所述氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 各自任选地被1、2或3个选自卤素、氰基、C1-C6烷基、C3-C6环烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、磺基、C1-C6烷基磺酰基、C1-C6烷氧基磺酰基、C1-C6烷基羰基、卤代C1-C6烷基羰基、C1-C6烷氧基羰基、卤代C1-C6烷氧基羰基、-NR aR b和羟基的取代基取代;其中,R a和R b各自独立为H或C1-C4烷基。
- 如权利要求43至45之一所述的式III化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 0为-NR 3R 4取代的C1-C6烷基,其中,R 3和R 4与其所连接的氮原子一起形成氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 所述氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 各自任选地被1、2或3个选自卤素、氰基、C1-C6烷基、C3-C6环烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代;其中,R a和R b各自独立为H或C1-C4烷基。
- 如权利要求43至46之一所述的式III化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型 物、前药或代谢产物,其特征在于,R c和R d各自独立为H或甲基。
- 如权利要求43至47所述的式III化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,L 2选自键和C1-C6亚烷基,其中,所述C1-C6亚烷基任选地被1、2或3个选自卤素、C1-C3烷基、C3-C5环烷基和羟基的取代基取代。
- 如权利要求43至48之一所述的式III化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 2任选地被1、2或3个选自-NR aR b、氰基、C1-C6烷基、卤素、羟基、C1-C6烷氧基、卤代C1-C6烷基、卤代C1-C6烷氧基、C3-C8环烷基、C3-C8环烷基-O-、6-14元芳基、5-10元杂芳基和氰基的取代基取代;其中,R a和R b各自独立为H或C1-C6烷基;并且其中,所述杂芳基优选为含有1或2个环氮原子的杂芳基,优选选自吡唑基、咪唑基、吡啶基、吡嗪基和哌嗪基。
- 如权利要求43至49之一所述的式III化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 2选自6-14元芳基、5-10元杂芳基和4-10元杂环基,所述6-14元芳基、5-10元杂芳基和4-10元杂环基任选地被1、2或3个选自-NR aR b、氰基、C1-C6烷基、卤素、羟基、C1-C6烷氧基、卤代C1-C6烷基、卤代C1-C6烷氧基、C3-C8环烷基、C3-C8环烷基-O-、6-14元芳基、5-10元杂芳基和氰基的取代基取代。
- 如权利要求43至50之一所述的式III化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 2选自苯基、萘基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、杂氮环丁烷基、吡咯烷基、吗啉基、哌嗪基、高哌嗪基、哌啶基、吡喃基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基、2-哌嗪酮基、四氢吡喃基、四氢呋喃基、噁嗪基、四氢异喹啉基、苯并二氢呋喃基、十氢异喹啉基、咪唑啉基、咪唑烷基、6,7-二氢-5H-环戊烷[c]吡啶、喹嗪基、噻唑烷基、异噻唑烷基、异噁唑烷基、二氢吲哚基、八 氢吲哚基、八氢异吲哚基、吡咯烷基、吡唑烷基、 所述苯基、萘基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、杂氮环丁烷基、吡咯烷基、吗啉基、哌嗪基、高哌嗪基、哌啶基、吡喃基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基、2-哌嗪酮基、四氢吡喃基、四氢呋喃基、噁嗪基、四氢异喹啉基、苯并二氢呋喃基、十氢异喹啉基、咪唑啉基、咪唑烷基、6,7-二氢-5H-环戊烷[c]吡啶、喹嗪基、噻唑烷基、异噻唑烷基、异噁唑烷基、二氢吲哚基、八氢吲哚基、八氢异吲哚基、吡咯烷基、吡唑烷基、 任选地被1、2或3个选自-NR aR b、氰基、C1-C6烷基、卤素、羟基、C1-C6烷氧基、卤代C1-C6烷基、卤代C1-C6烷氧基、C3-C8环烷基、C3-C8环烷基-O-、6-14元芳基、5-10元杂芳基和氰基的取代基取代。
- 如权利要求43至51所述的式III化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,L 2为C1-C4亚烷基,R 2为6-14元芳基、5-10元含氮杂芳基或4-10元杂环基,优选为苯基、吡啶基、吡唑基、吡咯并吡啶基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基或吲哚基,所述6-14元芳基、5-10元含氮杂芳基或4-10元杂环基可任选地被1或2个选自C1-C6烷氧基、卤素、C1-C6烷基、氰基、C3-C8环烷基-O-和卤代C1-C6烷氧基的取代基取代。
- 如权利要求43所述的式III化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于:R 0为H或-NR 3R 4取代的C1-C4烷基,其中,R 3和R 4各自独立选自H、4-6元杂环基和任选被1、2、3、4、5或6个选自羟基、氰基和卤素的取代基取代的C1-C6烷基,或R 3和R 4与其所连接的氮原子一起形成任选被1、2或3个选自卤素、羟基、C1-C4烷氧基和C1-C4烷基取代的4-6元杂环基;其中,所述4-6元杂环基优选为含氧和/或氮的杂环基,优选选自氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、L 2为C1-C4亚烷基;R 2为6-14元芳基、5-10元含氮杂芳基或4-10元杂环基,优选为苯基、吡啶基、嘧啶基、吡唑基、吡咯基、咪唑基、吡嗪基、吲哚基、吡咯并吡啶基、吡啶并二氢呋喃基或吡啶并1,3-二氧环戊烯基,所述6-14元芳基、5-10元含氮杂芳基或4-10元杂环基各自任选被1或2个选自C1-C6烷氧基、C1-C4烷基、卤素、C3-C6环烷基-氧基、卤代C1-C4烷氧基和氰基的取代基取代;R c和R d各自独立为H或C1-C4烷基;X 6为C或O;q为1或2;并且R 7选自F、Cl、氰基、羟基、C1-C6烷基、氟代或氯代C1-C6烷基、羟基取代的C1-C6烷基、C1-C6烷氧基、氟代或氯代C1-C6烷氧基以及羟基取代的C1-C6烷基。
- 如权利要求43所述的式III化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,L 2为C1-C4亚烷基;R 2为苯基、5-10元含氮杂芳基或4-10元杂环基,优选为吡啶基、嘧啶基、吡唑基、吡咯基、咪唑基、吡嗪基、吡咯并吡啶基、吡啶并二氢呋喃基或吡啶并1,3-二氧环戊烯基或吲哚基,所述苯基、5-10元含氮杂芳基和4-10元杂环基各自任选地被1或2个选自C1-C6烷氧基、卤素、C1-C6烷基、氰基、C3-C8环烷基-O-和卤代C1-C6烷氧基的取代基取代;R 0为-NR 3R 4取代的C1-C4烷基;其中,R 3和R 4各自独立选自H,任选被1-6个选自羟基、氰基和卤素的取代基取代的C1-C6烷基和任选被1、2或3个选自卤素、C1-C6烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代的4-8元杂环基,其中,R a和R b各自独立为H或C1-C4烷基;或R 3和R 4与其所连接的氮原子一起形成任选被1、2或3个选自卤素、C1-C6烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代的4-8元杂环基,其中,R a和R b各自独立为H或C1-C4烷基;优选地,所述4-8元杂环基各自独立选自氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、R c和R d各自独立为H或C1-C4烷基;X 6为C或O;q为1或2;并且R 7选自F、Cl、氰基、羟基、C1-C6烷基、氟代或氯代C1-C6烷基、羟基取代的C1-C6烷基、C1-C6烷氧基、氟代或氯代C1-C6烷氧基以及羟基取代的C1-C6烷基。
- 如权利要求43所述的式III化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,L 2为C1-C4亚烷基;R 2为5-10元含氮杂芳基或4-10元杂环基,优选为吡啶基、嘧啶基、吡唑基、吡咯基、咪唑基、吡嗪基、吡咯并吡啶基、吡啶并二氢呋喃基或吡啶并1,3-二氧环戊烯基或吲哚基,所述5-10元含氮杂芳基或4-10元杂环基各自任选被1或2个选自C1-C6烷氧基、C1-C6烷基、C3-C8环烷基-O-、卤代C1-C6烷氧基、卤素和氰基的取代基取代;R 0为-NR 3R 4取代的C1-C4烷基,其中,R 3和R 4各自独立选自H和任选被1、2、3、4、5或6个选自羟基、氰基和卤素的取代基取代的C1-C6烷基,或R 3和R 4与其所连接的氮原子一起形成任选被1、2或3个选自卤素、羟基和C1-C4烷基取代的4-8元杂环基,优选地,所述4-8元杂环基选自氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、吗啉基、R c和R d各自独立为H或C1-C4烷基;X 6为C或O;q为1或2;并且R 7选自F、Cl、氰基、羟基、C1-C6烷基、氟代或氯代C1-C6烷基、羟基取代的C1-C6烷基、C1-C6烷氧基、氟代或氯代C1-C6烷氧基以及羟基取代的C1-C6烷基。
- 一种式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物:式中,环A为取代或未取代的3-8元饱和碳环或取代或未取代的3-8元饱和杂环,所述杂环含有1-2个独立选自N、O和S的杂原子;X 3选自CR 5和N;X 4选自任选取代的-(CH 2) n-、-C(=O)-和NR 6,其中,n为1、2或3;X 5选自N和CR 5;L 1选自键、任选取代的C1-C6亚烷基、任选取代的C1-C6亚烷基-O-、任选取代的C1-C6亚烷基-NH-、任选取代的C1-C6亚烷基-S-和任选取代的C2-C4亚链烯基;L 2选自键、任选取代的C1-C6亚烷基、任选取代的C1-C6亚烷基-O-、任选取代的C1-C6亚烷基-NH-、任选取代的C1-C6亚烷基-S-和任选取代的C2-C4亚链烯基;R 0选自任选取代的C1-C6卤代烷基、-C(O)NR 3R 4、-CH 2OR 3和-NR 3R 4取代的C1-C6烷基;R 1选自任选取代的环烷基、任选取代的芳基、任选取代的杂芳基、任选取代的杂环基、任选取代的氨基和胍基;R 2选自任选取代的环烷基、任选取代的芳基、任选取代的杂芳基和任选取代的杂环基;R 3和R 4各自独立选自H、任选取代的C1-C6烷基、任选取代的C1-C6烷氧基、任选取代的C1-C6卤代烷基、任选取代的4-10元杂环基和任选取代的5-10元杂芳基;或者,R 3和R 4与其所连接的氮原子一起形成任选取代的4-10元杂环基或5-10元杂芳基;R 5选自H、卤素、C1-C6烷基、卤代C1-C6烷基和C1-C6烷氧基;并且R 6选自H、C1-C6烷基、卤代C1-C6烷基和C1-C6烷氧基。
- 如权利要求56所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A为C3-C8环烷基或3-7元杂环基。
- 如权利要求56或57所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A选自环丙基、环丁基、环戊基、环己基、氮杂环丙基、氮杂环丁基、吡咯烷基、哌啶基、哌嗪基、氧杂环丙基、氧杂环丁基、四氢呋喃基、四氢吡喃基和吗啉基。
- 如权利要求56至58之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A被1、2或3个选自卤素、羟基、氰基、C1-C6烷基、卤代C1-C6烷基、羟基取代的C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基和-NR aR b的取代基取代;其中,所述R a和R b各自独立选自H和C1-C6烷基。
- 如权利要求56至59之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A为环丙基、环丁基、环戊基、氮杂环丁基、氧杂环丁基、氮杂环戊基或四氢呋喃基,
- 如权利要求56至60之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A任选地被1、2或3个选自F、Cl、Br、CF 3、CH 3、-OH、-OCH 3、-NH 2、-NHCH 3,-NH 2(CH 3) 2的取代基取代。
- 如权利要求56至61之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 0为-NR 3R 4取代的C1-C6烷基;其中,R 3和R 4各自独立选自H,任选被1、2、3、4、5或6个选自卤素、氰基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代的C1-C6烷基,或者R 3和R 4与其所连接的氮原子一起形成氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 所述氮杂环丁烷基、吡咯烷基、哌啶 基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 各自任选地被1、2或3个选自卤素、氰基、C1-C6烷基、C3-C6环烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、磺基、C1-C6烷基磺酰基、C1-C6烷氧基磺酰基、C1-C6烷基羰基、卤代C1-C6烷基羰基、C1-C6烷氧基羰基、卤代C1-C6烷氧基羰基、-NR aR b和羟基的取代基取代,其中,R a和R b各自独立为H或C1-C4烷基。
- 如权利要求56至62之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 0为-NR 3R 4取代的C1-C6烷基,并且其中,R 3和R 4与其所连接的氮原子一起形成氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 所述氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 各自任选地被1、2或3个选自卤素、氰基、C1-C6烷基、C3-C6环烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、磺基、C1-C6烷基磺酰基、C1-C6烷氧基磺酰基、C1-C6烷基羰基、卤代C1-C6烷基羰基、C1-C6烷氧基羰基、卤代C1-C6烷氧基羰基、-NR aR b和羟基的取代基取代;其中,R a和R b各自独立为H或C1-C4烷基。
- 如权利要求56至63之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 0为-NR 3R 4取代的C1-C6烷基,其中,R 3和R 4与其所连接的氮原子一起形成氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 所述氮杂环丁烷基、吡咯烷基、 哌啶基、哌嗪基、2-哌嗪酮基、吗啉基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、 各自任选地被1、2或3个选自卤素、氰基、C1-C6烷基、C3-C6环烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代;其中,R a和R b各自独立为H或C1-C4烷基。
- 如权利要求56至64之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,X 3和/或X 5为CR 5。
- 如权利要求56至65之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 5选自H和C1-C4烷基。
- 如权利要求56至66之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,X 4为-(CH 2) n-,n为1或2;并且其中,所述-(CH 2) n-任选被1或2个选自卤素、羟基、氨基、C1-C6烷基和卤代C1-C6烷基的取代基取代。
- 如权利要求56至67之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,X 3和X 5均为CR 5;并且X 4为任选取代的-(CH 2)-。
- 如权利要求56至68之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,L 1选自C1-C6亚烷基、C1-C6亚烷基-O-、C1-C6亚烷基-NH-、C1-C6亚烷基-S-和C2-C4亚链烯基,所述C1-C6亚烷基、C1-C6亚烷基-O-、C1-C6亚烷基-NH-、C1-C6亚烷基-S-和C2-C4亚链烯基任选被1、2或3个选自卤素、C1-C4烷基和羟基的取代基取代。
- 如权利要求56至69之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,L 1选自C1-C6亚烷基和C1-C6亚烷基-NH-,所述 C1-C6亚烷基和C1-C6亚烷基-NH-任选被1、2或3个选自卤素、C1-C4烷基和羟基的取代基取代。
- 如权利要求56至70之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 1选自任选取代的C3-C8环烷基、任选取代的6-14元芳基、任选取代的5-10元杂芳基和任选取代的4-10元杂环基,并且所述环烷基、芳基、杂芳基和杂环基各自可任选地被1、2或3个选自任选取代的氨基、C1-C6烷基、卤素、羟基、C1-C6烷氧基、C1-C6卤代烷基和氰基的取代基取代;其中,所述任选取代的氨基是-NR aR b,其中,R a和R b各自独立为H或C1-C6烷基。
- 如权利要求56至71之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 1选自任选取代的苯基、萘基吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吡啶并咪唑基、吲哚基、异吲哚基、吲唑基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、吡咯烷基、吗啉基、哌嗪基、高哌嗪基、哌啶基、吡喃基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基、四氢吡喃基、四氢呋喃基、噁嗪基、四氢异喹啉基、十氢异喹啉基、咪唑啉基、咪唑烷基、喹嗪基、噻唑烷基、异噻唑烷基、异噁唑烷基、二氢吲哚基、八氢吲哚基、八氢异吲哚基、吡咯烷基、吡唑烷基、邻苯二甲酰亚氨基、
- 如权利要求56至73所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,L 2选自键和C1-C6亚烷基,其中,所述C1-C6亚烷基任选地被1、2或3个选自卤素、C1-C3烷基、C3-C5环烷基和羟基的取代基取代。
- 如权利要求56至74之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 2任选地被1、2或3个选自-NR aR b、氰基、C1-C6烷基、卤素、羟基、C1-C6烷氧基、卤代C1-C6烷基、卤代C1-C6烷氧基、C3-C8环烷基、C3-C8环烷基-O-、6-14元芳基、5-10元杂芳基和氰基的取代基取代;其中,R a和R b各自独立为H或C1-C6烷基;并且其中,所述杂芳基优选为含有1或2个环氮原子的杂芳基,优选选自吡唑基、咪唑基、吡啶基、吡嗪基和哌嗪基。
- 如权利要求56至75之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 2选自6-14元芳基、5-10元杂芳基和4-10元杂环基,所述6-14元芳基、5-10元杂芳基和4-10元杂环基可任选地被1、2或3个选自-NR aR b、氰基、C1-C6烷基、卤素、羟基、C1-C6烷氧基、卤代C1-C6烷基、卤代C1-C6烷氧基、C3-C8环烷基、C3-C8环烷基-O-、6-14元芳基、5-10元杂芳基和氰基的取代基取代。
- 如权利要求56至76之一所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,R 2选自苯基、萘基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、杂氮环丁烷基、吡咯烷基、吗啉基、哌嗪基、高哌嗪基、哌啶基、吡喃基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基、四氢吡喃基、四氢呋喃基、噁嗪基、四氢异喹啉基、苯并二氢呋喃基、十氢异喹啉基、咪唑啉基、咪唑烷基、6,7-二氢-5H-环戊烷[c]吡啶、喹嗪基、噻唑烷基、异噻唑烷基、异噁唑烷基、二氢吲哚基、八氢吲哚基、八氢异吲哚基、吡咯烷基、吡唑烷基、 所述苯基、萘基、吡啶基、吡咯基、吡唑基、咪唑基、三唑基、嘧啶基、吡嗪基、三嗪基、吲哚基、异吲哚基、吲 唑基、苯并吡咯基、苯并咪唑基、苯并三唑基、苯并噁唑基、苯并异噁唑基、喹啉基、杂氮环丁烷基、吡咯烷基、吗啉基、哌嗪基、高哌嗪基、哌啶基、吡喃基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基、四氢吡喃基、四氢呋喃基、噁嗪基、四氢异喹啉基、苯并二氢呋喃基、十氢异喹啉基、咪唑啉基、咪唑烷基、6,7-二氢-5H-环戊烷[c]吡啶、喹嗪基、噻唑烷基、异噻唑烷基、异噁唑烷基、二氢吲哚基、八氢吲哚基、八氢异吲哚基、吡咯烷基、吡唑烷基、 任选地被1、2或3个选自-NR aR b、氰基、C1-C6烷基、卤素、羟基、C1-C6烷氧基、卤代C1-C6烷基、卤代C1-C6烷氧基、C3-C8环烷基、C3-C8环烷基-O-、6-14元芳基、5-10元杂芳基和氰基的取代基取代。
- 如权利要求56至77所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,L 2为C1-C4亚烷基,R 2为6-14元芳基、5-10元含氮杂芳基或4-10元杂环基,优选为苯基、吡啶基、吡唑基、吡咯并吡啶基、吡啶并二氢呋喃基、吡啶并1,3-二氧环戊烯基或吲哚基,所述6-14元芳基、5-10元含氮杂芳基或4-10元杂环基可任选地被1或2个选自C1-C6烷氧基、卤素、C1-C6烷基、氰基、C3-C8环烷基-O-和卤代C1-C6烷氧基的取代基取代。
- 如权利要求56所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A为C3-C6环烷基或4-8元杂环基,所述环烷基或杂环基任选地被1、2或3个选自卤素、C1-C4烷基、卤代C1-C4烷基、C1-C4烷氧基和卤代C1-C4烷氧基的取代基取代;X 3和X 5均为CH;X 4为CH 2;L 1为C1-C4亚烷基;L 2为C1-C4亚烷基;R 2为苯基、5-10元含氮杂芳基或4-10元杂环基,优选为吡啶基、嘧啶基、吡唑基、吡咯基、咪唑基、吡嗪基、吡咯并吡啶基、吡啶并二氢呋喃基或吡啶并1,3-二氧环戊烯基或吲哚基,所述苯基、5-10元含氮杂芳基和4-10元杂环基各自任选地被1或2个选自C1-C6烷氧基、卤素、C1-C6烷基、氰基、C3-C8环烷基-O-和卤代C1-C6烷氧基的取代基取代;R 0为-NR 3R 4取代的C1-C4烷基;其中,R 3和R 4各自独立选自H,任选被1-6个选自羟基、氰基和卤素的取代基取代的C1-C6烷基和任选被1、2或3个选自卤素、C1-C6烷基、C3-C6环烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代的4-8元杂环基,其中,R a和R b各自独立为H或C1-C4烷基;或R 3和R 4与其所连接的氮原子一起形成任选被1、2或3个选自卤素、C1-C6烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、-NR aR b和羟基的取代基取代的4-8元杂环基,其中,R a和R b各自独立为H或C1-C4烷基;优选地,所述4-8元杂环基各自独立选自氮杂环丁烷基、吡咯烷基、哌啶基、哌嗪基、吗啉基、
- 如权利要求56所述的式I化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,其特征在于,环A为C3-C6环烷基,所述环烷基任选地被1、2或3个选自卤素、C1-C4烷基和卤代C1-C4烷基的取代基取代;X 3和X 5均为CH;X 4为CH 2;L 1为C1-C4亚烷基;L 2为C1-C4亚烷基;R 2为5-10元含氮杂芳基或4-10元杂环基,优选为吡啶基、嘧啶基、吡唑基、吡咯基、咪唑基、吡嗪基、吡咯并吡啶基、吡啶并二氢呋喃基或吡啶并1,3-二氧环戊烯基或吲哚基,所述5-10元含氮杂芳基或4-10元杂环基各自任选被1或2个选自C1-C6烷氧基、C1-C6烷基、C3-C8环烷基-O-、卤代C1-C6烷氧基、卤素和氰基的取代基取代;
- 一种药物组合物,其含有权利要求1-81中任一项所述的化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物,以及药学上可接受的载体或赋形剂。
- 权利要求1-81中任一项所述的化合物,或其药学上可接受的盐,或其对映异构体、非对映异构体、互变异构体、同位素取代物、溶剂化物、多晶型物、前药或代谢产物在制备用于治疗或预防WDR5介导的疾病的药物中的应用。
- 如权利要求83所述的应用,其特征在于,所述WDR5介导的疾病包括Kabuki综合征、以及各种实体瘤和血液肿瘤。
- 如权利要求83所述的应用,其特征在于,所述WDR5介导的疾病包括努南综合症、豹综合症、成神经细胞瘤、肉瘤、黑色素瘤、关节软骨瘤、胆管瘤、白血病、乳腺癌、胃肠间质瘤、组织细胞性淋巴瘤、肺癌、食道癌、胰腺癌、乳腺癌、前列腺癌、肝癌、皮肤癌、上皮细胞癌、宫颈癌、卵巢癌、肠癌、鼻咽癌、脑癌、骨癌、肾癌、口腔癌、头癌、成神经细胞瘤、头颈的鳞状细胞癌、间变性大细胞淋巴瘤或成胶质细胞瘤,其中,白血病优选为青少年髓单核细胞白血病、人髓性单核细胞白血病,肺癌优选为非小细胞肺癌、小细胞肺癌、肺鳞癌和肺腺癌。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21902742.2A EP4261211A1 (en) | 2020-12-11 | 2021-12-10 | Dihydroisoquinolinone derivative and application thereof |
CN202180083281.XA CN116783188A (zh) | 2020-12-11 | 2021-12-10 | 一种二氢异喹啉酮衍生物及其应用 |
US18/256,796 US20240101535A1 (en) | 2020-12-11 | 2021-12-10 | Dihydroisoquinolinone derivative and application thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011459208 | 2020-12-11 | ||
CN202011459208.1 | 2020-12-11 | ||
CN202110261282.0 | 2021-03-10 | ||
CN202110261282 | 2021-03-10 | ||
CN202110861847 | 2021-07-29 | ||
CN202110861847.9 | 2021-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022122037A1 true WO2022122037A1 (zh) | 2022-06-16 |
Family
ID=81973092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/137254 WO2022122037A1 (zh) | 2020-12-11 | 2021-12-10 | 一种二氢异喹啉酮衍生物及其应用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240101535A1 (zh) |
EP (1) | EP4261211A1 (zh) |
CN (1) | CN116783188A (zh) |
WO (1) | WO2022122037A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024108765A1 (zh) * | 2022-11-25 | 2024-05-30 | 英矽智能科技(上海)有限公司 | 一类螺环衍生物作为kif18a抑制剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150361067A1 (en) * | 2014-06-17 | 2015-12-17 | Pfizer Inc. | Substituted dihydroisoquinolinone compounds |
WO2020086857A1 (en) * | 2018-10-24 | 2020-04-30 | Vanderbilt University | Wdr5 inhibitors and modulators |
WO2021026672A1 (en) * | 2019-08-09 | 2021-02-18 | Novartis Ag | Heterocyclic wdr5 inhibitors as anti-cancer compounds |
-
2021
- 2021-12-10 US US18/256,796 patent/US20240101535A1/en active Pending
- 2021-12-10 CN CN202180083281.XA patent/CN116783188A/zh active Pending
- 2021-12-10 WO PCT/CN2021/137254 patent/WO2022122037A1/zh active Application Filing
- 2021-12-10 EP EP21902742.2A patent/EP4261211A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150361067A1 (en) * | 2014-06-17 | 2015-12-17 | Pfizer Inc. | Substituted dihydroisoquinolinone compounds |
WO2020086857A1 (en) * | 2018-10-24 | 2020-04-30 | Vanderbilt University | Wdr5 inhibitors and modulators |
WO2021026672A1 (en) * | 2019-08-09 | 2021-02-18 | Novartis Ag | Heterocyclic wdr5 inhibitors as anti-cancer compounds |
Non-Patent Citations (9)
Title |
---|
"Methods in Molecular Biology", vol. 243, 2004, article "Chiral Separations, Methods and Protocols" |
"VOGEL'S ENCYCLOPEDIA OF PRACTICAL ORGANIC CHEMISTRY", 1991, LONGMAN SCIENTIFIC AND TECHNICAL LTD., pages: 809 - 816 |
A.M. STALCUP: "Chiral Separations", ANNU. REV. ANAL. CHEM., vol. 3, 2010, pages 341 - 63 |
CAREYSUNDBERG, VOLS.: "ADVANCED ORGANIC CHEMISTRY 4TH ED.", 2000, PLENUM PRESS |
DATABASE REGISTRY 26 September 2014 (2014-09-26), ANONYMOUS : "Spiro[cyclopentane-1,4'(1'H)-isoquinoline]-1',3'(2'H)-dione, 7'-amino-2'-(cyclopropylmethyl)- (CA INDEX NAME)", XP055941711, retrieved from STN Database accession no. 1627175-04-5 * |
GREENE, T. W.P. G. M. WUTS: "Protective Groups in Organi Synthesis", 1999, WILEY |
HELLER, ACC. CHEM. RES., vol. 23, 1990, pages 128 |
MATTHÄUS GETLIK, ET AL.: "Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1)", J. MED. CHEM., vol. 59, no. 6, 9 March 2016 (2016-03-09), XP055413735, DOI: 10.1021/acs.jmedchem.5b01630 * |
TETRAHEDRON LETTERS, vol. 49, no. 44, 2008, pages 6368 - 6370 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024108765A1 (zh) * | 2022-11-25 | 2024-05-30 | 英矽智能科技(上海)有限公司 | 一类螺环衍生物作为kif18a抑制剂 |
Also Published As
Publication number | Publication date |
---|---|
US20240101535A1 (en) | 2024-03-28 |
CN116783188A (zh) | 2023-09-19 |
EP4261211A1 (en) | 2023-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3712151B1 (en) | (s)-1'-(8-((2-amino-3-chloropyridin-4-yl)thio)imidazo[1,2-c]pyrimidin-5-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidine]-5-amine as shp2 inhibitor for the treatment of cancer | |
WO2020239123A1 (zh) | 芳香杂环类衍生物调节剂、其制备方法和应用 | |
CN113637005A (zh) | 用于癌症治疗的kras抑制剂 | |
WO2021088945A1 (zh) | 作为shp2抑制剂的化合物及其应用 | |
CN106749233B (zh) | 一类磺酰胺衍生物及其应用 | |
WO2021249057A1 (zh) | 杂环化合物及其用途 | |
CN102372698A (zh) | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 | |
CN111918868A (zh) | 作为蛋白激酶调节剂的二芳基大环化合物 | |
CN107207504B (zh) | 酞嗪酮衍生物、其制备方法及用途 | |
CN110950876B (zh) | 一类呋喃并内酰胺类化合物、制备方法和用途 | |
CN113387962A (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 | |
TW201917129A (zh) | 含吡唑基的三并環類衍生物、其製備方法和應用 | |
WO2022135590A1 (zh) | 一类嘧啶并杂环类化合物、制备方法和用途 | |
WO2022089406A1 (zh) | 含氮稠杂环类化合物及其制备方法和应用 | |
CN114302886A (zh) | 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途 | |
WO2021032004A9 (zh) | 氮杂芳基化合物及其应用 | |
WO2023165551A1 (zh) | 六元芳环并吡咯酮衍生物、其药物组合物及应用 | |
TW202102511A (zh) | 噻吩并雜環類衍生物、其製備方法及其在醫藥上的應用 | |
CN114805311A (zh) | 螺环茚 | |
WO2022122037A1 (zh) | 一种二氢异喹啉酮衍生物及其应用 | |
CN113429410A (zh) | 多杂环取代的嘧啶或吡啶胺衍生物、其组合物及医药上的用途 | |
CN111747954B (zh) | 吡嗪化合物和其用途 | |
CN112689636A (zh) | 新型杂原子芳香族酰胺衍生物以及含有其的药剂 | |
CN113264945B (zh) | 一种螺环衍生物、其制备方法及其在医药上的应用 | |
CN112300129B (zh) | 作为bcr-abl抑制剂的杂环化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21902742 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180083281.X Country of ref document: CN Ref document number: 18256796 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021902742 Country of ref document: EP Effective date: 20230711 |